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Abstract 
The human BTG/TOB protein family comprises six members (BTG1, 
BTG2/PC3/Tis21, BTG3/Ana, BTG4/PC3B, TOB1/Tob, and TOB2) that 
display anti-proliferative activity in a number of cell types. They are 
characterised by a conserved N-terminal BTG domain that mediates 
interactions with the Caf1a (CNOT7) and Caf1b (CNOT8) deadenylases. It was 
unclear whether the anti-proliferative activity of the BTG/TOB proteins was 
mediated through interactions with Caf1a (CNOT7) and Caf1b (CNOT8). To 
address this we further characterised the amino acid residues located along 
the BTG2 and TOB1 interaction surface with Caf1a (CNOT7)/Caf1b (CNOT8) 
to identify residues required for the interaction. We then analysed the role of 
BTG2 and TOB1 in the regulation of cell proliferation, translation and mRNA 
abundance using a mutant that is no longer able to interact with Caf1a 
(CNOT7)/Caf1b (CNOT8). We conclude that the anti-proliferative activity of 
BTG/TOB proteins is mediated through interactions with the Caf1a (CNOT7) 
and Caf1b (CNOT8) deadenylase enzymes. We also demonstrate that 
recruitment of BTG2 and TOB1 to mRNA leads to reduced protein levels and 
mRNA degradation. Furthermore, we show that the regulation of mRNA 
abundance and protein levels is dependent on Caf1a (CNOT7)/Caf1b 
(CNOT8), but does not appear to require other Ccr4-Not components, 
including the Ccr4a (CNOT6)/Ccr4b (CNOT6L) deadenylases, or the non-
catalytic subunits CNOT1 or CNOT3. 
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1. Introduction 
1.1 Eukaryotic transcription and nuclear RNA processing 
1.1.1 Eukaryotic Transcription 
The survival and development of multi-cellular organisms is directly linked 
to the rigorous control of gene expression. Any loss of this control can lead to 
disease, cancer and cell death. Transcription is the first step in gene 
expression and one of the most tightly regulated. It is the process by which 
the DNA sequence of a gene is copied into a complementary messenger RNA 
strand. Genomic DNA is organised into chromatin where the DNA strand is 
wrapped around histone proteins, which in turn are packaged into fibres. 
Chromatin acts to protect DNA from damage, reduce its volume and functions 
to control gene expression by altering the availability of DNA to transcription 
factors and RNA polymerases. A geneǯs complementary mRNA strand, 
produced by transcription, is mobile and also less structured than genomic 
DNA, making it a preferred template for protein synthesis. In eukaryotes, 
transcription can be divided into three major steps: initiation Ȃ the 
recruitment of RNA polymerase to the DNA; elongation Ȃ the extension of the 
mRNA molecule; and termination Ȃ the removal of the RNA polymerase 
enzyme and release of the nascent mRNA.  
There are five types of RNA polymerase enzymes present in eukaryotic cells 
and they all transcribe different sub-sets of genes. All protein coding genes 
are transcribed by RNA polymerase II (RNAPII) (along with most micro 
RNAs) making it the most studied of the RNA polymerase enzymes. RNAPII is 
unable to initiate transcription alone as it cannot directly recognise DNA 
binding motifs, it therefore requires the presence of transcription factors and 
other protein co-factors to localise it to DNA (Juven-Gershon et al., 2008). To 
this end, genes are flanked by a series of regulatory elements that denote the 
start site, end point and regulate the level and timing of the transcription. For 
transcription initiation to begin a transcription complex must be formed on 
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the promoter of the target gene. Promoter regions are a complex series of 
regulatory DNA sequences that can be located close to, or some distance 
away from, an ATG start codon. The region to which RNAPII is recruited is 
called the core promoter and is normally located close to the transcriptional 
start site (Juven-Gershon and Kadonaga, 2010). Core promoters are not 
formed from a generic sequence but display wide diversity in terms of 
structure and function.  
There are two main types of core promoter in eukaryotes: focused and 
dispersed. In focused promoter initiation, transcription begins within a 
narrow region of nucleotides which usually contains just one transcriptional 
start site (Juven-Gershon et al., 2008). This type of promoter is commonly 
found on tightly regulated genes allowing greater accuracy of gene 
expression levels. The second type of initiation is dispersed; here promoters 
contain multiple weak start sites over a broad region of 50 to 100 
nucleotides. Dispersed initiation is more common in complex organisms like 
vertebrates where around two thirds of all genes are regulated by diverse 
promoters (Juven-Gershon et al., 2008). These promoters are also found to 
control more constitutively expressed genes that do not require tight 
regulation of gene expression (Juven-Gershon and Kadonaga, 2010). It is 
because of the biological significance of tightly regulated genes that focused 
promoters have been most highly studied and shown to contain a 
combination of conserved sequence motifs. These motifs bind a number of 
different transcription factors that in combination recruit RNAPII. They are 
called the basal transcription factors and include TFIIA, TFIIB, TFIID, TFIIR, 
TFIIF and TFIIH (transcription factor for RNA polymerase II). TFIID is the key 
basal transcription factor and able to bind to several different promoter 
elements including the TATA box, the initiator and the downstream promoter 
elements (DPE). It is a multi-subunit complex comprising of the TATA box 
binding protein (TBP) and several association factors (Figure 1.1) (Thomas 
and Chiang, 2006).  
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Figure 1.1 Schematic representation of a eukaryotic core promoter.  Typical 
mammalian genes are regulated by sequence elements located up and down stream 
of the transcription initiation site (Inr). The down stream promoter element (DPE) 
work in conjunction with the Inr sequence to recruit the TFIID complex and RNA Pol 
II to the start codon. The distance between the Inr and DPE is highly regulated at 28-
32 nucleotides. The TATA box promoter sequence is bound by the TATA box binding 
protein (TBP) which forms part of the TFIID complex and is flanked by B 
recognition element (BRE elements) located with upstream or downstream 
of the TATA box, which recruit further proteins that can promote or inhibit 
transcription initiation.   
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Before elongation can begin the Negative Elongation Factor (NELF) must be 
released from RNAPII. This is driven by the phosphorylation of the C-
terminal domain of RNAPII, causing a mass exchange of protein factors and 
the release of the polymerase from the promoter (Buratowski, 2009; 
Kostrewa et al., 2009). This frees the polymerase to progress along the DNA, 
synthesising the mRNA. This newly formed mRNA is unstable and by the time   ?ǯ   left the RNAPII enzyme it is modified and given a 7-methyl-
guanosine cap (m7G). Along with stabilisation the cap is also responsible for 
nuclear transport, mRNA processing and translation. This early elongation is 
subject to pauses and stalling during synthesis of the first 50 nucleotides 
until the elongation complex has undergone the necessary conformational 
changes (Nechaev and Adelman, 2011). The recruitment of the Positive 
Transcription Elongation Factor b (P-TEFb) drives the phosphorylation of 
RNAPII from primarily Ser-5 to Ser-2, which encourages elongation and 
termination factor binding to promote mRNA extension (Peterlin and Price, 
2006).  
 
1.1.2 mRNA processing and termination of transcription 
The mRNA molecule produced by RNAPII is known as the pre-mRNA and 
contains protein coding exons and non-coding introns. The pre-mRNA 
undergoes three primary modifications to convert it to a mature mRNA: the     ?ǯ 7-methyl-guanosine cap (m7G), intron removal and 
polyadenylation. The m7G cap is added to the mRNA during transcription 
elongation as the newly formed mRNA exits the nucleus. A guanylyl  ?ǯ ?ǯtriphosphate bridge attaching a guanidine residue    ?ǯ    Ǥ This guanidine residue is then methylated at 
position seven by a methyltransferase to form the  ?ǯ cap that stabilises the 
mRNA. The cap structure is required for efficient nuclear export of the mRNA, 
translation initiation and to prevent mRNA degradation via exonucleases.  
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Introns are removed during splicing to leave the protein coding exon 
sequence. The process of alternative splicing is unique to eukaryotes and 
involves connecting the exons of a gene in multiple different ways to 
produced alternative mRNA transcripts (Johnson et al., 2003; Johnson and 
Vilardell, 2012). This process increases the number of proteins that can be 
coded for in one mRNA molecule. The splicing reaction is catalysed by the 
spliceosome, a multi-subunit complex of proteins and small nuclear RNA 
(snRNA) molecules (McManus and Graveley, 2011).  
The final step to produce a mature mRNA is the addition of a  ?ǯ poly 
adenosine tail. This step signals the end of transcription and stimulates the 
release of the mature mRNA. The poly(A) tail is the key element responsible 
for mRNA half-life and stability. It has been widely published that mRNA 
molecules with longer poly(A) tails are more stable with increased half-lives. 
In fact,  ?ǯconfined 
to the nucleus and quickly degraded (Colgan and Manley, 1997; Eckmann et 
al., 2011; Mandel et al., 2008; Proudfoot, 2012). The polyadenylation site is 
defined by three conserved primary sequence elements and regulated by two 
auxiliary sequence elements (Mandel et al., 2008; Millevoi and Vagner, 2010), 
each of which associate with a complex of proteins forming   ?ǯ end 
processing machinery (Figure 1.2). This complex include: cleavage and 
polyadenylation specificity factor (CPSF), cleavage stimulation factor (CstF), 
cleavage factor I (CFIm), and cleavage factor II (Mandel et al., 2006). The 
polyadenylation signal (PAS) was the first identified sequence element      ?ǯǤ This sequence is an AAUAAA 
hexamer located upstream of the pre-mRNA cleavage site and is recognised 
by the CPSF complex (Mandel et al., 2008; Proudfoot, 2012).  Point mutations 
within the PAS sequence significantly reduce the levels of polyadenylation 
and can lead to misregulation of gene expression and disease.  
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Figure: 1.2 Mammalian pre-  ?ǯ  . Schematic of 
the pre-mRNA 3ǯǤ
specificity factor (CPSF) 160 recognises the polyadenylation signal (PAS). Cleavage 
stimulation factor (CstF) 64 recognises the downstream element (DSE) (Mandel et 
al., 2008). 
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The PAS signal is recognised by an RNA binding protein, CPSF-160, the 
largest component of the CPSF complex and the most well studied. CPSF-160 
has also been shown to interact with TFIID a member of the basal 
transcription factor machinery indicating it may play a role in transcription 
rates and termination (Proudfoot, 2004). The CPSF complex also binds 
directly to the pre-mRNA cleavage site via the CPSF-73 subunit Ȃ a suspected 
zinc dependant nuclease (Mandel et al., 2008). The optimal cleavage site is 
generally a CA sequence with cleavage taking place after the adenosine 
residue (Mandel et al., 2006). Located downstream of the cleavage site is the 
U/GU-rich region that is recognised by the CstF protein complex, in particular 
CstF-64 (Takagaki and Manley, 1998; Takagaki et al., 1996). Eventual 
termination of transcription occurs though the    ?ǯ 
processing factors, PAP and termination factors onto the nascent mRNA. 
Evidence indicates that poly(A) site cleavage can occur while RNAPII is still 
bound to the mRNA with factors in the elongation complex affecting 
termination. The release of RNAPII is encouraged though exonuclease 
degradation downstream of the PAS signal by XRN2 (West et al., 2008).     
 
1.1.6 NuclearȂcytoplasmic mRNA transport 
The three primary modifications required to form a mature mRNA (5ǯ
capping, splicing and polyadenylation) impact on mRNA nuclear export. Each 
processing step acts to recruit protein factors that build the nuclear export 
complex (NEC), without which nuclear export is severely inhibited. Studies in 
Xenopus oocytes demonstrated that uncapped mRNA was poorly exported or 
not exported to the cytoplasm because it was no longer able to bind the cap 
binding complex (Cheng et al., 2006). During splicing the exon junction        ?ǯ     -
export complex (TREX) (Cheng et al., 2006; Masuda et al., 2005). This 
conserved complex consists of the THO complex along with numerous export 
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factors including, ALY and a DEAD-box RNA helicase called UAP56 (Table 
1.1) (Carmody and Wente, 2009).  
Most mRNA is exported from the nucleus via a non-karyopherin mechanism 
involving a heterodimer of Nxf1 (metazoan; also known as TAP; Mex67 in S. 
cerevisiae) and Nxt1 (metazoan; also known as p15; Mtr2 in S. cerevisiae). 
The binding of the Nxf1-Nxt1 dimer requires a series of recruitment steps to 
build up the NEC on the mRNA. Firstly the DEAD box RNA helicase UAP56, in 
an ATP bound state, recruits ALY; hydrolysis of the ATP transfers the mRNA 
to ALY and releases UAP56 (Taniguchi and Ohno, 2008). ALY is then able to 
recruit Nxf1-Nxt1 before being released resulting in a messenger 
ribonuclearprotein (mRNP) bound to export receptors (Hautbergue et al., 
2008). Not all mRNAs are exported via this mechanism. There are a small 
subset that use a karyopherin receptor mechanism. The karyopherin Crm1 
(Xpo1 in S. cerevisiae) can mediate the export of unspliced, partially spliced 
and some viral mRNAs. Crm1 cannot bind directly to mRNA but requires 
adaptor proteins which are often mRNA specific (Cullen, 2003).  
Both karyopherin and non-karyopherin mechanisms for nuclear export 
require the mRNP to dock with FG-Nups proteins that are found on the 
neucleoplasmic face of the nuclear pore complex (NPC). It is thought that the 
mRNP passes through the pore by a means of facilitated diffusion before 
entering into the cytoplasm (Weis, 2007). For Crm1 transported mRNAs this 
is achieved through the hydrolysis of RanGTP. For the majority of mRNAs 
transported via the Nxf1-Nxt1 pathway, release is driven by two export 
factors Dbp5 and Gle1 and further requires inositol hexakisphosphate (IP6) 
(Cole and Scarcelli, 2006). Dbp5 is an RNA-dependent ATPase of the DEAD-
box protein family, and binds to the NPC cytoplasmic face (Schmitt et al., 
1999; Tseng et al., 1998). Gle1 specifically binds to IP6 and docks to a 
neighbouring NPC protein hCG1 (Alcazar-Roman et al., 2006; Strahm et al., 
1999). IP6 bound Gle1 stimulates the ATPase activity of Dbp5 inducing a 
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conformational change in Dbp5 triggering the directional release of the 
mRNA to the cytoplasm (Carmody and Wente, 2009; Tran et al., 2007).  
 
Protien Function 
ALY 
CBC 
Crm1 
Dbp5 
EJC 
Gle1 
hCG1 
hnRNPs 
IP6 
Nup214 
Nup358 
Nxf1 
Nxt1 
THO complex 
 
TREX complex 
 
UAP56 
Member of TREX complex, recruites Nxf1-Nxft1 to mRNP  ?ǯ 
Karyopherin protein export recrptor 
DEAD-box protein, RNA-dependant ATPase that dock at the NPC 
Exon-junction complex, recruits THO complex 
Docks at NPC, binds IP6 and stimulates Dbp5 ATPase activity 
Cytoplasmic nucleoporin protein  
Hetergenousous nuclear ribonucleoprotein  
Inositol hexakisphosphate 
Cytoplasmic nucleoporin protein  
Cytoplasmic nucleoporin protein  
mRNA export receptor 
Forms heterodimer with Nxf1 
Protein complex involved in transcription  elongation comprising 
of: Tho2, Hpr1, Mft1 and Thp2 
Transcription export complex comprising of THO complex, 
UAP56 and ALY 
DEAD-box protein, recruits ALY to TREX complex 
Table 1.1 Factors involved in mRNA export (table adapted from Carmody and 
Wente., 2009)  
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 1.2 Regulation of translation  
Translation is as highly regulated as transcription and it has as great an effect 
on overall gene expression. The rate of translation, the numbers of ribosomes 
present on an mRNA and the stability of mRNA all impact on the physical 
amount of protein being produced from a gene. Furthermore, features within 
an mRNA can intrinsically alter its translational efficiency. 
The key driving force in translation is the ribosome, a complex of RNAs and 
proteins with peptidyl transferase activity. The ribosome is divided into two 
subunits: the 40S which positions the mRNA codons in place to be read by 
the 60S subunit which recruits tRNA and catalyses peptide bond formation. 
To prime the 40S ribosome subunit for attachment to mRNA it forms a 
complex with several elongation initiation factors including eIF1, eIF1A, eIF2, 
eIF3 and eIF5. Subsequently the mRNA is activated with the addition of eIF4F 
and eIF4B or eLF4H   ?ǯ7G cap structure, opening it up to 
ribosome binding (Gingras et al., 1999; Jackson et al., 2010; Sonenberg and 
Dever, 2003).  
The initiation of translation can be regulated by two distinct mechanisms, 
sequence-specific regulation involving RNA binding proteins or microRNA 
(miRNA) and more general regulation through eIF protein modifications. The 
best-characterised mechanism for eIF regulated translation is via the 
phosphorylation status of eIF2. In mammals there are four protein kinases 
capable of phosphorylating eIF2 at Ser-51 (Jackson et al., 2010). These 
kinases are all activated through forms of cellular stress such as amino acid 
starvation, misfolded proteins or the presence of double stranded RNA, 
possibly due to viral infection. eIF2 is essential for protein synthesis and 
forms a ternary complex with Met-tRNA and GTP. The protein holds intrinsic 
GTPase activity and upon codon binding between Met-tRNA and the mRNA, 
the GTP is hydrolysed through the recruitment of eIF5, releasing eIF2. In 
order for eIF2 to be recycled for the next round of translation its GDP must be 
replaced by fresh GTP with the help of eIF2B, a guanine nucleotide exchange 
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factor. When phosphorylated eIF2 sequesters eIF2B, the strong bond 
between the two proteins disrupts its activity thus preventing GTP 
recharging. This causes a global reduction in active eIF2 and consequently a 
general reduction in translation (Jackson et al., 2010; Jiang and Wek, 2005).   
There are many cases linking translation activation to the phosphorylation of 
several of the eIF factors including eIF1, 	 ?Ⱦǡ	 ?ɂǡ	 ?ǡ
eIF4G, eIF4B, eIF4H, eIF5 and eIF5B (Jackson et al., 2010). For example, 
increased levels of eIF4E phosphorylation have been linked to growth factor 
stimulation, mitogens and changes in hormone levels (Scheper and Proud, 
2002). The MAP-kinases Mnk1 and Mnk2 phosphorylate eIF4E and appear to 
increase its ability to form the cap binding complex (Scheper and Proud, 
2002). Conversely the dephosphorylation of eIF4E causes a decrease in 
translation but its physiological importance is still unresolved (Goodfellow 
and Roberts, 2008).  
The poly(A) tail of mRNA plays a key role in promoting translation. Upon 
arrival into the cytoplasm the poly(A) tail is bound by poly A binding protein 
(PABP) which stabilises the mRNA and facilitates translation (Gorgoni and 
Gray, 2004). PABP has far reaching roles in mRNA biogenesis, translation 
efficiency and mRNA stability. It can bind directl ?ǯ
eIF4G, circularising the mRNA and bringing it into the  Ǯclosed loopǯ 
configuration for translation (Jackson et al., 2010). Studies in Xenopus 
oocytes revealed that disrupting the interaction between PABP and eIF4G 
dramatically reduces the translation rates of polyadenylated mRNAs 
(Wakiyama et al., 2000). Currently there are three suggested mechanisms to 
explain how this interaction stimulates translation: promoting ribosome 
recycling, stimulating the recruitment to the 60S ribosome and increasing the 
affinity of eIF4F for the cap (Kahvejian et al., 2005). However, it is likely that 
stimulation of translation by PABP is caused by a combination of these 
factors and may vary depending upon the specific mRNA. 
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1.3 Cytoplasmic messenger RNA decay 
The abundance of messenger RNA in the cytoplasm is highly regulated and 
acts as an alternative method to transcription for regulating gene expression. 
The rate of mRNA degradation often changes in response to stimuli and 
provides cells with a rapid method of altering or fine-tuning gene expression. 
Secondly mRNA quality control can also target specific mRNA for degradation 
due to the presence of premature termination codons (PTC), lack of a 
termination codon or due to errors in RNA biogenesis (Garneau et al., 2007; 
Goldstrohm and Wickens, 2008; Morozov and Caddick, 2012; Wu and 
Brewer, 2012). In most cases the precursor to cytoplasmic mRNA 
degradation is the removal of the poly(A) tail by deadenylase enzymes. 
Furthermore, deadenylation is often the rate limiting step for mRNA decay 
and transcriptional silencing, making it an ideal control point to regulate 
protein production. To stimulate mRNA degradation the poly(A) tail must be 
reduced to 15-25 nucleotides in length by one of a combination of 
deadenylase enzymes, after which the mRNA is exposed to ribonucleases 
(Couttet et al., 1997; Decker and Parker, 1993; Muhlrad et al., 1994). There 
are three major classes of RNA-degrading enzymes: endonucleases that cut ǡ ?ǯ ?ǯ ?ǯ       ?ǯ (Houseley and Tollervey, 
2009). Along with these enzymes there are further RNA degradation  ?ǯdecapping enzymes, RNA helicases, RNA binding proteins 
and recruitment factors that work together to degrade the mRNA (Table 1.2) 
(Houseley and Tollervey, 2009). After deadenylation Lsm proteins (1-7) bind 
in a ring-     ?ǯ     d aid the decapping 
enzymes DCP1 and DCP2  ?ǯ7
Ǥ ?ǯ
the mRNA to degradation via the exoribonucelase XRN1 (Houseley and 
Tollervey, 2009; Wu and Brewer, 2012). Conversely, deadenylation exposes   ?ǯ      ǡ  -subunit complex with 
RNase activity, RNA binding and helicase properties (Figure 1.3) (Houseley et 
al., 2006).      
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Complex  Human names  Function  
Decapping 
factors 
DCP1A, DCP1B 
DCP2  
Lsm 1-7 
 
Pat1 
Member of DCP decapping complex 
Catalytic subunit of decapping complex 
Lsm RNA binding complex containg Lsm 
subunits 1 to 7 
Required for mRNA decapping 
Exoribonuclease 
enzymes  
XRN1 
Exosome 
    
   Rrp44 
   EXOSC10 
 ?ǯ 
Multi subunit exonuclease containing two 
enzymatic subunits: 
Exosome  ?ǯlytic exonuclease  ?ǯ 
Deadenylase 
enzymes 
 CNOT6 (Ccr4a) 
 
CNOT6L (Ccr4b) 
 
CCRN4L 
(Nocturnin) 
Angel (Ccr4d) 
Angel2 (Ccr4e) 
CNOT7 (Caf1a) 
 
CNOT8 (Caf1b) 
 
TOE1 (Caftz) 
PARN 
 
PAN2 
EEP-type deadenylases of the Ccr4-Not 
complex 
EEP-type deadenylases of the Ccr4-Not 
complex 
EEP-type deadenylases 
 
EEP-type deadenylases 
EEP-type deadenylases 
DEDD-type deadenylases of the Ccr4-Not 
complex 
DEDD-type deadenylases of the Ccr4-Not 
complex 
DEDD-type deadenylases 
DEDD-type deadenylases stimulated by 
cap binding  
DEDD-type deadenylases  that forms a 
dimeric complex with PAN3 
Helicase 
enxymes 
SUPV3L1, SKIV2L 
 
 
UPF1 
Cytoplasmic helicases, members of the 
exosome cofactors Ski complex. Involved 
in nonstop-mediated decay 
RNA-dependent helicase and ATPase 
involved in nonsense-mediated decay 
Table 1.2 Factors involved in cytoplasmic mRNA degradation 
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Figure 1.3 mRNA degradation pathways.  In the nucleus deadenylases trim the 
poly(A) tail.  In the cytoplasm deadenylases enzymes shorten the poly(A) tail.  The 
Pat1-LSM complex can interact with the poly(A) tail to recruit the Ccr4-Not complex 
and DCP1-DCP2. Removal of the poly(A) tails stimulates mRNA degradation via two 
pathways, mRNA decapping by DCP1/DCP2    ?ǯĺ  ?ǯ  
XRN1, or  ?ǯĺ  ?ǯome complex.    
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1.3.1 Diversity of deadenylase enzymes 
There are a wide range of deadenylases including ten different enzymes in 
humans. All deadenylases are magnesium-dependant exoribonucleases that 
hydrolyse     ?ǯ   ?ǯ Ǥ    
deadenylases demonstrated that they belong to one of two groups: the DEDD 
type or the exonuclease-endonuclease-phosphate (EEP) family. The 
classifications are based on the conserved catalytic domains. The DEDD-type 
nucleases contain Asp and Glu residues that co-ordinate Mg2+ ions across 
three exonuclease motifs (Zuo and Deutscher, 2001). The EPP-type 
deadenylases have conserved Asp and His residues in their nuclease domain 
(Dlakic, 2000). In humans the DEDD deadenylase include Caf1a (CNOT7), 
Caf1b (CNOT8), TOE1, Poly(A)-specific ribonuclease (PARN) and the PAN 
family (Table 1.2). The EEP-type nucleases use Asp and His residues to co-
ordinate Mg2+ ions. This group includes Ccr4a (CNOT6), Ccr4b (CNOT6L), 
ANGLE,  ?ǯȋ ?ǯȌǤ
enzymes exist in multiple forms in several species possibly due to genome 
duplication events, for example Caf1a (CNOT7) and Caf1b (CNOT8) in 
humans share 89% similar sequence identity. The advantage of having so 
many different deadenylases remains unclear. Do the different enzymes 
target different mRNAs, are they expressed under specific conditions or do 
they overlap to provide genetic security? The Drosophila Nocturnin enzyme is 
necessary during a narrow time window at late pupal stage for proper wing 
morphogenesis in adult flies. Knockdown of this gene leads to the well-
known curled wing phenotype (Gronke et al., 2009). This enzyme is widely 
expressed during the lifetime of the fly however strong transcript enrichment 
occurs in specific regions like the salivary glands and the ring gland during 
development. This deadenylase appears to regulate a specific gene and only 
in specific locations in Drosophila. The expression levels of Nocturnin are also 
modulated by the circadian clock in several species including Xenopus and 
mice where levels peak at night and are thought to regulate metabolism and 
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lipid trafficking (Douris et al., 2011). Together, this provides evidence that 
this deadenylase may regulate defined sets of genes. 
PDE12 is a human mitochondrial deadenylase for the phosphodiesterase 
family. It forms part of an antiviral defence mechanisms through its ability to  ?ǯ- ?ǯ (Kubota et al., 2004).  
The Pan deadenylases were first identified in yeast as DEDD type nucleases 
required to trim poly(A) tails to their required length of ~80 nucleotide in 
the nucleus. They do not play a role in deadenylation once the mRNA has 
entered the cytoplasm hence appear specific to nuclear RNA processing 
(Brown et al., 1996). In humans PAN2 conducts initial poly(A) tail shortening  Ⱦ-globin reporter constructs (Yamashita et al., 2005). Like many 
deadenylases PAN2 cannot bind directly to mRNA but must form a complex 
with PAN3 which in turn associates with PABP (Uchida et al., 2004). Recently 
the Pan complex has also been linked to miRNA-mediated gene silencing 
through interactions with AIN1 a protein capable of binding to Ago the 
structural backbone of the miRNA RISC complex. Whether the function here 
is to initiate poly(A) shortening as demonstrated in previous published 
works remains undetermined but it does demonstrate a role for this 
deadenylase in gene silencing (Kuzuoglu-Ozturk et al., 2012).   
PARN is a unique deadenylase in that its activity is enhanced in the presence  ?ǯǤ subunit is composed of 
three DEDD structural motifs. It is believed that PARN is recruited through 
AU-r    ǯ  ?ǯǤ nce bound it interferes with the 
eIF4E, eIF4G, and PABP interaction disrupting translation and initiating 
deadenylation (Gao et al., 2000). Conversely, mRNA stability factors like HuR 
proteins bind to the AU-rich element and prevent PARN binding to increase 
mRNA stability (Gao et al., 2001). The presence of PABP on the poly(A) tail 
inhibits the activity of PARN, the exact reason for this is unknown but it is 
suspected that it may simply prevent access of the deadenylase to its poly(A) 
substrate (Gao et al., 2000).  
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The Caf1a (CNOT7), Caf1b (CNOT8) DEDD-type and Ccr4a (CNOT6), Ccr4b 
(CNOT6L) EEP-type enzymes form part of a multi-subunit complex called the 
Ccr4-Not complex which is involved both in transcription and translational 
regulation. They were first identified as the predominant cytoplasmic 
deadenylases in yeast (Caf1 and Ccr4), where they regulate global poly(A) tail 
lengths and mRNA turnover of a wide variety of genes (Tucker et al., 2001). 
The enzymes form heterodimers conferring high levels of sequence similarity 
with Caf1a (CNOT7)/Caf1b (CNOT8) sharing 89% sequence similarity and 
Ccr4a (CNOT6)/ Ccr4b (CNOT6L) 88%. Caf1a (CNOT7) and Caf1b (CNOT8) 
bind directly to the Ccr4-Not complex but only one of these DEDDȂtype 
nucleases can be bound at any one time (Lau et al., 2009). These 
deadenylases are recruited to mRNA through a variety of different cofactors. 
In addition to their catalytic role, Caf1a (CNOT7)/Caf1b (CNOT8) also 
interact with the leucine-rich repeat domains of Ccr4a (CNOT6)/Ccr4b 
(CNOT6L), thereby associating them with the complex (Basquin et al., 2012; 
Clark et al., 2004). Like most deadenylases, Ccr4a (CNOT6) and Ccr4b 
(CNOT6L) do not contain RNA binding domains but require a variety of 
interaction partners to target them to specific mRNAs.  
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1.3.2 ARE-mediated mRNA decay  
Bioinformatic analysis indicated that between 5-8% of the transcriptome 
contains AREs (Halees et al., 2008). These are AU-rich elements 
predominantly found in  ?ǯ-lived mRNAs and act to modulate 
mRNA translation, stability and degradation (Wu and Brewer, 2012). ARE 
sequences are diverse but can be broadly grouped into three classifications 
(Chen and Shyu, 1995; Wilusz et al., 2001). Class I AREs contain 1-3 
interspersed copies of AUUUA pentamers surrounded by U-rich regions and 
are found in mRNAs for FOS and MYC. Class II AREs contain multiple 
overlapping copies of the AUUUA motif and are found in Tumour Necrosis 
FȽȋ	Ƚ). Finally, class III AREs contain U-rich sequences but lack the 
AUUUA motif present in class I and class II (Wu and Brewer, 2012). These 
different classes of AREs confer binding specificity for RNA binding proteins 
that often act as cofactors to recruit degradation and deadenylase enzymes. 
For example PABP can directly recruit the deadenylase enzymes Pan2-Pan3 
to stimulate deadenylation (Garneau et al., 2007). Furthermore, the anti-
proliferative protein TOB1 can function as a binding intermediate between 
PABP and the Ccr4-Not complex deadenylase Caf1a (CNOT7) (Ezzeddine et 
al., 2007). However RNA binding protein recruitment is not limited to 
deadenylases; many RNA binding proteins gather together a number of 
different mRNA processing factors to further increase the rate of 
degradation. For example the human protein Tristetraprolin (TTP) binds to 
AU-rich ele ?ǯ UTR regions and functions as a scaffold protein 
to recruit the decapping enzymes DCP1 and DCP2, the Ccr4-Not deadenylase 
Ccr4a (CNOT6) and the exoribonuclease XRN1 (Lykke-Andersen and Wagner, 
2005).  
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1.3.3 Nonsense-mediated mRNA decay (NMD) 
The NMD pathway is a surveillance system designed to detect premature 
termination codons (PTC) in mRNA and prevent them from being translated 
into truncated proteins. There are two proposed pathways for identifing PTC-
containing mRNA over normal mRNA. This first hypothesis suggests that the 
exon-exon junction complex (EJC) plays a key role in PTC identification. 
During the pioneering round of translation the EJC is displaced. However if 
the ribosome encounters a PTC upstream of the EJC, the ribosome stalls, the 
SURF complex (containing SMG1, UPF1 and eRFs) is recruited and the mRNA 
is targeted for NMD (Wen and Brogna, 2010; Wu and Brewer, 2012). Key 
components of NMD are the UPF genes (UPF1, UPF2 and UPF3) that form a 
trimeric complex with a prematurely terminating ribosome and the SMG 
phosphatidylinositol 3-kinase-related kinase proteins (Conti and Izaurralde, 
2005; Wu and Brewer, 2012). Phosphorylation of UPF1 by SMG1 increases its 
affinity for mRNA decay factors thereby recruiting decapping factors (DCP1-
DCP2), deadenylases, exoribonucleases (XRN1) and in some cases the 
exosome to stimulate mRNA degradation (Figure 1.4) (Brogna and Wen, 
2009; Eulalio et al., 2007; Wu and Brewer, 2012).  
A second hypothesis suggests the main regulator of NMD is the distance 
between the stop codon and the poly(A) tail of an mRNA. In this case an 
inability of PABPC1 to interact with the terminating ribosome or the EJC may 
signal for NMD, however debate still exists between the two models (Silva 
and Romao, 2009; Wen and Brogna, 2010; Wu and Brewer, 2012). 
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Figure 1.4 Nonsense-mediated decay (NMD). During pre-mRNA splicing the exon 
junction complex (EJC) is deposited 20-24nt upstream of an exon-exon junction. 
Upon export to the cytoplasm the cap-binding complex interacts with UPF1 during 
the pioneer round of translation. If the ribosome encounters a premature 
termination stop codon (PTC), CBC-UPF1 promotes SMG1-UPF1 formation and 
binding to eRF1-eRF3 to form the SURF complex. SMG1-UPF1 bind to UPF2-UPF3 in 
the EJC before SMG1 induces the phosphorylation of UPF1 and subsequent 
recruitment of decapping, deadenylation and endoribonuclease enzymes to degrade 
the mRNA (modified from Wu and Brewer 2012). 
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1.3.4 Nonstop-mediated mRNA decay (NSD) 
Messenger RNAs lacking a termination codon are unstable and subject to 
degradation (Frischmeyer et al., 2002; van Hoof et al., 2002; Wu and Brewer, 
2012). During translation of an mRNA lacking a stop codon the ribosome 
continues scanning bey ?ǯ
and poly(A) tail. When the ribosome reaches the end of the mRNA its 
unoccupied A-site is recognised and bound by the C-terminal domain of Ski7. 
Ski7 then forms a complex with Ski2, Ski3 and Ski8 which together recruit      ?ǯ Ȃ  ?ǯ  (van Hoof et al., 2002; Wu and 
Brewer, 2012). Furthermore the mRNA is subject to decapping via DCP1 and 
DCP2    ?ǯ Ȃ  ?ǯ by XRN1, however this process is 
noticeably less efficient than exosome degradation (Figure 1.5) (Frischmeyer 
et al., 2002).  
 
Figure 1.5 Nonstop-mediated decay (NSD). Upon translation of mRNAs lacking a ǡ ?ǯ UTR and stall in the poly(A) 
tail. PABP dissociates from the mRNA before binding of Ski7 onto the stalled 
ribosome to release it from the transcript. Ski7 then forms a complex with Ski2, Ski3   ?        ?ǯ-  ?ǯ  Ǥ
Furthermore, decapping via DCP1 and DCP2  ?ǯȂ  ?ǯ ? ?ǯȋ ? ? ? ?Ȍ. 
Chapter 1: Introduction 
 
23 
 
1.3.5 MicroRNA-mediated decay 
Micro-RNAs (miRNAs) are short (~21 nucleotides) non coding RNA 
molecules capable of altering protein expression through direct binding to a 
specific mRNA. Hundreds of miRNAs have been identified and bioinfomatic 
studies indicate they may each regulate numerous genes covering a large 
proportion of the transcriptome (Bushati and Cohen, 2007). Most miRNAs 
repress transcription through imperfectly base pairing to a target mRNA,      ?ǯ Ǥ      
translation and/or deadenylation and mRNA decay (Huntzinger and 
Izaurralde, 2011). The repression of gene expression by miRNAs is thought to 
take place by one of four methods: (1) co-translational protein degradation, 
(2) inhibition of translation initiation, (3) inhibition of translation elongation 
and (4) premature termination of translation (Eulalio et al., 2007). 
Translation may also be silenced by sequestering mRNA away to Processing 
bodies (P-bodies) where the mRNA can remain in an idle state before being 
released back into the cytoplasm for translation at a later point. During 
miRNA biogenesis the newly created single stranded miRNA incorporates 
into microRNA ribonucleoprotein (miRNP) known as the RNA induced 
silencing complex (miRISC) (Huntzinger and Izaurralde, 2011; Wu and 
Brewer, 2012). Ago proteins (of which there are four in humans) form the 
core of the miRISC complex and recruit an assortment of accessory factors 
including the RNA helicase Rck and the GW182 proteins (Eulalio et al., 
2008b; Hutvagner and Zamore, 2002; Jackson et al., 2010; Wu and Brewer, 
2012). The miRISC complex facilitates translational silencing and mRNA    Ǥ  ?  ǲǳ   
directly catalyse endoribonucleic cleavage if there is near-perfect 
complementarity between the mRNA and miRNA (Figure 1.6A). This   ?ǯ   ?ǯ   oducts which are degraded by XRN1 
and the exosome (Huntzinger and Izaurralde, 2011; Wu and Brewer, 2012). 
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Figure 1.6 MicroRNA-mediated mRNA decay. (A) Ago2 catalysed 
endoribonuclease degradation. Ago2 possesse Ǯǯ    
endoribonuclease activity when there is near perfect complementarity between the 
miRNA   Ǥ     ?ǯ   ?ǯ 
products which are targeted by XRN1 for degradation. (B) miRNA-mediated 
recruitment of the Ccr4-Not complex to mRNA. miRNA bound to Ago recruits 
GW182 through GW repeats in GW182 and in turn interacts with PABP via a PAM 
motif. GW182 recruits the Ccr4-Not complex through CNOT1. The Ccr4-Not complex 
contains two deadenylase enzymes, Caf1a (CNOT7) or Caf1b (CNOT8) that bind to 
CNOT1 and Ccr4a (CNOT6) or Ccr4b (CNOT6L) that bind via Caf1a (CNOT7)/Caf1b 
(CNOT8). These deadenylase enzymes degrade the poly(A) tail to reduce 
translational efficiency and stimulate mRNA degradation.  
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The second mode of mRNA degradation via miRNA binding is the recruitment 
of decapping and deadenylation enzymes. RNA tethering assays 
demonstrated that the miRISC component GW182 promotes deadenylation 
initially via Pan2-Pan3 before complete poly(A) tail removal via the Ccr-Not 
complex followed bu decapping via DCP1-DCP2 (Behm-Ansmant et al., 2006; 
Chekulaeva et al., 2011; Fabian et al., 2011; Pillai et al., 2004; Zipprich et al., 
2009). GW182 contains numerous distinct protein interaction domains 
including an N-terminal Ago binding domain and a C-terminal protein 
binding domain that interacts with CNOT1 of the Ccr4-Not complex  (Figure 
1.6B) (Behm-Ansmant et al., 2006; Chekulaeva et al., 2011; Eulalio et al., 
2008b; Fabian et al., 2011; Wu and Brewer, 2012) 
 
1.3.3 Degradation of mRNAs without a poly(A) tail  
Not all mRNAs possess a poly(A) tail. In the case of histone mRNAs,   ?ǯ
end is stabilised by a series of stem loop motifs that are bound by stem loop 
binding proteins (SLBP) (Dominski and Marzluff, 2007). Histone mRNA 
degradation is stimulated by the addition of uridine residues to the  ?ǯ ?ǯ(Mullen and Marzluff, 2008; Schmidt et al., 2011). 
To date, the extent of pyrimidine tagging of polyadenylated mRNAs in 
eukaryotes remains unclear, however tagging has been demonstrated in 
Aspergillius nidulans and Schizosaccharomyces pombe (Morozov et al., 2010a; 
Rissland and Norbury, 2009). Furthermore, poly(U) tagging has been shown 
to target mRNA for degradation by increasing the affinity of the Lsm-Pat1 
complex (Morozov and Caddick, 2012; Rissland and Norbury, 2009; Song and 
Kiledjian, 2007) and via the NMD pathway through interactions with Upf1 
(Isken and Maquat, 2008; Morozov and Caddick, 2012). 
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1.3.7 RNA processing bodies 
P-bodies are cytoplasmic foci that contain proteins involved in a diverse 
range of post-transcriptional mRNA processing. Factors required for 
deadenylation, degradation, NMD and miRNA-mediated gene silencing co-
localise with target mRNAs within dynamic centres termed P-bodies 
(Kulkarni et al., 2010). Upon arrival in the cytoplasm not all mRNAs are 
immediately translated. Some enter a silenced state before being transported 
to a desired location for activation. mRNAs are also subject to quality control 
and made available to regulatory proteins or miRNAs that alter their 
translation rates before eventually being degraded. P-bodies function as    ǯ ǡ    
proteins and RNAs to improve the efficiency of mRNA processing. The 
existence of P bodies was first hypothesised in 1997 when the 
exoribonuclease XRN1 showed punctuated cytoplasmic localisation in a 
mouse fibroblast cell line (Bashkirov et al., 1997). The significance of this 
discovery was only realised years later when the decapping enzyme DCP2 
and its co-factors also demonstrated the same granular staining pattern in 
mammalian and yeast cells (Sheth and Parker, 2003; van Dijk et al., 2002). 
Furthermore P bodies have also been found to contain the Lsm proteins, the 
decapping enhancer Pat1, RNA helicases like Rck and deadenylases such as 
Pan2-Pan3, Caf1 (CNOT7/8) and Ccr4 (CNOT6/6L). Interestingly, the 
exosome is one mRNA processing enzyme not found in P-bodies, suggesting 
that the two mRNA degradation pathways may occur in different cellular 
locations (Lebreton et al., 2008; Sheth and Parker, 2003).  
Interestingly the inhibition of the deadenylase CCR4 in S. cerevisiae causes 
the disappearance of P-bodies (Sheth and Parker, 2003). This result is 
replicated in mouse cells where the knockdown of the Caf1 deadenylases - or 
over expression of catalytically inactive Caf1 - prevents P-body formation 
(Zheng et al., 2008). Furthermore, disruption of Caf1 activity has been shown 
to prevent the formation and dynamic response of P-bodies to environmental 
stimuli in Aspergillus nidulans (Morozov et al., 2010b). Noticeably, blocking 
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the later stages of mRNA decay through XRN1 knockdown or blocking 
decapping increases P-body numbers, suggesting that P-body formation is 
dependent upon deadenylation (Sheth and Parker, 2003). This is further 
confirmed with the presence of deadenylation intermediates within P-bodies 
and the absence of PABP from P-bodies, inferring that mRNAs localised to a 
P-body have shorter poly(A) tails (Kedersha et al., 2005). One current model 
for P-body function is that mRNAs undergoing deadenylation actively move 
into P-bodies where they become trap  ?ǯ- ?ǯ 
degradation. However entering a P-body does not always signal the 
degradation of that mRNA, as there have been several documented accounts 
of mRNAs exiting P-bodies and re-entering translation (Kulkarni et al., 2010). 
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1.4 The Ccr4-Not complex  
1.4.1 Enzymatic properties of the Ccr4-Not complex 
The Ccr4-Not complex is a heterogeneous multi-subunit complex containing 
one DEDD-type deadenylase, either Caf1a (CNOT7) or Caf1b (CNOT8), and 
one EEP-type subunit, either Ccr4a (CNOT6) or Ccr4b (CNOT6L). In addition 
to the enzymatic subunits, the complex also contains several non-catalytic 
components including the scaffold protein CNOT1 (Figure 1.7).  
The Ccr4-Not complex is a global regulator of gene expression that is 
conserved from yeast to humans. It has the ability to affect both 
transcriptional regulation and mRNA turnover and has been shown to 
localise in both the nucleus and cytoplasm. First identified and most highly 
studied in yeast, the Ccr4-Not yeast protein complex consists of nine core 
subunits: CCR4, CAF1, CAF40, CAF130 and five NOT proteins (which exist in 
two complex formations: one of 1.9 MDa and another at 1.0 MDa in size) 
(Chen et al., 2001; Collart, 2003). 
Two enzymatic roles are associated with the Ccr4-Not complex: 
deadenylation and ubiquitination. The CNOT4 protein possesses an N-
terminal RING domain that can interact with the UbcH5b E2 enzymes and 
provide ubiquitin protein ligase activity (Albert et al., 2002). This enzyme is a 
permanent member of the yeast Ccr4-Not complex but has a transitory 
association in humans (Jeske et al., 2006; Lau et al., 2009). CNOT4 also 
contains an RRM motif which provides putative RNA-binding activity. Given 
its association with the Ccr4-Not deadenylase complex, it is tempting to 
speculate that it will interact with oligo(A) residues, but this remains to be 
confirmed. The deadenylase activity is conferred by Ccr4 and Caf1 in yeast 
and its human homologs Ccr4a (CNOT6) and Ccr4b (CNOT6L), Caf1a 
(CNOT7) and Caf1b (CNOT8) (Collart and Panasenko, 2012; Dupressoir et al., 
2001). One Ccr4-Not subunit capable of binding directly to nucleic acids is 
RQCD-1, a dimeric protein containing six armadillo-repeat like structures 
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that form the nucleic acid binding cleft. Surprisingly this protein 
discriminates against poly(A) sequences, preferring poly(G), poly(C) or 
poly(T), suggesting it may not be involved in mRNA degradation (Garces et 
al., 2007). There remains insufficient evidence linking direct binding of Ccr4-
Not components to mRNA, however a convincing model is emerging which 
demonstrates that RNA-binding co-factors act to target the Ccr4-Not 
deadenylase to mRNA (Ezzeddine et al., 2007; Ezzeddine et al., 2012; 
Funakoshi et al., 2007; Hosoda et al., 2011; Mauxion et al., 2008; Sandler et al., 
2011).   
Despite the crystallisation of several individual Ccr4-Not members, the 
overall structure of the complex remains a mystery. Recent electron 
microscopy data has begun to shed light on the global shape of the complex. 
Crosslinking, followed by purification of the yeast scaffold protein Not1 
(homologue of human CNOT1), produced an L shaped complex with two 
arms of similar length (Basquin et al., 2012; Nasertorabi et al., 2011). The 
largest subunit, NOT1, contains HEAT-repeat organisation  (rod-like helical 
structures) with MIF4G related regions reminiscent of other scaffold proteins 
related to mRNA metabolism (Basquin et al., 2012). Yeast two-hybrid and 
pull down assays demonstrated that most factors associate with the C-
terminal domain of Not1/CNOT1, with Caf1a (CNOT7) or Caf1b (CNOT8) 
bound into the centre (Basquin et al., 2012; Lau et al., 2009). The current 
model suggests binding availability of the Not1 N-terminal for regulatory 
factors and rationalises how cross-talk may occur between the deadenylases 
and other Not proteins (Basquin et al., 2012; Lau et al., 2009). However the 
protein composition of the Ccr4-Not complex may shift and alter depending 
upon cellular factors like localisation, the cell cycle, or through stimulation of 
signalling molecules. This heterogeneity explains why there is little 
confirmed structural data available (Collart and Panasenko, 2012).  
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Figure 1.7 Schematic representation of the Ccr4-Not complex.  CNOT1 scaffold 
protein in purple, core components in grey, interchangeable components in blue 
(deadenylases) and green (E3 ligase). Based on Lau et al., 2009. 
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1.4.2 The role of the Ccr4-Not complex in mRNA decay 
Following decapping and deadenylation, both ends on an mRNA are exposed 
and subject to exonucleolytic degradation. The exoribonuclease Xrn1 acts in a  ?ǯ ?ǯd in P body-like struc ?ǯ to  ?ǯ
degradation occurs via the exosome (Parker and Song, 2004). In both cases 
the event that stimulates mRNA degradation is the removal of the poly(A) 
tail. 
The Ccr4-Not deadenylases show specificity for poly(A) substrates and their 
catalytic activity in vitro is independent of other Ccr4-Not components 
(Bianchin et al., 2005; Chen et al., 2002). Humans possess four Ccr4-Not 
deadenylases grouped into two pairs based on their catalytic site: the DEDD 
type Caf1a (CNOT7) and Caf1b (CNOT8) and the EEP type Ccr4a (CNOT6) and 
Ccr4b (CNOT6L) (Figure 1.8). A human Ccr4-Not complex can only contain 
two deadenylase enzymes, one from each sub-family (Lau et al., 2009). Using 
siRNA-mediated knockdown approaches in combination with genome-wide 
expression profiling, it is evident that the Caf1a (CNOT7) and Caf1b (CNOT8) 
regulate largely identical gene sets (Aslam et al., 2009). The same 
observation was made for Ccr4a (CNOT6) and Ccr4b (CNOT6L), which also 
regulate the mRNA abundance of identical gene sets (Aslam et al., 2009). 
Intriguingly upon comparison Caf1a (CNOT7)/Caf1b (CNOT8) and Ccr4a 
(CNOT6)/Ccr4b (CNOT6L) appear to regulate the expression of distinct 
groups of mRNA with little overlap (Aslam et al., 2009). Thus, despite the fact 
that both enzymes have similar substrate specificity and reside in the same 
protein complex, they appear not to cooperate in regulating the same mRNAs. 
This is particularly intriguing because Ccr4a (CNOT6)/Ccr4b (CNOT6L) bind 
to the Ccr4-Not complex via Caf1a (CNOT7)/Caf1b (CNOT8). The mechanism 
through which the two deadenylase types specifically target different 
mRNAs, despite spatially being in close proximity, is an interesting question 
yet to be answered. 
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Several members of the Ccr4-Not complex are required for effective cell 
proliferation including CNOT1, CNOT3, Caf1a (CNOT7)/Caf1b (CNOT8) and 
Ccr4a (CNOT6)/Ccr4b (CNOT6L) but a role in survival and senescence 
appears to be specific to Ccr4a (CNOT6)/Ccr4b (CNOT6L) (Mittal et al., 2011; 
Morita et al., 2007). P-body numbers and their constituent components also 
appear to be affected by the Ccr4-Not deadenylases. The knockdown of Caf1a 
(CNOT7)/Caf1b (CNOT8) leads to the reduction of P bodies containing RCK, 
DCP1a and eIF4E suggesting that deadenylation may stimulate P-body 
formation. The reduction in P-bodies is less pronounced with Ccr4a 
(CNOT6)/Ccr4b (CNOT6L) knockdown and interestingly foci containing 
eIF4E actually increases (Mittal et al., 2011). This suggests that Ccr4a 
(CNOT6)/Ccr4b (CNOT6L) may act at a different stage of the deadenylation 
process, causing the accumulation of alternate P-body components.  
 
 
 
Figure 1.8 Relationship between the Ccr4-Not deadenylases. The schematic 
representation of the Ccr4-Not deadenylases highlights conserved domains, DEDD 
endonuclease domain (red), EPP endonuclease domain (blue), LRR domains (green). 
Also indicated are the size of the proteins.      
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1.4.3 Regulation and recruitment of the Ccr4-Not complex 
As described above, the deadenylase activity of the Ccr4-Not complex does 
not degrade poly(A) tails indiscriminately. Thus, the Ccr4-Not complex is 
selectively targeted to specific mRNAs by the action of RNA-binding proteins, 
as well as components involved in microRNA-mediated repression (Doidge et 
al., 2012). 
 
1.4.3.1 Interactions with members of the BTG/TOB protein family 
The six BTG/TOB proteins (BTG1, BTG2, BTG3, BTG4, TOB1 and TOB2) 
display anti-proliferative activity and are identified through a conserved N-
terminal domain, which can bind to Caf1a (CNOT7)/Caf1b (CNOT8) 
(Ikematsu et al., 1999; Prevot et al., 2001; Rouault et al., 1998; Yoshida et al., 
2001). The BTG/TOB proteins have divergent C-terminal domains, which 
allow them to mediate further protein-protein interactions. The C-terminal 
domain of TOB1 contains a PAM2 motif which mediates an interaction with 
the C-terminal domain of PABP. This interaction suggests a role for TOB1 as 
an adaptor protein that facilitates the recruitment of the Ccr4-Not complex to 
specific mRNAs (Figure 1.9A) (Ezzeddine et al., 2007; Funakoshi et al., 2007; 
Mauxion et al., 2008). By examining the crystal structures of the TOB1ȂCaf1a 
(CNOT7) complex and the related DEDD-type deadenylase PARN bound to 
RNA, it can be predicted that the N-terminal domain of TOB1 binds to Caf1a 
(CNOT7) away from its active site (Winkler, 2010). This suggests that the 
binding of TOB1 to Caf1a (CNOT7) does not affect the catalytic activity of 
Caf1a (CNOT7) further strengthening the hypothesis that the BTG/TOB 
proteins function as adaptor proteins that recruit Caf1a (CNOT7)/Caf1b 
(CNOT8) to mRNA.  
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Figure 1.9 Speculative models for the recruitment of the Ccr4-Not deadenylase 
complex. The Ccr4-Not complex may be recruited via (A) the BTG/TOB proteins, 
(B) sequence specific RNA binding proteins involved with PABP interactions, (C) 
factors involved with the miRNA machinery. 
 
 
Chapter 1: Introduction 
 
35 
 
1.4.3.2 Role of RNA-binding proteins   
The Ccr4-Not complex can be recruited to mRNA through interactions with 
RNA binding proteins, often mediated via the BTG/TOB proteins. 
Deadenylation can be stimulated through interaction with eukaryotic release 
factor eRF1-eRF3 mediated via their PAM2 motifs. Competitive interactions 
between the PAM2 motifs of eRF3, TOB1 and the deadenylase Pan3 with 
PABPC1 stimulate the activation of the Pan2-Pan3 and Ccr4-Not 
deadenylases (Fabian et al., 2011; Uchida et al., 2002). In addition to 
activating general mRNA degradation, the Ccr4-Not deadenylases and TOB1 
can stimulate more targeted sequence-specific mRNA degradation. 
Cytoplasmic Polyadenylation Element-Binding protein 3 (CPEB3) binds to 
the C-terminal domain of TOB1 (Hosoda et al., 2011). CPEB3 also binds 
directly to U-rich RNA sequences through two RRM domains located in the 
proteinǯs C-terminal (Hosoda et al., 2011). Recruitment of CPEB3 to the  ?ǯ 
UTR of mRNA results in deadenylation and mRNA turnover, which is 
dependent on both the presence of TOB1 and Caf1a (CNOT7)/Caf1b (CNOT8) 
(Figure 1.9B). This suggests that Caf1a (CNOT7)/Caf1b (CNOT8) are 
recruited to specific sequences of mRNA to stimulate their degradation 
mediated by RNA binding proteins and TOB1. 
Recruitment of the Ccr4-Not to mRNA is not entirely dependent upon 
accessory factors linking the complex to RNA binding proteins. The Ccr4-Not 
complex is directly recruited to Nanos2, an RNA binding protein that is 
required for the development of germ cells and male fertility (Suzuki et al., 
2010). The absence of Nanos2 leads to the accumulation of several Nano2 
target mRNAs suggesting that its interaction with the Ccr4-Not complex  
causes mRNA degradation (Suzuki et al., 2010). The Ccr4-Not scaffold protein 
CNOT1 can interact with TTP protein, which directly binds to AREs present in 
mRNA sequences. This interaction mediates the rapid deadenylation and 
decay of the mRNA utilising the Caf1a (CNOT7) and Caf1b (CNOT8) 
deadenylases (Sandler et al., 2011). Finally, cells lacking one copy of CNOT3 
show evidence of defects in the mRNA decay pathway suggesting that CNOT3 
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may play a role in recruiting the Ccr4-Not complex to mRNA (Morita et al., 
2011). Together this data indicates that Ccr4-Not subunits, other than the 
deadenylase enzymes, can function to recruit the complex to mRNA and 
stimulate its degradation.  
 
1.4.3.3 Relationships with microRNA-mediated gene repression  
The observation that miRNA binding can induce deadenylation which 
depends on the activity of the Ccr4-Not complex was originally made in cells 
from the fruit fly and is conserved in human cells (Chekulaeva et al., 2011).  
The Drosophila model indicated that GW182, a component of the RISC 
complex, recruits PABP, in turn recruiting the Ccr4-Not complex (Figure 
1.9C) (Eulalio et al., 2008b; Huntzinger and Izaurralde, 2011; Zekri et al., 
2009). The knockdown or overexpression of a dominant negative Caf1 
deadenylase inhibits miRNA dependant mRNA degradation suggesting that 
the Ccr4-Not complex plays a pivotal role in driving miRNA gene silencing 
(Behm-Ansmant et al., 2006; Eulalio et al., 2008a).  
Interestingly deadenylation induced by miRNAs involve both the Ccr4-Not as 
well as the Pan2-Pan3 complex. Recent publications show the recruitment of 
both complexes is mediated by the three GW182/TNRC6A-C paralogues, 
which interact with the Ago proteins through their N-terminal domain 
(Behm-Ansmant et al., 2006; Braun et al., 2011; Fabian et al., 2011; Fabian et 
al., 2009; Kuzuoglu-Ozturk et al., 2012; Zekri et al., 2009). The C-terminal 
domain of GW182/TNRC6s has the ability to induce translational repression  ?ǯR of mRNA. Through a series of 
W-motifs (comprising the amino acids G/S/T W or W G/S/T) the C-terminus 
of GW182 interacts with CNOT1. Recruitment of both the Ccr4-Not 
deadenylases as well as the Pan2-Pan3 deadenylase is dependent on these 
W-motifs (Chekulaeva et al., 2011; Fabian et al., 2011; Kuzuoglu-Ozturk et al., 
2012). Some debate still exisits as to whether PABP is required for effective 
mRNA degradation. Conflicting evidence shows that PABP is not required or 
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is an essential co-activator of miRNA-mediated deadenylation. However in 
the latter case PABP must be displaced from the mRNA before deadenylation 
can occur (Fabian et al., 2011). To date, the link between miRNA-mediated 
degradation and deadenylation via the Ccr4-Not complex has been 
demonstrated, however the involvement of both the Caf1-type and Ccr4-type 
deadenylases has yet to be established. 
 
1.4.4 Regulation of physiological processes and relevance for disease 
The Ccr4-Not deadenylases are ubiquitously expressed however evidence 
suggests that some subunits are particularly important for specific 
physiological processes (Chen et al., 2011). Through phenotypic analysis of 
Caf1a (CNOT7) knockout mice, a link was shown between this enzyme and 
the correct differentiation of male germ cells and in bone formation in adult 
mice (Washio-Oikawa et al., 2007; Washio-Oikawa et al., 2006). It would be 
expected that Caf1a (CNOT7)-/- mice appear normal due to the extensive 
redundancy it shares with Caf1b (CNOT8) (Aslam et al 2009). However Caf1a 
(CNOT7)-/- mice display defects in the early stages of male germ cell 
differentiation and exhibit a higher bone mass and bone density as compared 
to wild type mice (Washio-Oikawa et al., 2007). This increased bone density 
phenotype is shared with TOB1 null mice suggesting that the role Caf1a 
(CNOT7) is playing when regulating bone formation is mediated by 
interactions with TOB1.  
Further evidence suggests that Ccr4-Not components other than the 
deadenylases also possess specific physiological roles. CNOT3 knockout mice 
are not viable with loss of CNOT3 resulting in early embryonic death at the 
pre-implantation stage (Morita et al., 2011). Heterozygous CNOT3+/- mice 
display defects in cardiac function and develop cardiomyopathy. CNOT3+/- 
mice are protected against obesity and have a reduced fat content in 
adipocytes. Furthermore, it was identified that the deadenylase Ccr4b 
(CNOT6L) recruitment to specific genes was reduced in CNOT3+/- mice. This 
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correlated with the observation that several metabolic mRNAs were up-
regulated, poly(A) tails lengths increased and mRNA turnover reduced 
(Morita et al., 2011). Interestingly this demonstrates a possible link between 
CNOT3 and the recruitment of deadenylases to target mRNAs. Together these 
observations indicate that individual components of the Ccr4-Not complex 
have specific physiological roles in defined tissue or cell types and possess a 
significant impact on the progression of human disease.  
 
1.4.5 The Role of the Ccr4-Not complex in transcription 
The Ccr4-Not complex was first identified in yeast as a transcription factor 
through genetic selection experiments. There is no enzymatic connection 
between the Ccr4-Not complex and transcription but as demonstrated 
through protein interaction studies, the complex elicits an effect in the 
nucleus. The Ccr4-Not complex can bind to the general transcription 
machinery TFIID, TBP and TBP-association factors (Collart and Panasenko, 
2012) and the distribution of TFIID on promoters is in part regulated by the 
Ccr4-Not complex (Deluen et al 2002). Evidence indicates that the complex 
has a role in regulating histone modifications. For example in yeast Not2 
interacts with the histone acetyltransferase Gcn5 and the deubiqutination 
enzyme Ubp8 (Daniel and Grant, 2007). In humans CNOT2 can repress 
transcription by stimulating histone de-acetylation through recruiting 
HDAC3 to target genomic DNA (Jayne et al., 2006; Zwartjes et al., 2004). 
Furthermore CNOT1 can interact with nuclear receptors and is recruited to 
target promoters where it modulates transcription. Binding of CNOT1 to the 
ligand-binding domain of estrogen   ȋȽȌ  -
dependant and disruption of this interaction (i.e. through siRNA knockdown 
of  ?Ȍ      Ƚ   (Winkler et al., 
2006). In agreement with a role in transcription the human Ccr4-Not 
complex shuttles between the nucleus and cytoplasm, however some of its 
impact on transcription may be indirect. The Ccr4-Not complex plays such a 
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wide role in the polyadenylation status of many mRNAs that it may 
fundamentally alter the protein levels of transcription regulators, chromatic 
factors, proteome proteins and the exosome all leading to indirect changes in 
transcription (Collart and Panasenko, 2012). The majority of the Ccr4-Not 
complex appears to be located in the cellular cytoplasm suggesting that the 
main role of the complex is related to its deadenylase activity of cytoplasmic 
mRNA. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction 
 
40 
 
1.5 The BTG/TOB protein family 
1.5.1 Discovery of the BTG/TOB protein family 
The human BTG/TOB proteins form a small family of six proteins which 
share a conserved N-terminal domain and anti-proliferative activity 
(Matsuda et al., 2001; Tirone, 2001; Winkler, 2010). BTG2 was discovered 
first by two laboratories: as the immediate/early response gene PC3 in rat 
PC12 cells upon stimulation with nerve growth factor, and as TIS21 in mouse 
3T3 fibroblasts in response to treatment with 12-O-tetradecanoylphorbol-
13-acetate (TPA) (Bradbury et al., 1991; Fletcher et al., 1991; Zhang et al., 
2010). The identification of a new family of anti-proliferative genes was 
confirmed with the discovery of BTG1 (B-cell translocation gene 1), a gene 
involved in a chromosomal translocation associated with chronic 
lymphocytic leukemia (Bhattacharyya et al., 2006; Rouault et al., 1992). To 
add to this TOB1 was discovered as an interacting protein of the ErbB2 
tyrosine-kinase receptor (HER2) that affects cell proliferation (Matsuda et al., 
1996). The remaining three members BTG3 (ANA), BTG4 (PC3B) and TOB2 
were identified based on sequence homology of the conserved N-terminal 
domain.  The BTG/TOB family is unique to metazoans where most 
vertebrates contain all six BTG/TOB members, however only two isoforms 
are present in D.melangaster and just one in C.elegans (Jia and Meng, 2007; 
Tirone, 2001).  
 
1.5.2 Structure and defining characteristics  
The conserved N-terminal BTG domain encompasses 104-106 amino acids 
and contains two regions of particularly high-sequence conservation known 
as Box A and Box B. This conserved region functions as a protein-protein 
interaction domain and is unique to the BTG/TOB family (Matsuda et al., 
2001; Tirone, 2001). Through sequence alignments of the six members it is 
apparent that TOB1 and TOB2 are the most closely related followed by BTG1 
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and BTG2, with BTG3 and BTG4 more distantly related (Figure 1.10) 
(Winkler, 2010). Sequence alignments also demonstrate that the BTG/TOB C-
terminal regions are far more diverse. TOB1 and TOB2 possess the largest C-
terminal which contains a further protein interaction domain, the PAM motif, 
allowing it to bind with PABP (Ezzeddine et al., 2007; Funakoshi et al., 2007; 
Mauxion et al., 2008; Zhouravleva et al., 1995). BTG1 and BTG2 have the 
shortest C-terminal domain which contains a second conserved motif known 
as Box C, located adjacent to the BTG domain. This region is a protein-protein 
interaction domain and is required for BTG1 and BTG2 to interact with the 
protein methyltransferase PRMT1 (Lin et al., 1996).   
 
 
 
 
Figure 1.10 Schematic over view of the BTG/TOB family of proteins.  Diagram 
base on amino acid sequences.  BTG domain highlighted (blue), conserved PAM 
motif (light grey), Box C motif (dark grey) and LXXLL motif (black). Also shown is 
protein size (amino acids) and percentage of identical (similar) amino acids. 
Modified from Winkler, 2010. 
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The conserved N-terminal mediates the majority of the BTG/TOB protein 
interactions. In humans all members of the BTG/TOB family apart from BTG4 
have been shown, in experiments, to interact with Caf1a (CNOT7) and Caf1b 
(CNOT8). However due to the similarity of the BTG4 N-terminal region 
compared to the other BTG/TOB members, an interaction with Caf1a 
(CNOT7)/Caf1b (CNOT8) is expected (Ikematsu et al., 1999; Prevot et al., 
2001; Rouault et al., 1998; Yoshida et al., 2001). The BTG domain is highly 
structured as demonstrated through the crystal structures of BTG2 and 
TOB1, whereas the C-terminal region is unstructured and does not crystallise 
(Horiuchi et al., 2009; Yang et al., 2008). For BTG2 the approximate  ? ? ? ? ? ?% ?Ƚ- ?Ⱦ-strands forming 2 anti-parallel sheets (Figure 1.11) (Yang et 
al., 2008). Ⱦ-ȋȾ ?ȌǡȽȋȽ ?ȌȽ ?e connecting loop between them. Box B is formed of two 
anti-Ⱦ-ȋȾ ?Ⱦ ?ȌȾ ?. The third domain, Box 
C, found in BTG1 and BTG2, is located just beyond Box B and is composed of 
an extending C-terminal loop Ⱦ-sheet (Horiuchi et al., 2009; Yang et al., 
2008).  
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Figure 1.11 Structure of the BTG domain. Schematic representation of the crystal 
structure of BTG2 (PDB 3DJU). Indicated are the highly conserved Box regions: Box 
A (wheat), Box B (blue) and Box C (green).  
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1.5.3 BTG/TOB and mRNA turnover  
The ability of BTG/TOB proteins to interact with Caf1a (CNOT7)/Caf1b 
(CNOT8) and (in the case of TOB1/TOB2) PABP suggests a role in mRNA 
deadenylation and turnover. These molecular interfaces are located on 
different faces of the protein indicating that TOB1/TOB2 may be capable of 
interacting with more than one target at once. Through analysis of the 
available crystal structure of the TOB1ȂCaf1a (CNOT7) complex and BTG2, it 
is apparent that both Box A and Box B domains come into close proximity to 
Caf1a (CNOT7) and may be required for the interaction. Furthermore amino 
acid substitutions within these domains are capable of disrupting this 
interaction (Horiuchi et al., 2009; Yang et al., 2008). This structural data 
allows a predicated model of BTG/TOB binding to Caf1a (CNOT7)/Caf1b 
(CNOT8). This interaction is away from the deadenylase catalytic site and 
leaves the C-terminal domain of the BTG/TOB proteins available to associate 
with other possible RNA-binding proteins (Winkler, 2010). The effect 
BTG/TOB proteins have on mRNA turnover is still under debate. The binding 
of BTG2 to Caf1a (CNOT7)/Caf1b (CNOT8) causes suppression of 
deadenylase activity in vitro. However suppression of deadenylase activity is 
not seen when the interaction is disrupted by amino acid substitutions, 
suggesting the interaction somehow modulates catalytic activity (Yang et al., 
2008).  TOB1 has also been shown to repress the deadenylase activity of the 
Ccr4-Not complex primarily through Ccr4a (CNOT6L), again in vitro 
(Miyasaka et al., 2008). In contrast a purified N-terminal fragment of TOB1 
had no effect on the deadenylase activity of Caf1a (CNOT7) (Horiuchi et al., 
2009).  
In vivo transcriptional chase studies demonstrated TOB1 may act to increase 
mRNA deadenylation and co-localise to P-bodies, suggesting a role in mRNA 
turnover (Ezzeddine et al., 2007). Further in vitro evidence indicates that 
BTG2 may function as a general activator of mRNA decay in mammalian cells. 
C   ?ǯ UTR of a known BTG2 target gene into a reporter construct 
causes the mRNA half-life of that construct to significantly decrease, 
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indicating that BTG2 may affect mRNA stability. Interestingly in that study 
the half-life of the control reporter mRNA decreased by the same amount as 
the BTG target gene suggesting that BTG2 may function as a non-specific up-
regulator of mRNA decay (Mauxion et al., 2008).   
Evidence suggests that the anti-proliferative activity of the BTG/TOB 
proteins is mediated through their Caf1a (CNOT7)/Caf1b (CNOT8) 
interaction. Overexpression of TOB1 in COS-1 and HEK293 cells reduces cell 
proliferation. This inhibition of cell proliferation is relieved after the 
introduction of amino acid substitutions in Caf1a (CNOT7) that disrupt the 
TOB1-Caf1a (CNOT7) interaction (Horiuchi et al., 2009). Remarkably MCF-7 
breast cancer cells not expressing Caf1a (CNOT7) also show reduced 
proliferation rates, but this is independent of an interaction with BTG/TOB 
proteins (Aslam et al., 2009).  
 
1.5.4 BTG/TOB proteins as effectors in signalling pathways 
The BTG/TOB proteins target and are utilised in a variety of different 
signalling pathways to alter a cellǯs proliferation rate. In addition to their 
interactions with mRNA processing factors, BTG/TOB proteins are also 
capable of interacting with a number of transcription factors to modulate 
their ability to bind their cognate DNA sequence elements. Both BTG1 and 
BTG2 can interact with Hoxb9, a homeobox DNA-binding transcription factor, 
through their extreme N-terminus (Prevot et al., 2000). This interaction 
enhances the ability of Hoxb9 to bind to its consensus DNA sequence. Thus 
this may increase the transcription rates of Hoxb9 target genes, which may 
contribute to the anti-proliferative function of BTG1 and BTG2 (Prevot et al., 
2000; Tirone, 2001). 
BTG1 and BTG2 are also able to interact with Protein Arginine Methyl-
Transferase 1 (PRMT1), suggesting that BTG1/BTG2 could be involved in 
chromatin modifications (Lin et al., 1996). This interaction occurs within the 
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conserved BǡȾ-sheet located at the proteinǯs N-terminal. PRMT1 
methylates the arginine three residue of histone H4, which facilitates the 
subsequent acetylation of histone H4 tails by p300. The p300 gene is a 
transcriptional co-activator responsible for chromatin remodelling and plays 
an important role in cell proliferation and differentiation. BTG2 favours 
differentiation of HL-60 cells through the gene-specific modification of 
arginine methylation and acetylation of histone H4. The current hypothesis 
suggests that BTG2 is modulating the recruitment of PRMT1 after arginine 
methylate and thus affect transcription (Passeri et al., 2006). BTG1 also 
contributes to muscle differentiation and represses myoblast proliferation      ?ȽȀȾ    
transcription factors (Busson et al., 2005; Rodier et al., 1999).  
In MCF-7 cells (an estrogen receptor-expressing breast cancer cell line) BTG2 
expression can be regulated both positively and negatively through signalling 
via members of the nuclear receptor family of transcription factors. 
Treatment of MCF-7 cells with retinoic acid activates BTG2 expression 
through direct binding of the retinoic acid receptor (RAR/RXR) heterodimers 
to three retinoic acid response elements (RARE) in the BTG2 promoter 
region (Donato et al., 2007). This leads to a reduction in cell proliferation 
rates. Conversely cell proliferation rates increase when MCF-7 cells are 
treated with estrogen. Activation of  Ƚ   -repressor REA 
leads to the repression of BTG2 expression and drives cell proliferation 
(Frasor et al., 2003). One method through which BTG1 and BTG2 have been 
shown to reduce cell proliferation rates is by mediating changes in Cyclin D1 
expression. Upon retinoic acid treatment, the subsequent increase in 
expression of BTG2 leads to reduced Cyclin D1 transcription and decreased 
CDK4 activity (Donato et al., 2007; Guardavaccaro et al., 2000). Both Cyclin 
D1 and active CDK4 are required for cell cycle progression. BTG2 can also 
downregulate the expression of Cyclin D1, Cyclin E1 and reduce the 
phosphorylation of retinoblastoma (Rb) in response to oncogenic 
transformation. In embryonic mouse fibroblasts BTG2 plays a critical role in 
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suppressing transformation through oncogenic Ras by acting as a 
downstream effector of p53 (Boiko et al., 2006). BTG2 and BTG3 are direct 
transcriptional targets for p53, containing p53 binding motifs within their 
promoters and also play a role in the p53-mediated DNA damage response 
(Ou et al., 2007; Rouault et al., 1996). 
The C-terminal region of TOB1 mediates interactions with a number of Smad 
transcription factors, altering their ability to bind to DNA (Tzachanis et al., 
2001; Yoshida et al., 2000). TOB1 increases the binding affinity of Smad4 for 
its consensus DNA sequences and can enhance transcription of synthetic 
reporter constructs activated by Smad factors (Tzachanis et al., 2001). As a 
consequence TOB1 regulates the expression of Smad target genes, such as the 
cytokine IL-2 promoter in quiescent T-cells, which is negatively regulated by 
Smads. The inhibitory Smads like Smad6 and Smad7 demonstrate the 
strongest interaction with TOB1, however interactions with others Smads 
have been demonstrated (Yoshida et al., 2003a). 
A further example of gene regulation through alterations in transcription 
factor binding is demonstrated by BTG3 and its interaction with E2F1, a 
transcription factor important for S-phase entry and cell cycle progression. 
BTG3 binds E2F1 through its N-terminal Box A region, which, in this case, 
inhibits DNA binding of the E2F1, thereby reducing the overall transcription 
rate of E2F1-responsive promoters (Ou et al., 2007). The E2F1 transcription 
factor is important for S-phase entry and inhibiting its action supports the 
general consensus that BTG/TOB factors inhibit S-phase progression.  
Post-translation modifications such as phosphorylation and ubiquitination 
can alter the activity of BTG/TOB proteins. Several serine and threonine 
residues in the C-terminal domain of TOB1 are subject to phosphorylation by 
the Erk1 and Erk2 kinases (Maekawa et al., 2002; Matsuda et al., 1996; 
Suzuki et al., 2002; Suzuki et al., 2001). These kinases are part of the MAP 
signalling pathway which is activated in NIH3T3 cells upon growth factor 
stimulation. Phosphorylation of TOB1 causes its deactivation and a 
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subsequent increase in Cyclin D1 and CDK4 activity relieving TOB1ǯs 
repression on cell proliferation (Suzuki et al., 2002). The phosphorylation of 
BTG2 at Ser-147 and Ser149 also occurs via Erk1 and Ekr2 and induces 
binding of BTG2 to PIN-1, a peptidyl-prolyl cis/trans isomerases (Hong et al., 
2005). This interaction leads to cell death with increased mitochondrial 
depolarisation. The disregulation of PIN-1 has been connected to many 
disease states, in particular its up-regulation with tumorigenesis and cancer, 
however the physiological implications of the BTG2-PIN-1 interaction remain 
unclear (Brenkman et al., 2008; Ryo et al., 2002; Winkler, 2010) 
 
1.5.5 The role of BTG/TOB protein in cancer and tumourigenesis 
The BTG/TOB proteins have been identified as important factors in the 
prevention of cancer and tumourigenesis (Table 1.3). BTG2 is a direct 
transcriptional target for the tumour suppressor p53 and Ras-mediated 
transformation is impaired by TOB1 activity (Boiko et al., 2006; Suzuki et al., 
2002). Indeed upon stimulation by growth factors TOB1 is targeted for 
phosphorylation by the Ras signalling components Erk1 and Erk2, causing 
TOB1 to lose its anti-proliferative activity. TOB1 knockout mice develop 
spontaneous carcinogenesis at a higher frequency than wild-type mice 
(Yoshida et al., 2003a). This increase in tumour formation is accelerated with 
the combined removal of p53 suggesting that TOB1 works synergistically 
with p53 to prevent tumour formation (Yoshida et al., 2003a). Mice lacking 
BTG3 display a similar phenotype with an increased incidence of lung 
tumours (Yoneda et al., 2009). Conversely expression of BTG/TOB proteins 
can protect against tumour formation. When BTG2 is over expressed in a 
medulloblastoma transgenic mouse model, the appearance of this form of 
cancer is reduced (Farioli-Vecchioli et al., 2007). Furthermore induced 
expression of TOB1 inhibits tumour growth of intraperitoneal injected 
pancreatic cancer cells (Yanagie et al., 2009). 
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Direct involvement of BTG/TOB proteins in cancers has also been identified 
in human clinical cancer samples. BTG1 and BTG2 are frequently found to be 
mutated in non-Hodgkin lymphomas. Such mutations are seemingly present 
in a mutually exclusive manner compared to p53 mutations, suggesting a 
causative role as a component of the p53 pathway in this type of cancer 
(Morin RD, 2011; Waanders et al., 2012). Expression of BTG1 can be used as a 
biomarker to monitor remission of patients suffering from acute myeloid 
leukaemia because BTG1 expression is only detected in normal cells or cells 
from patients in complete remission (Cho et al., 2004; Rouault et al., 1992). It 
is frequently observed in lung and thyroid cancer samples that TOB1 is 
inactivated by phosphorylation or its expression is reduced (Ito et al., 2005; 
Yoshida et al., 2003a). In particular an increase in inactive phosphorylated 
TOB1 correlated to tumour grade in a panel of lung cancer samples (Iwanaga 
et al., 2003). Down-regulation and impaired expression of BTG2 is often seen 
in a variety of cancers including prostate cancer, breast cancer and clear 
renal cell carcinomas (Ficazzola et al., 2001; Kawakubo et al., 2006; 
Kawakubo et al., 2004; Struckmann et al., 2004). Interestingly a shift in 
subcellular localisation of BTG2 correlates with tumour grade where BTG2 
expression shifts from a nuclear localisation pattern to cytoplasmic 
(Kawakubo et al., 2006). This pattern of impaired expression in carcinomas is 
also seen for BTG3, the expression of which is reduced by promoter 
inactivation via DNA methylation (Majid et al., 2009). Together the evidence 
indicates that the inactivation or impaired expression of the BTG/TOB 
proteins contribute to carcinogenesis and tumour progression.  
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Gene  Cancer   Reference  
TOB1 
Lung  
Lung  
 
Lymph node  
Liver 
 
Breast 
 
Thyroid  
Pancreatic 
Spontaneous tumor formation§  
Decreased expression/increased 
phosphorylationȘ  
Spontaneous tumor formation§  
Spontaneous tumor formation§  
Reduced expression in human 
breast cancer cell lines  
Decreased mRNA expressionȘ  
Induced expression inhibits 
tumorigenesis in nude mice  
Yoshida et al., 2003a.  
Iwanaga et al., 2003  
 
Yoshida et al., 2003a 
Yoshida et al., 2003a  
Helms et al., 2009 
 
Ito et al., 2005  
Yanagie et al., 2009  
BTG1  
Leukemia  
 
Lymphoma  
Reduced/undetectable expression Ș  
Somatic mutationsȘ  
Cho et al., 2004 
Morin et al., 2011  
BTG2  
   
   
Breast  
 
 
Renal  
Prostate  
Brain 
 
 
Lymphoma  
Reduced expression and 
relocalization (nuclear to 
cytoplasm) Ș  
Reduced mRNA levelsȘ  
Low/undetectable mRNA levelsȘ  
Induced expression inhibits 
medulloblastomas (transgenic 
mice)  
Somatic mutations Ș  
Kawakubo et al., 2006  
 
 
Stuckman et al., 2004 
Ficazzola et al., 2001  
 
Farioli-Vecchiolo et 
al., 2007  
Morin et al., 2011  
BTG3  
   
Lung  
Lung  
 
Renal  
Increased lung tumor formation§  
Reduced expression in 
adenocarcinoma samples Ș  
Reduced mRNA expression Ș  
Yoneda et al., 2009  
Yoneda et al., 2009  
 
Majid et al., 2009 
 BTG4  Colon  Reduced mRNA expression Ș  Toyota et al., 2008  
Table 1.3 Relationship of BTG/TOB expression and cancer. § Observations made 
using mouse knock- Ǥ Ș      
samples and biopsies. To date, no changes in TOB2 expression are reported in 
human cancer samples.  
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 1.5.6 Role of BTG/TOB protein in bone morphology 
TOB1 and BTG2 are implicated in the signalling of TGF-family members 
through Smad transcription factors. Bone morphogenic protein (BMP), a 
member of the TGF-family, activates Smad transcription factors. This 
signalling is repressed in the presence of TOB1. In osteoblast cells TOB1 co-
localises with Smad 1, 5 and 8 transcription factors in nuclear bodies upon 
BMP2 stimulation causing a repression of the Smad target genes negatively 
regulating osteoblast proliferation and differentiation (Yoshida et al., 2000). 
Interestingly BTG2 appears to enhance Smad-regulated transcription in 
response to BMP signalling, which regulates vertebral patterning (Park et al., 
2004).    
The generation of mice containing null alleles of TOB1, TOB2, BTG2 and BTG3 
uncovered a role for these proteins in bone formation and resorption. Mice 
lacking TOB1 are apparently normal but display increased bone volume and 
bone density due to enhanced bone formation (Yoshida et al., 2003b). As 
described previously Caf1a (CNOT7) null mice also display a similar increase 
in bone density (Washio-Oikawa et al., 2007). Osteoclast parameters remain 
unchanged for both TOB1-/- and Caf1a (CNOT7)-/- mice suggesting that 
TOB1 may act through its interaction with Caf1a (CNOT7) when regulating 
bone formation. Surprisingly TOB2 null mice display the opposite phenotype 
with decreased bone mass due to an increased number of differentiated 
osteoclast cells (Ajima et al., 2008). Currently there is no evidence that TOB2 
regulates Smad transcription factors like other family members TOB1 and 
BTG2. TOB2 affects bone formation through an interaction with the vitamin D 
receptor to reduce the expression of RANKL, a vitamin D induced gene, which 
increases the number of differentiated osteoclast cells. 
Together this data demonstrates that the BTG/TOB proteins can regulate 
bone formation and are therefore required for more processes than simply 
the prevention of cancer through their anti-proliferative properties.     
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1.6 Study Aims 
The BTG/TOB proteins are known anti-proliferative proteins that have been 
shown to interact with a wide variety of different proteins. This study will 
aim to further investigate the interactions between BTG/TOB proteins and 
the Caf1a (CNOT7) and Caf1b (CNOT8) deadenylase subunits of the Ccr4-Not 
complex. In particular the work will focus on the interactions between the 
BTG/TOB proteins BTG2 and TOB1 and the Caf1a (CNOT7)/Caf1b (CNOT8) 
enzymes and the importance of these interactions for the anti-proliferative 
activities of the BTG/TOB proteins.  
To address these questions, essential amino acids located in BTG2 or TOB1 
required for the interaction with Caf1a (CNOT7) and Caf1b (CNOT8) will be 
identified, guided by multiple sequence alignments and structural 
information. These amino acids will be substituted using site-directed 
mutagenesis and screened to identify those that disrupt the BTG2/TOB1 - 
Caf1a (CNOT7)/Caf1b (CNOT8) interaction. Successful amino acid 
substitutions that disrupt the interactions will be used to investigate the role 
of the BTG/TOB Ȃ Caf1a (CNOT7)/Caf1b (CNOT8) interactions on cell 
proliferation of MCF-7 cells. Finally an RNA tethering approach will be used 
to correlate the anti-proliferative activities of BTG/TOB proteins to their 
roles in regulating deadenylation and mRNA abundance of a reporter mRNA.  
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1.7 Experimental approaches 
1.7.1 Yeast two-hybrid 
The budding yeast Saccharomyces cerevisiae is a powerful model used to 
study eukaryotic protein interactions. Due to the ease of transformation and 
quick doubling time the yeast two-hybrid assay can be used to quickly screen 
multiple protein interactions. Furthermore the transcriptional control and 
post-translation protein modifications of S.cerevisiae are well conserved in 
mammals. Together this makes S.cerevisiae a powerful and widely used tool 
for initial protein-protein interaction screening.   
This method takes advantage of the ability to separate the DNA binding 
domain (DBD) and transcriptional activation domain (AD) of transcription 
factors. The DBD can bind to DNA without activating transcription; the AD 
domain cannot bind to DNA and recruit RNA Pol II alone. Both the DBD and 
AD domains must be brought together onto the promoter to initiate 
transcription, normally of a reporter gene like Ⱦ-Galactosidase. These two 
fragments of the transcription factor are fused to two target proteins. If the 
target proteins interact they bring together the DBD and AD domain onto the Ⱦ-Galactosidase promoter and initiate transcription (Figure 1.12A). If the two 
target proteins do not interact or if that interaction has been disrupted by 
amino acid substitutions then transcription will be prevented because the AD 
domain will not be brought to the promoter (Figure 1.12A). The primary 
drawback to the yeast two-hybrid system is the high incidence of intrinsic 
transcriptional activation caused by the protein being tested. To that end all 
proteins must be tested individually to ensure they are not capable of 
stimulating Ⱦ-Galactosidase transcription alone. In this project the yeast two-
hybrid system will be used to screen amino acid substitutions that aim to 
disrupt the interaction between BTG2 and TOB1 with the deadenylases Caf1a 
(CNOT7) and Caf1b (CNOT8). Co-immuno precipitation assays performed in 
HEK293T cells were used to confirm that any interaction disruption was 
conserved in human cells.  
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Figure 1.12 Schematic representation of the experimental techniques used in 
this thesis. (A) Yeast two-hybrid. AD, Gal4 activation domain; BD, Gal4 DNA 
binding domain. When an interaction occurs between protein A and protein B, the 
Gal4-BD and Gal4-AD are brought in close proximity on the Ⱦ-Galactosidase 
promoter thereby inducing transcription (left panel). In the absence of an 
interaction, Ⱦ-Galactosidase transcription is not initiated (right panel). (B) EdU 
labelling of cells in S-phase. Mammalian cells are seeded onto glass cover slips and 
transfected with plasmid DNA or siRNA. After 48 h the thymidine analogue EdU is 
added to the cell media and is incorporated into newly synthesised DNA. The cells 
are fixed onto the cover slips and the incorporated EdU detected via coupling of 
Alexa Fluo  ? ? ?   Ǯǯ Ǥ       -phase are 
counted using a Zeiss LSM 510 Meta microscope and compared to total cells 
determine via a Hoechst staining. (C) RNA tethering assay. Upon expression of 
protein A fused to the ɉN peptide it will bind to the 5 BoxB motifs located in the     ?ǯ Ǥ          ?ǯ UTR that may affect mRNA translation or stability.  
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1.7.2 S-phase labelling assay to monitor cell proliferation 
In this study the effect of BTG/TOB expression on cell proliferation was 
assessed. In particular experiments were conducted to determine if the 
interaction between BTG/TOB proteins and Caf1a (CNOT7)/Caf1b (CNOT8) 
was required for their anti-proliferative effect. The BTG/TOB proteins are 
known anti-proliferative proteins and have been shown to target the G1 to S-
phase cell cycle check point (Donato et al., 2007; Guardavaccaro et al., 2000; 
Hata et al., 2007). To observe changes in mammalian cell proliferation rates 
the S-phase labelling assay was utilised, which monitors the number of cells 
in S phase. The assay labels newly synthesised DNA making it an accurate 
method of monitoring cell proliferation. Here a thymidine analogue EdU (5-
ethynyl-2´-deoxyuridine) is added to the cell media for a pre-determined 
time. Any cells entering S-phase during this period will incorporate EdU into 
their newly synthesised DNA (Figure 1.12B). The EdU detection occurs 
through a click reaction between an azide and alkyne, catalysed by copper. 
The EdU contains the alkyne which is detected upon addition of an Alexa 
Fluor dye containing azide. This Alexa Fluor dye causes all cells in S-phase to 
fluoresce green under fluorescent microscopy. The assay is based on the 
standard BrdU (bromo-deoxyuridine) thymidine analogue but holds some 
advantages. BrdU requires the DNA to be denatured before antibody 
detection, the azide used to detect EdU is small and can access the DNA 
without the need for it to be denatured. This means milder conditions can be 
used for EdU detection and the process is quicker and more accurate.  
To determine the numbers of cells in S-phase, cells are fixed onto glass cover 
slips, EdU is detected and cells are counter stained with Hoechst that binds 
indiscriminately to DNA. Using fluorescent microscopy the number of cells in 
S phase are counted, followed by the total number of cells visualised by the 
Hoechst stain (Figure 1.12B). This allows for the percentage of cells in S-
phase to be counted for any particular sample.        
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1.7.3 RNA tethering reporter assay 
TOB1 and TOB2 contain PAM2 motifs that allow them to bind to PABP. This 
suggests that TOB1/TOB2 may be present in the complex of proteins that 
bind to an mRNA poly(A) tail (Ezzeddine et al., 2007). This poses the 
question: can the BTG/TOB proteins recruit the deadenylases Caf1a (CNOT7) 
and Caf1b (CNOT8) to an mRNA and stimulate poly(A) tail removal and 
mRNA decay? To study this a modified luciferase reporter experiment was 
conducted using plasmids donated by Prof N Gehring (Gehring et al., 2008). 
The assay utilises the RNA binding properties of the bacteriophage lambda-
antiterminator protein N (lambda N-peptide). This 22 amino acid peptide is 
fused to a target protein of interest (here the BTG/TOB proteins) allowing it 
to bind to specific RNA motifs. A renillia luciferase plasmid was modified to 
include the corresponding RNA motifs in it  ?ǯ UTR. These Box B sequences 
form hairpin loop structures that bind to the lambda N-peptide and therefore 
cause the target protein to be tethered to the luciferase  ?ǯ UTR (Figure 
1.12C). This reporter system can be used to monitor changes in translation 
and mRNA stability in response to the presence of BTG/TOB proteins bound 
to mRNA.  
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2. Materials and Methods 
2.1 Bacterial growth and transformation 
2.1.1 Reagents, stock solutions and buffers for use in bacterial methods: 
Luria-Bertoni (LB) media and agar: 10g/L tryptone, 5g/L yeast extract, 5g/L 
NaCl, pH 7.2 (NaOH), for LB agar include 15g/L bacteriological agar. The 
medium was sterilised by heat using a Prestige medical 2100 classic bench-
top autoclave and stored at room temperature. 
Ampicillin 1000x stock solution: 100mg/ml in 50% ethanol/water. Sterilised 
by filtration (0.22 Pm pore size). Stored at -20°C 
Chloramphenicol 1000x stock solution: 34mg/ml in 100% ethanol. Sterilised 
by filtration (0.22 Pm pore size). Stored at -20°C 
Kanamycin 1000x stock solution: 50mg/ml in H2O. Sterilised by filtration 
(0.22 Pm pore size). Stored at -20°C 
TBF1 buffer: 100mM CaCl2, 100mM RbCl, 50mM MgCl2, 30mM KCl, 15% 
glycerol, pH 5.8 (0.2M glacial acetic acid). Sterilised by heat using a Prestige 
medical 2100 classic bench-top autoclave and stored at at 4°C 
TBF2 solution: 75mM CaCl2, 10mM RbCl, 10mM MOPS, 15% glycerol, pH 6.5 
(1M KOH). Sterilised by heat using a Prestige medical 2100 classic bench-top 
autoclave and stored at at 4°C 
1M IPTG:  Ⱦ-2-1-thiogalactopyranoside, in H2O. Sterilised by 
filtration (0.22 Pm pore size). Stored at -20°C 
X-Gal solution: a solution of 5-bromo-4-chloro-indolyl-Ⱦ-D-galactopyranoside 
(50mg/ml in dimethylformimide) was purchased from Promega. Stored at -
20°C 
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2.1.2 Culture of E. coli  ?Ƚ 
The bacterial strain E. coli  ?Ƚ was used for all DNA manipulations. To 
obtain single colonies the bacteria were streaked onto agar plates (containing 
the appropriate antibiotics) and grown at 37°C. Once colonies had formed the 
plates were stored at 4°C for up to several weeks. Liquid cultures were 
inoculated with single colonies and grown in into universal screw-cap tubes 
containing LB medium (with appropriate antibiotics) and incubated at 37°C, 
200rpm for 12-24 h. For larger cultures glass conical flakes were used.  
 
2.1.3 Preparation of E. coli competent cells 
E. coli  ?Ƚ       
chloride/calcium chloride. A single E. coli colony from an LB plate was used 
to inoculate 5ml of LB medium and grown overnight at 37°C, 200rpm. The 
following morning the culture was diluted 1:100 in LB medium and grown at 
37°C to an optical density (OD600) of 0.5. The culture was incubated on ice for 
10 min in pre-chilled 50ml falcon tubes, cells were then harvested by 
centrifugation at 1100g, 4°C for 10 min. Cell pellets were re-suspended gently 
with 20ml of ice cold TBF1 and centrifuged again at 1100g, 4°C for 10 min. 
Each cell pellet was then gently re-suspended in 2ml of ice cold TBF2, the cell 
suspensions were then combined and distributed into 200µl aliquots in 
microfuge tubes before being snap frozen in liquid nitrogen. Competent cells 
were stored at -80°C.  
 
2.1.4 Transformation of competent cells 
Between 50 and 100µl of competent cells were used for each transformation. 
When transforming plasmids, <500ng of DNA was used to give a good 
transformation yield, when transforming ligations or mutagenesis reactions, 
10µl of ligation reaction mix was used. Competent E. coli cells and DNA were 
mixed in pre-chilled round bottomed universal tubes and incubated on ice for 
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5-20 min. The transformation mix was heat shocked by incubation at 42°C for 
90 sec followed by incubation on ice for 2 min. One millilitre of LB medium 
(pre-warmed at 37°C) was added to the cells and they were incubated at 
37°C, 200rpm for 1 h. For plasmid transformation 100µl of the cell 
suspension was spread onto LB agar plates (containing the appropriate 
antibiotic). For ligations or mutagenesis transformations the cells suspension 
was centrifuged at 3000g for 2 min, 900µl of supernatant removed and the 
cells re-suspending in the remaining 100µl of LB. All the re-suspended cells 
were then spread onto LB agar plates (containing the appropriate antibiotic). 
For blue/white screening (for E. coli transformed with derivatives of the 
pBluescript II KS(+) cloning vector), the cells were plated along with 17µl of 
X-Gal (50mg/ml, Promega) and 4µl of 1M IPTG. 
 
 
2.2 Molecular biology 
2.2.1 Reagents, stock solutions and buffers for use in molecular biology 
methods: 
5x TBE: 40mM Tris base, 40mM boric acid, 1mM EDTA, pH 8.0, stored at 
room temperature 
6x Ficoll loading dye: 16% Ficoll, 0.2% orange G in H2O, stored at room 
temperature. 
TE Buffer: 10mM Tris-HCl pH 8.0, 1mM EDTA 
Oligonucleotides: Lyophilised primers were dissolved in TE to give a 100mM 
solution and stored at -20϶C. 
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2.2.2 Small scale plasmid DNA preparation 
Typically, Macherey-Nagel plasmid mini prep kits (Cat# 740588.250) were 
used for the small scale preparation of plasmid DNA. A single bacterial colony 
was picked and used to inoculate either 2ml (for small scale) or 5ml (for use 
in mammalian cell transient transfections and yeast transformations) of LB 
containing the appropriate antibiotic and grown overnight in an orbital 
shaker at 37°C, 200rpm. All of the overnight culture was pelleted by 
centrifugation in a microfuge tube at 4000g for 2 min. The plasmid DNA was ǯǡ
can be found in the Macherey-Nagel plasmid mini prep handbook. Small scale 
plasmid extractions were eluted in 50µl of elution buffer pre-warmed to 
70°C, or in 100µl of pre-warmed buffer when DNA was isolated from 5ml. All 
plasmid DNA was assessed using a Nanodrop ND-1000 spectrophotometer to 
check the concentration and purity before being stored at -20°C. 
 
2.2.3 Large scale plasmid DNA preparation 
For the production of large quantities of high quality plasmid DNA for 
transient mammalian transfections, the Sigma GenElute HP maxi prep kit was 
used. A single E. coli colony containing the desired plasmid was picked and 
used to inoculate 5ml of LB (containing the appropriate antibiotic), this 
culture was grown for 4-6h in an orbital shaker at 37°C, 200rpm. All 5ml of 
this culture was used to inoculate 200ml of LB containing the appropriate 
antibiotic and the culture grown overnight in an orbital shaker at 37°C, 
200rpm. The overnight culture was pelleted by centrifugation at 4000g for 
15min. The cell pellet was re-    ǯ
standard protocol. Typically, the plasmid DNA was eluted in 500µl of elution 
buffer and stored at -20°C. 
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2.2.4 Determination of DNA/RNA concentration 
All DNA was quantified by spectrophotomertry using a NanoDrop ND-1000 
UV-Vis Spectrophotometer (NanoDrop Technologies). The A260/A280 ratio 
values were calculated to estimate sample purity. A ratio between 1.8 and 2.0 
was deemed acceptable for DNA samples, while a ration between 2.0 and 2.2 
was expected for RNA. 
 
2.2.5 Agarose gel electrophoresis 
DNA was fractionated by size using 0.8%-2% agarose gels (w/v) as 
appropriate to the size of the DNA fragment being resolved. To the gels, 
0.5µg/ml of ethidium bromide was added. Agarose gels were made and run 
with 0.5x TBE buffer. DNA samples were loaded in a 1x Ficoll sample buffer. 
DNA gels were run at 80V for between 45 min and 2 h depending upon the 
sample being run. Following electrophoresis gels were visualised by 
transillumination with ultraviolet light and documented using either a Gel-
Doc 2000 (Bio-Rad) and BioRad Quantity One computer software or using a 
Fujifilm LAS-4000 imager reader and the accompanying computer software 
(Fujifilm, Japan).  
 
2.2.6 DNA extraction and purification from agarose gel 
To purify DNA fragments from gels, DNA bands were excised from the 
agarose gel using a surgical scalpel. Purification was conducted according to  ǯ ocol provided in the Macherey-Nagel Gel/PCR 
purification kit (Cat# 740609.50). Briefly, the gel slice was dissolved at 65°C 
in binding buffer (100µl of binding buffer per 100µg of gel). Samples were 
applied to the spin columns, centrifuged briefly in a bench top microfuge and 
the flow-through discarded. Columns were washed twice with Wash Solution 
I and subsequently, the DNA was eluted in 50µl of the pre-heated 65°C 
elution buffer provided. For small DNA fragments (< 500bp) used in cloning 
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the DNA was eluted in 30µl of pre-heated 65°C elution buffer to increase the 
DNA concentration.  
 
2.2.7 Annealing of DNA oligos 
To anneal complementary DNA oligos 1µl of each oligo (100µM stock in TE 
buffer) was incubated with 3µl of 10x T4 DNA ligase buffer and 25µl of H2O. 
The sample was placed into the peqlab Primus 96 advanced thermal cycler at 
85°C and allowed to cool slowly at 1°C per minute until the temperature 
reached 20°C. The oligos were used in restriction digests or blunt end 
ligation reactions.  
 
2.2.8 Restriction enzyme digestion of DNA 
Plasmid DNA was digested with restriction endonucleases in order to 
generate compatible ends for cloning and to verify newly created plasmids. 
All restriction endonucleases and corresponding buffers were supplied by 
NEB and useǯǤ 
To verify plasmids after ligation reactions, 100ng of plasmid DNA was 
digested in 10µl total reaction volume; to digest large quantities of DNA for 
cloning and ligations 5µg of plasmid DNA was digested in 50µl total reaction 
volume. Digests lasted 1-5h depending on the amount of DNA and were 
conducted at the optimal temperature for the enzyme used.  
 
2.2.9 Removal of  ?ǯlinearised plasmid DNA     ?ǯ    ction enzyme digested 
plasmid was conducted to prevent DNA from self ligating in ligation Ǥ   ?ǯ       
Phosphatase, 1µl of enzyme was added to the digested plasmid DNA (1-5µg of 
plasmid DNA) and incubated at 37°C for 30 min. A further 1µl of enzyme was 
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added and the sample and incubated for a further 30 min at 37°C. To 
deactivate the enzyme, the mixture was incubated at 65°C for 5 min.  
 
2.2.10 Ligation of DNA fragments 
Recombinant plasmids were created by ligating DNA fragments using T4 
DNA ligase (NEB). Ligation reactions were set up by mixing approximately 
100ng of digested vector with a 3-fold molar excess of insert along with 0.5µl 
of T4 DNA ligase in 1x T4 DNA ligase buffer and a final reaction volume of 
10µl. Reactions were left overnight at room temperature.  
 
2.2.11 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) was performed using peqlab Primus 96 
advanced thermal cycler. PCR was used for the generation of DNA fragments 
for cloning and the screening of recombinant plasmids. 
For the screening of newly generated plasmids (colony PCR), single clones 
from a ligation reaction were used to inoculate 500µl of LB with the 
appropriate antibiotic and grown for 4-6h in an orbital shaker at 37°C, 
200rpm. A standard Taq Polymerase PCR reaction was set up as shown in 
Table 2.1. The primers used are shown in Tables 2.3 and 2.4. Samples were 
initially denatured at 95°C for 3 min followed by 25 cycles each consisting of 
a denaturing step of 95°C for 20 sec, annealing at 55°C for 30 sec, then 
elongation at 72°C for 1 min/kb. A final elongation step for 5min at 72°C was 
included at the end. To check the insert was the correct size, 10µl of the 
reaction was loaded onto a 1% agarose gel.  
For the synthesis of blunt end DNA fragments for cloning, Phusion DNA  ȋ	Ȍ   ?ǯ -  ?ǯ    Ǥ 
standard reaction was set up as shown in Table 2.2. The primers used are 
shown in Tables 2.3 and 2.4. Samples were initially denatured at 95°C for 3 
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min followed by 30 cycles consisting of a denaturing step of 95°C for 10 sec, 
annealing at 50°C for 30 sec, then elongation at 68°C for 1 min/0.5 kb. A final 
elongation step for 10 min at 68°C was included at the end. To check newly 
generated PCR fragments were the correct size, 10µl of the reaction was run 
on a 1% agarose gel. 
 
Volume Component/Reagent 
2µl Bacterial culture 
1.0µl 10mM forward primer (Invitrogen), stock at 100mM in TE 
1.0µl 10mM reverse primer (Invitrogen), stock at 100mM in TE 
2.5µl 10x Taq Pol buffer (NEB) 
1.0µl 10mM dNTP mix (NEB) 
0.25µl 
 
Taq DNA Polymerase (NEB) 
 17.25µl nuclease-free H2O 
Table 2.1 Standard Taq DNA polymerase PCR reaction 
 
 
Volume Component/Reagent 
x µl 100ng DNA template 
1.0µl 10mM forward primer (Invitrogen), stock at 100mM in TE 
1.0µl 10mM reverse primer (Invitrogen), stock at 100mM in TE 
10.0µl 5x Phusion HF buffer (Finnzyme) 
1.0µl 10mM dNTP mix (NEB) 
0.5µl Phusion High Fidelity DNA Polymerase (Finnzyme) 
up to 
50.0µl 
nuclease-free H2O 
Table 2.2 Standard Phusion DNA polymerase reaction 
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2.2.12 Site-directed mutagenesis 
For site-directed mutagenesis, overlapping primers with the desired 
mutations were designed (Table 2.5) using the PrimerX programme 
(http://www.bioinformatics.org/primerx) using the primer design protocol 
optimised for the Stratagene Quikchange protocol.  Reactions were set up as 
shown in Table 2.2. Reactions were initially incubated at 95°C for 3 min 
followed by 30 cycles consisting of a denaturing step of 95°C for 10 sec, 
annealing for 30 sec, then elongation at 68°C for 1 min/0.5 kb. A final 
elongation step for 10 min at 68°C was included at the end. The annealing 
temperature could be varied between 40 and 60°C to optimise the reaction 
efficiency.  
To remove template DNA from site directed mutagenesis reactions, the 
enzyme DpnI was used. One microlitre of DpnI was added to each 50µl 
mutagenesis reaction and incubated at 37°C for 2 h. Ten microlitres of the 
reaction was then loaded and run on a 1% agarose gel. The remaining sample 
was then used to transform E. coli  ?Ƚ
to confirm the presence of the desired mutations.  
 
2.2.13 List of Primers 
 
Name Sequence 
pBD-Gal4 Seq primer 5' GTGCGACATCATCATCGGAAG 
pAD-Gal4 Seq primer 5' AGGGATGTTTAATACCACTAC 
M13 rev CACACAGGAAACAGCTATGACCAT 
T3 ATTAACCCTCACTAAAG 
T7 Fw TAATACGACTCACTATAGGG 
T7 Rv GCTAGTTATTGCTCAGCGG 
Table 2.3 Primers used for DNA sequencing 
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Name Sequence 
CNOT7-XbaI Rv CGACTCTAGACTATGACTGCTTGTT 
CNOT8-XbaI Rv CGACTCTAGACTACTGCTGCATGTT 
CNOT8-MluI Rv ACGCGTCTACTGCTGCATGTT 
BTG2 XhoI Fw CCTCGAGATGAGCCACGGGAAGGGAACCG 
BTG2 BamHI Fw GGATCCATGAGCCACGGGAAGGGAACCG 
BTG2 EcoRI Fw AAAAAGAATTCATGAGCCACGGGAAGGGAACCG 
HA-BTG2 FW GGATCCCGCTTACCCATACGATGTTCCAGATTACGCTATGA
GCCACGGGAAGGGAACCG 
HA-
 ?ȏɉȐ CAGCACCCTCGAGGCTTACCCATACGATGTTCCAGATTACG
CTATGAGCCACGGGAAGGGAAC 
TOB1-XbaI Rv CGACTCTAGACTAGTTAGCCATAAC 
TOB1 EcoRI Fw AAAAAGAATTCATGCAGCTTGAAATCCAAGTAGC 
HA- ?ȏɉȐ CAGCACCCTCGAGGCTTACCCATACGATGTTCCAGATTACG
CTATGCAGCTTGAAATCC 
HA BamHI 
Bottom 
GATCAGCGTAATCTGGAACATCGTATGGGTAAGCTT 
HA BamHI Top GATCAAGCTTACCCATACGATGTTCCAGATTACGCT 
PRMT1 fw GGATCCATGGCGGCAGCCGAGGCCGCGA 
PRMT1 rv GTCGACACCGACTACCGGATGCGCTGA 
PABPC1 fw GGATCCATGAACCCCAGTGCCCCCAGCT 
PABPC1 rv GTCGACTTAAACAGTTGGAACACCGGT 
Gal4-HA FW AATTGTACCCATACGATGTTCCAGATTACGCTGGATCCGCC
CGGGAATTCCCGTCGG 
Gal4-HA RV TCGACCGACGGGAATTCCCGGGCGGATCCAGCGTAATCTGG
AACATCGTATGGGTAC 
Table 2.4 Primers used for DNA cloning 
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Name Sequence 
BTG2_H53A FW CAGAGCACTACAAACACGCCTGGTTTCCCGAAAAGC 
BTG2_H53A RV GCTTTTCGGGAAACCAGGCGTGTTTGTAGTGCTCTG 
BTG2_H53A_long 
FW 
CAGAGCACTACAAACACGCCTGGTTTCCCGAAAAGCCG 
BTG2_H53A_long 
RV 
CGGCTTTTCGGGAAACCAGGCGTGTTTGTAGTGCTCTG 
BTG2_Y65A FW GTCCAAGGGCTCCGGCGCCCGCTGCATTCGCATC 
BTG2_Y65A RV GATGCGAATGCAGCGGGCGCCGGAGCCCTTGGAC 
BTG2_D75A FW CAACCACAAGATGGCCCCCATCATCAGCAG 
BTG2_D75A RV CTGCTGATGATGGGGGCCATCTTGTGGTTG 
BTG2_W103A FW CAGCGAGCTGACCCTGGCGGTGGACCCCTATGAG 
BTG2_W103A RV CTCATAGGGGTCCACCGCCAGGGTCAGCTCGCTG 
BTG2_D105A FW GACCCTGTGGGTGGCCCCCTATGAGGTGTC 
BTG2_D105A RV GACACCTCATAGGGGGCCACCCACAGGGTC 
BTG2_E108A FW GTGGGTGGACCCCTATGCAGTGTCCTACCGCATTG 
BTG2_E108A RV CAATGCGGTAGGACACTGCATAGGGGTCCACCCAC 
BTG2_E115A FW CTACCGCATTGGGGCGGACGGCTCCATCTG 
BTG2_E115A RV CAGATGGAGCCGTCCGCCCCAATGCGGTAG 
BTG2_E115Along 
FW 
CCTACCGCATTGGGGCAGACGGCTCCATCTGCGTCTTG 
BTG2_E115Along 
RV 
CAAGACGCAGATGGAGCCGTCTGCCCCAATGCGGTAGG 
BTG2 S147 149A 
FW 
CTGCTGGGCCGGAGCGCCCCCGCCAAGAACTACGTG 
BTG2 S147 149A 
RV 
CACGTAGTTCTTGGCGGGGGCGCTCCGGCCCAGCAG 
Tob1 H43A FW GAAGAAATATGAAGGGGCCTGGTATCCTGAAAAGC 
Tob1 H43A RV GCTTTTCAGGATACCAGGCCCCTTCATATTTCTTC 
Tob1 H45A FW GAAATATGAAGGGCACTGGGCACCTGAAAAGCCATACAAAG 
Tob1 H45A RV CTTTGTATGGCTTTTCAGGTGCCCAGTGCCCTTCATATTTC 
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Tob1 F55A FW CATACAAAGGATCGGGGGCTAGATGTATACACATAGG 
Tob1 F55A RV CCTATGTGTATACATCTAGCCCCCGATCCTTTGTATG 
Tob1 D65A FW CATAGGGGAGAAAGTGGCCCCAGTGATTGAACAAG 
Tob1 D65A RV CTTGTTCAATCACTGGGGCCACTTTCTCCCCTATG 
Tob1_W93A FW CACAGGATCTTAGTGTTGCGATCGACCCATTTGAG 
Tob1_W93A RV CTCAAATGGGTCGATCGCAACACTAAGATCCTGTG 
Tob1 D95A FW CTTAGTGTTTGGATCGCCCCATTTGAGGTTTC 
Tob1 D95A RV GAAACCTCAAATGGGGCGATCCAAACACTAAG 
Tob1 E98A FW GTTTGGATCGACCCATTTGCGGTTTCTTACCAAATTGG 
Tob1 E98A RV CCAATTTGGTAAGAAACCGCAAATGGGTCGATCCAAAC 
Tob1 E105A FW CTTACCAAATTGGTGCAAAGGGACCAGTGAAG 
Tob1 E105A RV CTTCACTGGTCCCTTTGCACCAATTTGGTAAG 
Tob1 S125 154 
164A FW 
CTCATCAGTGTCCAGCGCTCCAGCGCCTCCTTTTGGTCAC
TCTGCTGCTGTAGCCCCTACCTTCATGC 
Tob1 S125 154 
164A RV 
GCATGAAGGTAGGGGCTACAGCAGCAGAGTGACCAAAAGGA
GGCGCTGGAGCGCTGGACACTGATGAG 
7E247FW GAGAGAAATGTTCTTTGCCGATCATATTGATGATGCC 
7E247REV GGCATCATCAATATGATCGGCAAAGAACATTTCTCTC 
7Y260FW CAAATATTGTGGTCATTTGGCTGGCCTTGGTTCTGGTTC 
7Y260REV GAACCAGAACCAAGGCCAGCCAAATGACCACAATATTTG 
8E247FW GAAAGAGTTGTTTTTTGCGGACAGCATTGATGATG 
8E247REV CATCATCAATGCTGTCCGCAAAAAACAACTCTTTC 
8Y260FW CTGTGGGCGGCTCGCTGGCTTAGGCACAG 
8Y260REV CTGTGCCTAAGCCAGCGAGCCGCCCACAG 
CNOT7 D40A FW GAAAATATAATTACGTTGCTATGGCCACCGAGTTTCCAGGT
GTGGTTGC 
CNOT7 D40A RV GCAACCACACCTGGAAACTCGGTGGCCATAGCAACGTAATT
ATATTTTC 
CNOT8 D40A GTTATATTGCCATGGCCACAGAATTTCCAGG 
CNOT8 D40A RV CCTGGAAATTCTGTGGCCATGGCAATATAAC 
Table 2.5 Primers used for site-directed mutagenesis.  
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2.3 Yeast two-hybrid analysis  
2.3.1 Reagents, stock solutions and buffers for use in yeast culture  
YPD medium: 10g/L yeast extract, 20g/L glucose, 20g/L bacteriological 
peptone. For YPD agar, 20g/L bacteriological agar was added. The medium 
was sterilised by heat using a Prestige medical 2100 classic bench-top 
autoclave and stored at 4°C. 
Yeast selective complete (SC) medium: 6.7g/L yeast nutrient broth, 20g/L 
glucose, 1.4g/L amino acid drop out mix (minus histidine, uracil, tryptophan 
and leucine). For selective agar plates, 20g/L bacteriological agar was added. 
The medium was sterilised by heat using a Prestige medical 2100 classic 
bench-top autoclave and stored at 4°C. 
Histidine solution: stock 20mg/ml in H2O (add 4.3ml per 1L of medium). After 
sterilisation by filtration (0.22 Pm pore size), the solution was stored at room 
temperature. 
Uracil: stock 5mg/ml in H2O (add 17.2ml per 1l of medium). After 
sterilisation by filtration (0.22 Pm pore size), the solution was stored at room 
temperature. 
Single-stranded DNA: Herring Sperm single-stranded DNA (2 mg/ml, Abcam, 
ab46666) was heated to 98°C for 5min and placed on ice before use. Stored at 
-20°C. 
Lithium acetate solutions: LiAc solutions (1M and 0.1M; Sigma) were 
prepared and sterilised by filtration (0.22 Pm pore size). Stored at room 
temperature. 
PEG-3350 solution: a solution containing 50% (w/v) polyethylene glycol 
(PEG-3350; Sigma) was sterilisation by filtration (0.22 Pm pore size). The 
solution was stored at room temperature for up to several months. 
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SDS loading buffer (4x): 50% upper buffer, 40% glycerol, 1% Ⱦ-mercaptoethanol, 1.25% Bromophenolblue (0.1%), 0.25% H2O, stored 
at -20°C. Small aliquots were stored short-term at 4°C. 
 
2.3.2 Culture of Saccharomyces cerevisiae strain YRG2 
The yeast strain S. cerevisiae YRG2 (Stratagene; stored at -80϶C in YPD 
containing 50% glycerol) was used for all yeast twoȂhybrid analyses. To 
obtain single colonies the yeast was streaked onto YPD agar plates and grown 
at 30°C. Once colonies had formed (2-4 days) the plates were stored at 4°C 
for several weeks. Liquid cultures were inoculated with large single colonies 
and grown in universal screw-cap tubes containing YPD or SC medium and 
incubated at 30°C, 200rpm for 12-24 h. For larger cultures glass conical 
flakes were used.  
 
2.3.3 Transformation of YRG2 cells 
Derivatives of plasmids pBD-GAL4 Cam and pAD-GAL4-2.1 (Stratagene) were 
used for all yeast two-hybrid assays. Yeast YRG2 cells were first made 
competent though a heat shock treatment. Competent cells were always used 
on the day they were made. One large single yeast colony was used to 
inoculate 10ml of YPD medium and grown overnight at 30°C and 200rpm, 
this culture was then used to inoculate 50ml of YPD medium to give an OD600 
of 0.2. This culture was incubated at 30°C, 200prm until the OD600 had 
increased to 0.8 (3-5 h) at which point the culture was centrifuged to pellet 
the yeast at 3000g for 5 min. The supernatant was removed and the cells 
carefully re-suspended in 25ml of sterile water followed by another 
centrifuge step of 3000g for 5 min. The water was removed and the yeast re-
suspended in 1ml of 0.1M lithium acetate and transferred to a 1.5ml 
microfuge tube before being centrifuged at 4000g for 15 sec. The supernatant 
was removed and the cells re-suspended to a final volume of 500µl using 
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0.1M lithium acetate (requiring the addition of approximately 350 Pl 0.1M 
lithium acetate). One 50ml culture provided sufficient cells for ten 
transformations. The cell suspension was equally divided (~50µl) into ten 
1.5ml microfuge tubes, the cells pelleted as described above and the 
supernatant removed.  
 
Volume Component/Reagent 
50µl 500ng (combined) plasmid DNA diluted in H2O 
240µl 50% polyethylene glycol (PEG-3350) 
36µl 1M lithium acetate 
25µl Single-stranded DNA (2 mg/ml) 
Table 2.6 Mixture for yeast transformation 
 
The 50% PEG solution was first pipetted onto the yeast cell pellet followed by 
a mix of the other transformation components. Herring sperm ssDNA, 
(Abcam, ab46666) was boiled for 5 min and quickly chilled on ice before use 
(Table 2.6). After the addition of the all components, the transformation mix 
was vortexed until the pellet was completely resuspended. The yeast 
transformation mix was then incubated for 30 min at 30°C, 200rpm followed 
by 20 min incubation at 42°C in a water bath. The samples were then 
centrifuged at 4000g for 15 sec and the yeast pellet re-suspended in 500µl of 
sterile H2O. From this cell suspension 100µl was placed on SC selective plates 
(without tryptophan and leucine) and incubated at 30°C for 3-5 days until 
colonies formed. 
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2.3.4 Yeast two-Ⱦ-galactosidase assay 
For each transformation, three independent yeast clones were tested. Yeast 
colonies were streaked into small rectangles (approximately 0.5 x 1.0cm) on 
SC selective medium agar plates. After 48-72 h the resulting rectangle of 
yeast was used to inoculate 2ml of YPD medium. After incubation at 30°C, 
200rpm for 24 h, one millilitre of the yeast culture was used to obtain the 
OD600 value as a measure of the culture density. For dense cultures with an 
OD600 >1, the sample was diluted 10-fold with SC medium. From the 
remaining culture, 25µl was adde   ? ?  Ⱦ-Glo reagent (Promega) in a 
white 96 well flat bottom plate and incubated in the dark for 30min at room ǤȾ-Galactosidase luminescence was measured for 1 sec using a 
Berthold Orion microplate luminometer and Simplicity 4.02 software. For ǡȾ-galactosidase activity was tested in duplicate.  The Ⱦ-galactosidase activities were normalised using the OD600 values.   
 
2.3.5 Western blot analysis of yeast cell lysates  
To confirm expression of AD-Caf1a (CNOT7), AD-Caf1b (CNOT8), BD-HA-
BTG2 and BD-HA-TOB1, protein lysates were produced and subjected to 
western blot analysis. Individual yeast colonies were streaked into small 
rectangles and cultured in 2ml to SC medium. One millilitre of yeast culture 
was transferred to a 1.5ml microfuge tube and centrifuged at 3000g for 2 
min. The resulting cell pellet was re-suspended in 100µl of H2O. After the 
addition of 100µl of 0.2M NaOH, the cells were vortexed and incubated for 5 
min at room temperature. The cells were centrifuged again at 3000g for 2 
min, the supernatant was removed and the pellet re-suspended in 50µl of 1x 
SDS loading buffer. The samples were boiled at 98°C for 5 min before being 
analysed by SDS-PAGE or stored at -80°C until required. 
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2.4 Cell culture 
2.4.1 Reagents, stock solutions and buffers for use in tissue culture 
Phosphate buffered saline: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.47mM KH2PO4 (1x PBS without Ca2+, Mg2+; PAA, H15-002)   
HEPES-buffered saline: 50mM HEPES-KOH, 280mM NaCl, 1mM NA2HPO4, 
pH 7.1 
DMEM complete: DMEM (Sigma, D6546), 10% fetal calf serum (FCS; Biosera 
S1900-500, lot-S0611951900), 100units/ml penicillin and 100units/ml 
streptomycin (PAA, P11-010), glutamine (200mM; Lonza, BE17-60SE) 
Doxycycline (1000x): stock 1.0mg/ml in H2O, working concentration 
1.0µg/ml, stored at -80°C.  
Blasticidin solution: stock 100mg/ml in H2O (Invivo Gen), stored at -20°C.  
Zeocin solution: stock 100mg/ml in H2O (Invivo Gen), stored at -20°C.  
Trypsin/EDTA solutions: 10x concentrated solutions of phosphate-buffered 
saline containing 0.5% trypsin and 0.2% EDTA were purchased from (PAA, 
L11-003) stored at -20°C. 1x solutions obtained by the addition of PBS were 
stored at 4°C 
 
 
 
 
 
 
 
Chapter 2: Materials and Methods 
 
75 
 
2.4.2 Maintenance of cell lines 
Cell culture was performed in a Class II biological safety cabinet under 
aseptic conditions. 
Cell Line Origin 
HEK293T 
U2OS 
MCF-7 
Human embryonic kidney 
Human osteosarcoma 
Human mammary epithelium 
Table 2.7 Mammalian cell lines used 
 
2.4.3 Routine maintenance of cell lines 
Adherent cells (Table 2.7) were   ǯ  
medium (DMEM) supplemented with 10% foetal calf serum (FCS), 2mM 
glutamine, 100units/ml penicillin and 100units/ml streptomycin (complete 
DMEM), in a humidified incubator at 37°C and 5% CO2. When cells were 70-
80% confluent, they were washed with phosphate buffered saline (PBS; pre-
warmed at 37°C) and incubated with 1-2ml of trypsin/EDTA for 1-5 min 
(dependent upon cell type) at 37°C. Trypsin was deactivated by the addition 
of 10ml complete DMEM and the cells were resuspended into a single cell 
suspension. The cell suspension was centrifuged at 250g for 5 min to pellet 
the cells, the supernatant removed and then the pellet re-suspended in 
complete DMEM for dilution and plating.  
 
2.4.4 Freezing cells for long term storage 
To place cells into liquid nitrogen storage, cells were detached from a 
confluent 75cm2 flask using trypsin transferred to a 15ml Falcone tube and 
centrifuged at 250g for 5 min. After centrifugation, the cell pellet was re-
suspended in 2ml of complete DMEM containing 10% dimethylsulfoxide 
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(DMSO) and 1ml aliquots of the cell suspension were transferred into 
cryovials. The cryovials were then placed at -80°C in a Mr. Frosty 
cryocontainer (NALGENE Labware), which allows slow freezing of -1°C per 
minute. After one to several days, cryovials were placed in liquid nitrogen for 
long-term storage. 
 
2.4.5 Retrieving cells from liquid nitrogen storage 
To culture cells from liquid nitrogen storage they were first thawed quickly 
by incubation in a 37°C water bath, and then added to 9ml of complete DMEM 
medium (pre-warmed at 37°C). To allow for the removal of the DMSO, cells 
were pelleted by centrifugation at 250g for 5 min. The supernatant was 
discarded and the cell pellet re-suspended in 10ml of complete DMEM 
medium (pre-warmed at 37°C). The cell suspension was transferred to a 75 
cm2 flask and placed in the humidified incubator (5% CO2 and 37°C). After 
24 h, the medium was changed, and the cells were passaged between 48 and 
96 h after retrieval from liquid nitrogen.  
 
2.4.6 Generation of MCF-7 TR stable cells lines  
To generate cell lines that can be induced to express (mutant) BTG2, we used 
MCF-7 TR cells, which express the Tet repressor protein following stable 
integration of plasmid pcDNA6/TR (Invitrogen).  
MCF-7 TR cells were transfected with the appropriate vector (Table 2.8) 
using the calcium phosphate precipitation method. Cells were seeded at 60% 
confluency into 6 cm (diameter) culture dishes 24 h prior to transfection. 
Cells were washed with PBS before the addition of fresh DMEM medium. 
After the preparation of a 0.25M CaCl2 (pH 7.7) solution (100µl) containing 
six micrograms of plasmid DNA, 100µl of HEPES-Buffered Saline was added 
with gentle agitation. The mixture was left at room temperature to 
precipitate for 20 min, before being added to the cells. After transfection 
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(24 h), cells were washed with PBS and fresh DMEM medium added. Forty 
eight hours after transfection the plates were split into five 10cm (diameter) 
plates in medium containing zeocin (600Pg/ml) to select for transformants. 
Cells were first washed with PBS, then 1ml of trypsin was added and the 
plate and incubated for 5 min at 37°C. Once cells had detached from the plate, 
the cell suspension was aspirated several times to generate a single cell 
suspension, followed by centrifugation at 250g for 5 min. The supernatant 
was discarded and the pellet re-suspended in 10ml of DMEM containing 
zeocin (600Pg/ml). To each culture plate (10cm diameter) containing 8ml of 
complete medium containing zeocin (600Pg/ml), 2ml of cell suspension was 
added. Plates were kept in a humidified incubator (37°C, 5% CO2) for 
approximately three weeks until the antibiotic selection was complete and 
single colonies had formed. During this time the cells were washed with PBS 
and the medium replaced every 3-4 days. All cell lines were derived from 
MCF-7 TR cells containing stably integrated plasmid pcDNA6/TR. All cells 
were routinely maintained in complete DMEM medium containing 
10% tetracycline-free FCS, 5Pg/ml blasticidin, and 300Pg/ml zeocin. 
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Cell Line  Vector transfected 
MCR7 TR pcDNA4-TO pcDNA4-TO 
MCF-7 TR BTG2 pcDNA4-TO-HA-Flag-BTG2 
MCF-7 TR BTG2 53A pcDNA4-TO-HA-Flag-BTG2 53A 
MCF-7 TR BTG2 103A pcDNA4-TO-HA-Flag-BTG2 103A 
MCF-7 TR BTG2 105A pcDNA4-TO-HA-Flag-BTG2 105A 
Table 2.8 Stable cells lines containing a doxycycline-inducible expression 
cassette.  
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2.5 Immunoprecipitation analysis 
2.5.1 Reagents, stock solutions and buffers for use in co-
immunoprecipitation 
Cell lysis buffer containing 0.2% NP-40: 50mM 1M Tris-HCl pH8.0, 150mM 
NaCl, 5mM MgCl2, 0.5mM EDTA, 5% glycerol, 0.2% NP-40, 1mM DTT. After 
addition of one Roche complete protease inhibitor cocktail tablet to 50ml, the 
lysis buffer was stored at -20°C. 
1M Dithiothreitol (DTT): dissolved in H2O, stored at -20°C. 
SDS loading buffer (4x): 50% upper buffer, 40% glycerol, 1% Ⱦ-mercaptoethanol, 1.25% Bromophenolblue (0.1%), 0.25% H2O, stored 
at -20°C. Small aliquots were stored short-term at 4°C. 
Agarose beads: protein A-agarose beads and protein G-agarose beads were 
purchased from Roche and stored at 4϶C. 
Phosphate buffered saline: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.47mM KH2PO4 (1x PBS without Ca2+, Mg2+; PAA, H15-002)   
 
2.5.2 Preparation of protein lysates for immunoprecipitation  
HEK293T cells were seeded at 80% confluency in culture dishes (6cm 
diameter) and after 24 hours, transfected with the two appropriate 
expression vectors using the JetPEI transfection reagent. For each vector, 
2.5µg plasmid (5Pg total plasmid) was added to 10µl of JetPEI following 
instructions in the JetPEI handbook. The DNA/JetPEI mixture was incubated 
for 30 min before being added drop wise to the cells. Forty eight hours after 
transfection, cells were harvested by repeated pipetting of the medium 
directly onto the cells. The cell suspension was centrifuged at 4000g, 4°C for 
5min and the pellet re-suspended in 1ml of cold PBS (4°C) to wash the cells. 
The centrifugation step was repeated and the cell pellet re-suspended in 
500µl of cold cell lysis buffer containing 0.2% NP-40. The lysates were then 
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transferred to microfuge tubes and freeze/ thawed twice (-80°C), followed by 
centrifugation at 16,000g for 5 min at 4°C. Supernatants were stored at -80°C 
until required. 
 
2.5.3 Preparation of antibody-agarose beads and immunoprecipitation  
For each immunoprecipitation 10µl of protein A and 10µl of protein G 
agarose beads were required. Bead volumes were scaled up depending upon 
the number of samples being tested. To prepare agarose beads, 10µl of 
protein A and 10µl protein G agarose beads were mixed together in a 1.5ml 
microfuge tube and centrifuged at 3000g for 30 sec. The supernatant was 
discarded and the pellet resuspended in 500µl PBS. This wash step was 
repeated twice before the appropriate antibody was added to the beads 
(Table 2.9). One microgram of antibody was added per 10µl of beads (2Pg 
per immunoprecipitate) and the volume brought up to 500µl with PBS. The 
1.5ml microfuge tube containing the agarose bead/antibody mixture was 
packed into a 50ml falcon tube and left on a rotating shaker for 1 h at room 
temperature. Following antibody incubation the agarose beads/antibody 
mixture was centrifuged at 3000g for 30 sec and the supernatant removed 
carefully with a gel loading tip. The agarose beads were washed with 500µl of 
PBS and this step repeated three times followed by a final wash in cell lysis 
buffer containing 0.2% NP40. From this point on all the samples were kept 
on ice. To the antibody coated agarose beads in a 1.5ml microfuge tube, 450µl 
of protein lysate was added the microfuge tube packed into a 50ml falcon 
tube and the mixture incubated overnight at 4°C on a rotating shaker. The 
lysate/bead mixtures were centrifuged at 3000g for 30 sec and the 
supernatant carefully discarded using a gel loading tip. Beads were then 
washed three times with 500µl of lysis buffer containing 0.2% NP40. After 
the final wash, 10µl PBS and 10µl 4x SDS loading buffer was added to the 
bead and the sample was boiled for 5 min to denature the protein-antibody 
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complexes. The samples were then subjected to western blot analysis or 
stored at -80°C until needed.  
 
2.5.4 List of antibodies used for co-immunoprecipitation  
 
Primary Antibody Dilution Supplier 
Anti-Flag M2 
 
Anti-HA  
1µg per 10µl of agarose 
beads 
1µg per 10µl of agarose 
beads 
Sigma (F1805) 
 
Roche (1 867 423) 
 
Table 2.9 List antibodies used for co-immunoprecipitation  
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2.6 EdU labelling of S-phase cells 
To look at the effect of BTG/TOB proteins on cell proliferation, the Click-iT 
EdU Imaging kit (Invitrogen) was used to label cells in SȂphase. All conditions 
were tested in biological triplicate.  
 
2.6.1 Reagents, stock solutions and buffers for use in EdU labelling 
Lysis buffer containing 1% NP40: 50mM 1M Tris-HCl pH8.0, 150mM NaCl, 
5mM MgCl2, 0.5mM EDTA, 5% glycerol, 1% NP-40, 1mM DTT. The lysis buffer 
was stored at -20϶C after the addition of one Roche complete protease 
inhibitor cocktail tablet to 50ml buffer. 
4% paraformaldehyde (PFA): 4% PFS in H2O w/v, stored at -20°C. 
0.5% Triton X-100: 0.5% Triton X-100 in PBS, stored at 4°C 
3% Bovine serum albumin (BSA): 3% BSA in PBS, stored at 4°C  
Mounting medium: 90% glycerol, 10% PBS 
MG132 (1000x): 1mg/ml powder was dissolved in DMSO and stored at -80°C.  
siRNA: ǯ   ǡ    ? ?  ? 
buffer (Dharmacon, B-002000-UB-015), stored at -20°C. 
DMEM complete: DMEM (Sigma, D6546), 10% fetal calf serum (FCS; Biosera 
S1900-500, lot-S0611951900), 100units/ml penicillin and 100units/ml 
streptomycin (PAA, P11-010), glutamine (200mM; Lonza, BE17-60SE) 
Serum Free Media: DMEM, (Sigma, D6546) 
Phosphate buffered saline: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.47mM KH2PO4 (1x PBS without Ca2+, Mg2+; PAA, H15-002)   
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2.6.2 Cell seeding and transient transfection for EdU labelling 
Working in a class II biological safety cabinet, square glass cover slips (22mm 
x 22mm, 0.13-0.17mm thick) were sterilised by immersion in 100% ethanol 
before being passed through a flame. The cover slips were placed into 6-well 
culture plate. Cells were seeded (n=180,000 per well) in 2ml DMEM onto the 
coverslips. After 24 h, cells were at 70% confluency and either transfected 
using GeneJuice transfection reagent or BTG2 expression was induced by the 
addition of doxycycline (1Pg/ml) to the culture medium. For transfected cells 
1µg of plasmid DNA was diluted in 100µl of serum free media and mixed with 
3Pl of GeneJuice reagent as stated in the GeneJuice handbook. Genejuice/DNA 
mixture was incubated for 15 min before being added drop wise to the cells. 
One sample was transfected with a GFP containing plasmid to monitor 
transfection efficiency. Four hours after transfection, cell medium was 
removed and replaced with fresh medium to reduce cell toxicity. Forty eight 
hours after transfection cells were subjected to Click-iT EdU labelling. Each 
transfection was carried out in triplicate. 
 
2.6.3 Cell seeding and siRNA transfection for EdU labelling 
Working in a class II biological safety cabinet, square glass cover slips (22mm 
x 22mm, 0.13-0.17mm thick) were sterilised by immersion in 100% ethanol 
before being passed through a flame. The cover slips were placed into 6-well 
culture plate. Cells were seeded (n=100,000 per well) in 2ml DMEM onto the 
coverslips. After 24 h, cells were at 40% confluency and transfected using 
Interferin following the produce protocol. Briefly, 5nM of siRNA (Table 2.10) 
was added to 200µl of serum free media followed by 8µl of Interferin, the 
siRNA/Interferin mixture was vortexed and incubated for 10 min before 
being added drop wise to the cells. After 24 h the cell medium was removed 
and replaced with fresh 37°C complete DMEM, 72 h after siRNA knockdown 
Click-iT EdU labelling preformed. Each transfection was carried out in 
triplicate. 
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siRNA Product code 
siControl 
 
 
siBTG1 
 
 
siBTG2 
 
 
siTOB1 
 
 
siTOB2 
On-TARGET Plus 
Control non-targeting pool siRNA 
D-001810-10-05 
On-TARGET Plus 
Human BTG1 
L-011598-00 
On-TARGET Plus 
Human BTG2 
L-012308-00 
On-TARGET Plus 
Human TOB1 
L-010560-00 
On-TARGET Plus 
Human TOB2 
L-019434-00 
Table 2.10 siRNAs used for S phase analysisǤ  ǯ  
Dharmacon and stored 20nmol 
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2.6.4 Click-iT EdU labelling 
Forty eight hours after transfection or induction of BTG2 expression, 1ml of 
medium per well was removed and replaced with 1ml of fresh medium 
containing 20µM EdU to give a final working concentration of 10µM EdU per 
well. The GFP plasmid transfected cells were not incubated with EdU and 
stored at 4°C until the cell fixing step. MCF-7 cells were incubated with EdU 
for 2h, U2OS cells for 30 min in a humidified incubator at 37°C and 5% CO2. 
After labelling, medium containing EdU was removed and the cover slips 
were washed twice with 1ml of PBS. Cells were fixed though a 15 min 
incubation with 1ml of 4% PFA and washed twice with 3% BSA in PBS. Cover 
slips were then incubated with 1ml of ice cold 0.5% Triton X100 (diluted in 
PBS) for 20 min to permeabilise the cells before being washed twice with 1ml 
of 3% BSA in PBS. The Click-iT reaction cocktail was prepared as stated in the 
Click-iT handbook but all component volumes were reduced by a factor of ten 
to allow 50µl of cocktail per coverslip. When making the Click-iT reaction 
cocktail master mix, 50µl extra mix was made to allow for pipetting error. 
Fifty microlitre of Click-iT reaction cocktail was spotted onto parafilm in a 
humidification chamber and the coverslips placed face down onto the 
solution. This was incubated for 30 min at room temperature in the dark. 
Coverslips were then returned to a 6-well culture plate and washed twice 
with 1ml of 3% BSA in PBS followed by a wash with 1ml of PBS. To stain 
(nuclear) DNA, the PBS was removed and 1ml of Hoechst stain (5µg/ml) was 
added to each coverslip and incubated in the dark at room temperature for 
10 min. From this point onwards the coverslips were shielded from bright 
light as much as possible. After removal of the Hoechst stain, the coverslips 
were washed twice with 1ml of PBS. To mount the coverslips onto standard 
glass microscope slides, 50µl of mounting medium was spotted onto the slide 
before the coverslip was lowered onto it face down. The coverslips were 
sealed with clear nail varnish and slides were kept in the dark until imaging. 
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2.6.5 Calculating the number of cells in S-phase 
All samples were tested in biological triplicate and experiments repeated at 
least twice. For each coverslip, the numbers of cells in S-phase were counted 
at three randomly selected areas on the coverslip using a Zeiss LSM 510 Meta 
microscope and argon laser for excitation at 488 nm. Following the S-phase 
nuclei count, the total numbers of nuclei were counted for each area using 
the mercury bulb detecting Hoechst stained nuclei. On average 300 nuclei 
were counted for each coverslip. The number of nuclei in S-phase and the 
total number of nuclei were calculated for each coverslip. For each sample, 
the average number of cells in S-phase and the standard error of the mean 
were calculated from the biological triplicates. The GFP plasmid transfect 
samples were counted via the same method to monitor transfection 
efficiency, which typically varied between 50-70%. 
 
2.6.6 Western blot analysis for Click-iT EdU labelling 
To confirm expression of BTG2 and TOB1, cells were seeded as stated 
previously for the Click-iT EdU protocol. For the BTG2 stable cell lines, 48 h 
after doxycycline treatment, the cell medium was removed and cells washed 
with 1ml PBS. Cells were then scraped using a 1ml tip, collected in 500µl cold 
(4°C) PBS and transferred to a pre-chilled 1.5ml microfuge tube. Cell 
suspensions were centrifuged at 16,000g for 3 min at 4°C. Cell pellets were 
re-suspended in 100µl of 1% NP-40 lysis buffer. Cell lysates were 
freeze/thawed (-80°C) before a second centrifugation at 16,000g for 5 min at 
4°C. Cell lysates were then subjected to western blot analysis. 
For transiently transfected cells 48 h after transfection 1ml of cell media was 
removed and replaced with DMEM containing the protease inhibitor MG132. 
Four hours after addition of MG132 protein lysates were produced as 
described for BTG2 stable cell lines. Cell pellets were re-suspended in 50µl of 
1% NP-40 lysis buffer. 
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2.7 Immunofluorescence microscopy 
2.7.1 Reagents, stock solutions and buffers for use in 
immunofluorescence 
4% paraformaldehyde (PFA): 4% PFS in H2O w/v, stored at -20°C. 
0.5% Triton X-100: 0.5% Triton X-100 in PBS, stored at 4°C 
3% Bovine serum albumin (BSA): 3% BSA in PBS, stored at 4°C  
10% Bovine serum albumin (BSA): 10% BSA in PBS, stored at 4°C  
Mounting medium: 90% glycerol, 10% PBS 
Phosphate buffered saline: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.47mM KH2PO4 (1x PBS without Ca2+, Mg2+; PAA, H15-002)   
 
2.7.1 Preparation of mammalian cells for immunofluorescence 
Working in a class II biological safety cabinet, square glass cover slips (22mm 
x 22mm, 0.13-0.17mm thick) were sterilised by immersing in 100% ethanol 
before being passed through a flame. The cover slips were placed into 6-well 
culture plates. MCF-7 TR BTG2 cells were seeded (n=180,000 cells per well) 
in 2ml of DMEM onto the coverslips. After 24 h cells, were at 70% confluency 
and BTG2 expression was induced by the addition of doxycycline (1Pg/ml) to 
the medium. Forty eight hours after the addition of doxycycline, medium was 
removed and the cover slips washed twice with 1ml PBS. To fix the cells 1ml 
4% paraformaldehyde (4% PFA) was added to the coverslips and incubated 
at room temperature for 15 min followed by two washes with 1ml of PBS. 
After fixing, coverslips were stored at 4°C for 1-4 days or used immediately 
for permeabilisation and antibody incubation.  
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2.7.2 Immunofluorescence microscopy 
Cover slips were incubated with ice cold 0.5% Triton X-100 for 20 min to 
permeabilise the cells and washed twice with 1ml of PBS. Cells were then 
treated by the addition of 1ml of 10% bovine serum albumin (BSA) in PBS 
and incubated for 1 h at 37°C. Cover slips were then incubated with primary 
antibody at the appropriate dilution (Table 2.11). To this end, 50µl of 
antibody solution was spotted onto parafilm in a humidified chamber and the 
coverslips placed face down onto the solution. Primary antibodies were 
diluted in 3% BSA in PBS and incubated for 1 h at 37°C. After primary 
antibody incubation coverslips were transferred back to the 6-well culture 
plate and washed three times 5 min with 1ml PBS on an orbital shaker at 
60rpm. Coverslips were then incubated with 50µl of secondary antibody as 
described previously in the humidified chamber. Secondary antibodies were 
diluted in 3% BSA in PBS and incubated for 1 h at 37°C before coverslips 
were transferred back to the 6-well culture plate and washed three times for 
5 min with 1ml PBS on an orbital shaker at 60rpm. To stain DNA, 1ml of 
Hoechst stain at 5µg/ml was added to each coverslip and incubated in the 
dark at room temperature for 10 min. From this point on coverslips were 
shielded from bright light as much as possible. After removal of the Hoechst 
stain, the coverslips were washed twice with 1ml PBS. Cover slips were then 
mounted onto standard glass microscope slides: 50µl of mounting medium 
was spotted onto the slide before the coverslip was lowered onto it face 
down. The coverslips were sealed with clear nail varnish and slides were 
kept in the dark until imaging. Slides were imaged using a Zeiss LSM 510 
Meta microscope and HeNe laser for excitation at 594 nm. For each slide, two 
representative Z-stack images were taken.  
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 2.7.3 List of antibodies used for immunofluorescence  
 
Primary Antibodies Dilutiona Supplier 
Anti-BTG2 
Anti-Flag 
Anti-HA 
 
1/500  
1/500  
1/500  
Sigma (AV33561) 
Sigma (F1805) 
Roche (1 867 423) 
 
Secondary Antibodies Dilutiona Supplier 
Alexa Fluor 488 
Anti-Mouse 
Anti-Rat 
Alexa Fluor 594 
Anti-Mouse 
Anti-Rabbit 
 
1/1000  
1/1000  
 
1/1000  
1/1000  
 
Invitrogen (A414666) 
Invitrogen (A21212) 
 
Invitrogen (A21203) 
Invitrogen (A408192) 
Table 2.11 Antibodies used for immunofluorescence. aAntibodies were diluted in 
PBS containing 3% BSA. 
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2.8 Analysis of cell cycle regulators  
To determine if the expression of cell cycle regulatory proteins was changed 
due to BTG2 expression, relative protein and mRNA levels were assessed 
using western blot and qPCR analysis.  
 
2.8.1 Reagents, stock solutions and buffers used in analysis of cell cycle 
regulators 
Cell lysis buffer containing 1% NP-40: 50mM 1M Tris-HCl pH8.0, 150mM NaCl, 
5mM MgCl2, 0.5mM EDTA, 5% glycerol, 1% NP-40, 1mM DTT. After addition 
of one Roche complete protease inhibitor cocktail tablet to 50ml, the lysis 
buffer was stored at -20°C. 
1M Dithiothreitol (DTT): dissolved in H2O, stored at -20°C. 
Phosphate buffered saline: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.47mM KH2PO4 (1x PBS without Ca2+, Mg2+; PAA, H15-002)   
TE Buffer: 10mM Tris-HCl pH 8.0, 1mM EDTA 
 
2.8.2 Cell seeding, transfection and protein extraction for the analysis of 
cell cycle regulatory protein expression.  
To assess change in protein levels of cell cycle regulatory proteins, MCF-7 TR 
BTG2 stable cell lines were used. Working in a class II biological safety 
cabinet, MCF-7 TR BTG2 stable cell lines were seeded into 6-well culture 
plates at 200,000 cells per well. Cell medium was replaced three days after 
seeding with fresh medium containing doxycycline (1.0µg/ml). Seven days 
after seeding, cells were washed with 1ml PBS and harvested by scraping the 
cells in 500µl of PBS. After transfer microfuge tubes, the cell suspension was 
centrifuged at 16,000g, 4°C for 5 min and the pellet re-suspended in 100µl of 
cell lysis buffer containing 1% NP-40. The lysate was freeze/thawed once 
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(-80°C), followed by centrifugation at 16,000g for 5 min at 4°C. Samples were 
subjected to western blot analysis or stored at -80°C until required. 
 
2.8.3 Cell seeding, transfection and RNA extraction for the analysis of 
cell cycle regulatory protein expression.  
For assessing changes in mRNA levels, MCF-7 cells or MCF-7 TR BTG2 stable 
cell lines were seeded into 6-well culture plates at 180,000 cells per well. 
After 24 h, cells were at 70% confluency and either transfected using 
GeneJuice (following GeneJuice manual) or BTG2 expression induced via the 
addition of doxycycline (10µg/ml) to the cell medium. For transient 
transfection the cell medium was preplaced with fresh medium four hours 
after transfection to reduced cell toxicity.  
Forty eight hours after transfection total RNA was harvested using the 
E.N.Z.A Total RNA extraction kit (OMEGA Bio Tek, VWR). Cells were lysed 
with 350µl of TRK lysis buffer directly in the 6-well culture plate. Gentle 
pipetting of the cell lysate helped to disrupt all the cells and this was then 
transferred to a 1.5ml microfuge tube. The RNA extraction was then 
conducted as stated in the kit protocol, RNA is purified on a column and 
eluted in 50µl of DECP-treated water. RNA samples were kept on ice at all 
times and stored at -80. 
 
2.8.4 Production of cDNA for qPCR analysis to determine the levels of 
mRNA for cell cycle regulatory proteins 
Quantitative PCR (qPCR) was conducted to investigate the changes in mRNA 
levels of target genes. SuperScript III (Invitrogen) was used for cDNA 
synthesis as detailed in Table 2.12. Reactions were incubated in a peqlab 
Primus 96 advanced thermal cycler at 70°C for 5 min before being 
transferred onto ice for a further 1 min.  
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To this sample (reaction mix 1), a second master mix was added containing 
the reverse transcriptase and its corresponding buffer as shown in Table 
2.13. This was again placed in a peqlab Primus 96 advanced thermal cycler 
and incubated at 55°C for 60 min, followed by incubation at 70°C for 15 min 
to deactivate the enzyme. Resulting cDNA samples were diluted 1:5 with TE 
prior to use, and stored at -20°C until required. The qPCR analysis was 
conducted as described in section 2.10.2 
 
 
Volume Component/Reagent 
x µl 150-300ng RNA template 
0.4 µl  primer VN(dT)20 
0.5µl 10mM dNTPs 
up to 7.0µl RNase-free H2O 
Table 2.12 Superscript cDNA synthesis reaction mix 1 
 
 
Volume Component/Reagent 
7.0µl Reaction mix 1 
2.0 µl First Strand buffer 
0.5µl SuperScript III 
0.5µl  0.1M DTT 
Table 2.13 Superscript cDNA synthesis reaction mix 2 
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2.9 RNA tethering assay 
2.9.1 Reagents, stock solutions and buffers for use in RNA tethering 
assays 
TE Buffer: 10mM Tris-HCl pH 8.0, 1mM EDTA 
DMEM complete: DMEM (Sigma, D6546), 10% fetal calf serum (FCS; Biosera 
S1900-500, lot-S0611951900), 100units/ml penicillin and 100units/ml 
streptomycin (PAA, P11-010), glutamine (200mM; Lonza, BE17-60SE) 
Serum free media: DMEM (Sigma, D6546) 
Phosphate buffered saline: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.47mM KH2PO4 (1x PBS without Ca2+, Mg2+; PAA, H15-002)   
siRNA: ǯ   macon, stock at 20nmol in 1x siRNA 
buffer (Dharmacon, B-002000-UB-015), stored at -20°C. 
 
2.9.2 Cell seeding and transfection for RNA tethering assay 
Working in a class II biological safety cabinet, MCF-7 cells were seeded into 
12-well culture plates at 80,000 cells per well. After 24 hours, cells were at 
70% confluency and co-transfected using JetPEI transfection reagent. For 
each transfection 1µg of pRL-5boxB,  ? ?ɉ  ? ?
reagent was used (following instructions in the JetPEI manual). The 
DNA/JetPEI mixture was incubated for 30 min before being added drop wise 
to the cells. Four hours after transfection, cell medium was removed and 
replaced with fresh medium to reduce cell toxicity caused by JetPEI. Twenty 
four hours after transfection, cells were harvested for the luciferase assay. 
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2.9.3 Cell seeding and transfection for combined siRNA 
knockdown/RNA tethering assay 
Working in a class II biological safety cabinet, MCF-7 cells were seeded into 
12-well culture plates at 40,000 cells per well. After 24 hours, cells were at 
40% confluency and subjected to siRNA transfection using Interferin to 
knockdown desired genes. A total of 10nM siRNA (Table 2.14) was added to 
each well (5nM of siRNA1 and 5nM of siRNA2) in a total volume of 1ml 
DMEM. Twenty four hours after siRNA transfection, medium was removed 
and replaced with fresh medium. Forty eight hours after siRNA transfection, 
cells were transfected using GeneJuice transfection reagent. For each 
transfection 0.25µg of pRL-5boxB,  ?Ǥ ? ?  ɉ    ? ? 
Genejuice reagent was used (following instructions in the GeneJuice manual). 
The DNA/Genejuice mixture was incubated for 15 min before being added 
drop wise to the cells. Four hours after transfection, medium was replaced 
with fresh medium to reduce cell toxicity caused by the transfection regent. 
Twenty four hours after transfection cells were harvested for the luciferase 
assay. Each transfection was carried out in triplicate. 
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siRNA Product code 
siControl 
 
siCNOT1 D1 
 
siCNOT1 D2 
 
siCNOT3 D1 
 
siCNOT3 D2 
 
siCNOT7 D1 
 
siCNOT8 D2 
 
siCNOT6 (new) 
 
siCNOT6L (new) 
 
siGENOME Control siRNA, none targeting siRNA #1 
D-001210-01-20 
siGENOME duplex KIAA1007 
D-015369-01 
siGENOME duplex KIAA1007 
D-015369-02 
siGENOME duplex CNOT3 
D-020319-01 
siGENOME duplex CNOT3 
D-020319-02 
siGENOME duplex CNOT7 
D-012897-01 
siGENOME duplex CNOT8 
D-018791-02 
siGENOME siRNA Human KIAA1194 
D-019101-01 
siGENOME siRNA Human CNOT6L 
D-016411-02 
Table 2.14 siRNAs used in RNA tethering assay.  ǯ purchased from 
Dharmacon and stored 20nmol 
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2.9.4 RNA tethering reporter assay 
Twenty four hours after transfection, cells were harvested for the luciferase 
assay. First, cells were washed with 1ml PBS and then 100µl of 1x cell lysis 
buffer (Luciferase cell lysis buffer, NEB B3321S) was added directly to the 
cells in the 12-well culture plate. The plates were then placed at -80°C for 15 
min until completely frozen. Samples were then thawed and mixed by 
pipetting to aid the lysis process before transfer into 1.5ml microfuge tubes. 
Samples were then centrifuged at 16,000g for 5 min at 4°C and stored 
at -80°C or used immediately. 
The Gluc assay solution (BioLux Gaussia Luciferase Assay Kit, NEB E3300S/L) 
was prepared according to the manufactureǯs instructions. The BioLux GLuc 
substrate was diluted (1:100) with BioLux GLuc assay buffer and mixed by 
gentle inverting. In a white opaque flat bottom 96 well plate, 10µl of cell 
lysate was added and the plate was placed into a Berthold Orion microplate 
luminometer. After injection of 50µl of GLuc assay solution, 
chemiluminescence was measured for 2 sec after a 5 sec delay.  Each sample 
was tested in duplicate 
A Bradford assay was conducted for all samples (section 2.11.2) to determine 
total protein concentrations, which was used to normalise the luciferase 
activity.   
 
2.9.5 Cell seeding and transfection for mRNA analysis 
Working in a class II biological safety cabinet, MCF-7 cells were seeded into 
6-well culture plates at 180,000 cells per well. After 24 hours, cells were at 
70% confluency and subjected to DNA transfection using JetPEI transfection 
reagent. For each transfection 1.5µg of pRL-5boxB,  ?Ǥ ? ?  ɉ 
and 4µl of JetPEI reagent was used (following instructions in the JetPEI 
manual). The DNA/JetPEI mixture was incubated for 30 min before being 
added drop wise to the cells. Four hours after transfection, medium was 
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replaced to reduce cell toxicity. Forty eight hours after transfection total RNA 
was extracted and used for cDNA production and qPCR analysis. 
 
2.9.6 Preparation of RNA  
Total RNA was extracted using the RNeasy Plus mini kit (Qiagen, cat no. 
74134) including treatment with RNase-free DNase (Qiagen, cat no. 79254). 
Forty eight hours after transfection; cells were lysed by addition of 350µl RLT 
lysis buffer directly in the well. Gentle mixing of the cell lysate by pipetting 
helped to disrupt the cells. After transfer of the lysate to a 1.5ml microfuge ǡǯǤ
The RNase-free DNase was added directly to the column and incubated at 
room temperature for 15 min before RNA elution using 50µl of DECP-treated 
water. RNA samples were stored at -80.  
 
2.9.7 Production of cDNA  
For the production of cDNA free from plasmid DNA contamination the 
QuantiTect Reverse Transcriptase was used (Qiagen, cat no. 205310). A 
reaction mix was set up as shown in Table 2.15 and incubated in a peqlab 
Primus 96 advanced thermal cycler at 42°C for 2 min before being 
transferred onto ice for a further 1 min.  
To this sample (reaction mix 1) a second master mix was added containing 
the reverse transcriptase and its corresponding buffer as shown in Table 
2.16. This mixture was placed in a peqlab Primus 96 advanced thermal cycler 
and incubated at 42°C for 15 min, followed by incubation at 95°C for 3 min to 
deactivate the enzyme. Resulting cDNA samples were diluted 1:5 with TE 
prior to use, and stored at -20°C until required.  
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Volume Component/Reagent 
x µl 300ng RNA template 
1.0µl gDNA wipeout buffer x7 
up to 7.0µl RNase-free H2O 
Table 2.15 RNA tethering assay: cDNA synthesis reaction mix 1 
 
 
 
 
Volume Component/Reagent 
7µl Reaction mix 1 
2.0µl Reverse transcriptase buffer x5 
0.5µl Reverse transcriptase 
0.5µl  RT primer mix 
Table 2.16 RNA tethering assay: cDNA synthesis reaction mix 2 
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2.10 RNA analysis 
2.10.1 Reagents, buffers and stock solutions for use in RNA analysis 
TE: TE Buffer: 10mM Tris-HCl pH 8.0, 1mM EDTA 
Oligonucleotides: Lyophilised primers were dissolved in TE to give a 100mM 
solution and stored at -20϶C. 
 
2.10.2 Quantitative PCR analysis  
All qPCR reactions were performed using Brilliant II SYBR Green QPCR 
master mix (Stratagene), or Sensi mix SYBR Lox-ROX (Bioline) all samples 
were tested in technical triplicate using primers specific for the gene being 
tested and separately with primers for a housekeeping gene (either ACTB, 
GAPDH or 36B4), which were used for normalisation. A master mix was 
produced containing the appropriate primers (Table 2.18) and the Brilliant II 
SYBR Green master mix (Table 2.17).  
 
 
Volume Component/Reagent 
1.0µl cDNA template 
5.0µl Brilliant II SYBR Green QPCR or Sensi mix SYBR Lox-ROX master 
mix  0.05µl Oligo 1 (10mM) 
0.05µl Oligo 2 (10mM) 
3.9µl  RNase free H2O 
Table 2.17 qPCR reaction set-up 
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The qPCR master mix was pipetted into the appropriate wells of a 96-well 
plate before the cDNA was added. The 96-well plate was placed into the 
Stratagene Mx3005P qPCR machine and subjected to the following program, 
10 min 95°C, 40 cycles at 15 sec 95°C, 60 sec 60°C, followed by melt curve 
analysis of one cycle of 1 min 95°C, 30 sec 55°C, 30 sec 95°C.    
In order to calculate the initial template quantity of the mRNA being tested 
the samples were compared against reference cDNA produced from MCF-7 
cells. Reference cDNA was produced using the standard E.N.Z.A RNA 
extraction and cDNA production methods (section 2.8.2, 2.8.3) from an 
untreated population of cells. To make reference cDNA the standard cDNA 
production protocol was followed but 1µg of RNA was used. The reference 
cDNA was serially diluted 1:10 to produce a standard curve with 5 points 
from 100 to 10-4. These samples were run on the qPCR in duplicate along with 
an RNase free H2O control sample. The H2O control sample was used to 
confirm that there is no RNA, DNA or cDNA contamination in the reaction mix 
or primers. The duplicate standard samples were averaged before plotting as 
a standard curve using the MxPro RT-PCR software. This standard curve was 
then used to identify initial cDNA copy numbers in the samples being tested.  
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2.10.3 List of primers used for qPCR 
 
Name Sequence 
RT BTG1 [1] Fw TGCAGACCTTCAGCCAGAG 
RT BTG1 [1] Rv ATCCCTTGCATGGCTTTTC 
RT BTG2 [1] Fw GCGAGCAGAGGCTTAAGGT 
RT BTG2 [1] Rv GGGAAACCAGTGGTGTTTGTA 
RT BTG3 Fw GAAACCCAGTTCGGTGACTG 
RT BTG3 Rv GCCATTCCCTCGATACATTC 
RT BTG4 Fw GCCTCATCAGACGTTTCCTC 
RT BTG4 Rv AAGGGCTGTTTCAAGTTTTCAA 
CCND1 Fw TGTCCTACTACCGCCTCACA 
CCND1 Rv AGGGCTTCGATCTGCTC 
p21 Fw TCACTGTCTTGTACCCTTGTG 
p21 Rv GGCGTTTGGAGTGGTAGAAA 
p27 Fw CTGCAACCGACCATTCTTCTACT 
p27 Rv CTTCTTGGGCGTCTGCTC 
RT TOB1 [1] Fw TCTGTATGGGCTTGGCTTG 
RT TOB1 [1] Rv TGTTGCTGCTGTGGTGGT 
RT Tob2 Fw AGTCCCCACTCCCTTTCAG 
RT Tob2 Rv GACGAAGTGCTAATCTCCCTGTA 
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RT hRenLucif [1] Fw ATGGGTAAGTCCGGCAAGA 
RT hRenLucif [1] Rv CCAAGCGGTGAGGTACTTGT 
RT GAPDH Fw TCTGGTAAAGTGGATATTCTTG 
RT GAPDH Rv CATGGTGATGGGATTTCC 
RT Actin Fw AGAAAATCTGGCACCACACC 
RT Actin Rv AGAGGCGTACAGGGATAGCA 
RT 36B4 Fw GTGTTCGACAATGGCAGCAT 
RT 35B4 Rv GACACCCTCCAGGAAGCGA 
Table 2.18 Primer used for quantitative PCR. Primers were designed spanning 
exon-exon junctions (where possible) using the Roche Universal ProbeLibrary Assay 
Design Center.   
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2.11 Protein analysis 
2.11.1 Reagents, stock solutions and buffers for use in protein analysis 
Upper buffer (4x):  0.5M Tris base, 0.4% SDS, pH6.8; stored at room 
temperature 
Lower Buffer (4x):  1.5M Tris base, 0.4% SDS, pH8.8; stored at room 
temperature 
Running buffer (10x): 0.25M Tris Base, 1.0% SDS, 1.92M glycine; stored at 
room temperature 
Transfer buffer (10x): 0.25M Tris Base, 1.92M glycine; stored at room 
temperature 
SDS loading buffer (4x): =  ? ? ?  ǡ  ? ? ? ǡ  ? ? Ⱦ-
mercaptoethanol, 1.25% Bromophenolblue (0.1%), 0.25% H2O; stored stock 
at -20°C. Small aliquots were stored short-term at 4°C 
Tris buffer saline supplemented with 0.05% Tween-20 (TBST): = 50mM Tris-
HCl pH 7.8, 150mM NaCl , 0.1% Tween-20. Stored at room temperature. 
10% APS: 10% ammonium persulphate (APS) in H2O 
 
2.11.2 Bradford assay to determine protein concentration  
A Bradford assay was used to determine protein concentration of cell lysates. 
The Bio-Rad protein reagent was allowed to warm up to room temperature 
and diluted 1:5 with H2O before use. A protein standard curve was produced 
using BSA dissolved in water. Standards at 0.1mg/ml, 0.2mg/ml, 0.4mg/ml, 
0.6mg/ml, 0.8mg/ml and 1.0mg/ml were stored at -20°C. Ten microlitres of 
protein sample was added to 990µl of 1x Bradford reagent, vortexed and 
incubated for 1 min at room temperature. Samples were transferred to 1ml 
cuvettes and the absorbance read at OD600. The standard curve was obtained 
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by linear regression analysis using Microsoft Excel and used to calculate the 
protein concentration of the samples.  
 
2.11.3 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
The Invitrogen X-Cell SureLock Mini Cell system was used for SDS-PAGE 
analysis. Gels were prepared as shown in Table 2.19 based on the molecular 
mass of the protein of interest. Separating gels were cast in gel cassettes 
(Invitrogen) leaving ~1.5cm of room at the top for the stacking gel to be cast. 
The separating gel was cast first, 500µl of isopropanol carefully added on top 
and allowed to set for 30 min. The isopropanol was removed by inverting the 
gel and draining onto tissue paper before the stacking gel was applied and 
the appropriate comb inserted. The gels left to set for a further 30 min before 
use or stored for several days at 4°C. Before use the comb was removed and 
the wells washed with 1x running buffer. Protein extracts were denatured by 
boiling for 5 min in 1x SDS sample buffer immediately prior to loading. Gels 
were run in 1x running buffer at 180V for approximately 1-1.5 h. 
 
2.11.4 Western blotting and immunodetection 
Proteins separated on SDS-PAGE gels for western blotting were transferred 
to nitrocellulose (Whatman Protran 0.45µm) membranes using the 
Invitrogen X-Cell SureLock Mini Cell system for 1 h at 25V in transfer buffer. 
The membrane was then blocked in TBST containing 5% dried milk for 1 h at 
room temperature while mixing on a platform shaker. Subsequently, the 
membrane was transferred to a 50ml Falcon tube containing 5ml of the 
appropriate primary antibody solution (for working concentrations and 
diluents see Table 2.20) and incubated overnight at 4°C on a rotating shaker. 
Membranes were then washed three times with TBST for 5 min and then 
incubated with the corresponding secondary antibody (Table 2.21) for 1 h at 
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room temperature on a platform shaker at 60rpm. Another 3 x 5 min TBST 
wash cycle was applied before immunodetection. This involved incubation of 
the membrane with 500µl of ECL western blotting substrate (Pierce) for 
2 min prior to imaging using a Fujifilm LAS-4000 system and image reader 
computer software (Fujifilm, Japan).  
 
 
 Resolving Gel Stacking Gel 
 8% 10% 12% 4% 
Molecular mass 
resolved 
>80kDa 80-30kDa <30kDa  
40% acrylamide: 
bisacrylamide 
(29:1) 
1.6ml 2.0ml 2.4ml 300µl 
4x Lower buffer 2.0ml 2.0ml 2.0ml - 
4x Upper Buffer - - - 750µl 
H2O 4.4ml 4.0ml 3.6ml 1950µl 
10% APS 80µl 80µl 80µl 60µl 
TEMED 8µl 8µl 8µl 6µl 
Table 2.19 Preparation of SDS PAGE gels 
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2.11.5 List of western blot antibodies 
Primary Antibodies Dilution Supplier 
Anti-Actin 
Anti-BTG2 
Anti-BTG2 
Anti-BTG2 
Anti-CDK4 
Anti-CDK6 
Anti-CNOT1 
Anti-CNOT3 
Anti-CNOT7 
Anti-CNOT7 + CNOT8 
Anti-CNOT8 
Anti-CNOT6 
Anti-CNOT6L 
Anti-CNOT6 + CNOT6L 
Anti-CyclinD1 (DCS6) 
Anti-CyclinD3 
Anti-DDK 
Anti-Flag M2 
Anti-Gal4 DBD 
Anti-Gal4 TA 
Anti-HA 
Anti K-Alpha tubulin 
Anti-p15 INK4B 
Anti-p16 INK4A 
Anti-p21 Waf1 
Anti-p27 Kip1 
Anti-Tob1 
Anti-V5 probe 
Anti-ɀ 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 a  
1/1000a 
1/1000a 
1/500 a  
1/500 a 
1/500 a 
1/500 a 
1/500 a 
1/500 a 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 c 
1/5000 c 
1/1000 b 
1/1000 b 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 a 
1/1000 a 
Sigma (A5441) 
GeneTex (GTX1082795) 
Sigma (AV33561) 
Santa Cruz (sc-33775) 
Cell Signalling (#2906) 
Cell Signalling (#3136) 
Proteintech (14276-1AP) 
Abnova (4B8) 
Eurogentec d 
Eurogentec d 
Eurogentec d 
Eurogentec e 
Eurogentec e 
Eurogentec e 
Cell Signalling (#2926) 
Cell Signalling (#2936) 
OriGene (TA100011) 
Sigma (F1805) 
Santa Cruz (sc-510) 
Santa Cruz (sc-1663) 
Roche (1 867 423) 
Sigma (WH0010376M1) 
Cell Signalling (#4822) 
Cell Signalling (#4824) 
Cell Signalling (#2946) 
Cell Signalling (#2552) 
Santa Cruz (sc-33192) 
Santa Cruz (sc-81594) 
Santa Cruz (sc-7396) 
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Table 2.20 Primary antibodies used for western blotting. aAntibodies were 
diluted in TBST containg 5% dried milk powder. bAntibodies were diluted in TBST 
containing 5% BSA. cAntibodies were diluted in TBST. dAntibodies were generated 
through a custom order (Eurogentec project SY4043). eAntibodies were generated 
through a custom order (Eurogentec project SY4049). 
 
 
Secondary Antibodies Dilution Supplier 
Anti-Mouse HRP 
Anti-Rat HRP 
Anti-Rabbit HRP 
Anti-Goat HRP 
1/1000  
1/1000  
1/1000  
1/1000  
Santa Cruz (sc-2314) 
Santa Cruz (sc-2006) 
Santa Cruz (sc-2004) 
Santa Cruz (sc-2020) 
Table 2.21 Secondary antibodies used for western blotting. Antibodies were 
diluted in TBST containing 5% dried milk powder. 
  
 
 
Chapter 3 
 
Identification of amino acids mediating the 
interaction between BTG/TOB proteins and 
the deadenylases Caf1a (CNOT7) and Caf1b 
(CNOT8) 
 
 
 
 
 
 
 
Chapter 3: BTG2/TOB1 interactions with Caf1a (CNOT7)/Caf1b (CNOT8) 
 
109 
 
Chapter 3: Identification of amino acids mediating the 
interaction between BTG/TOB proteins and the 
deadenylases Caf1a (CNOT7) and Caf1b (CNOT8) 
3.1 Introduction  
The BTG/TOB family of proteins contains six members and all (apart from 
BTG4) have been shown to interact with Caf1a (CNOT7) and Caf1b (CNOT8), 
two deadenylase enzymes that form part of the Ccr4-Not complex. The 
interaction has been mapped to the structurally conserved BTG domain as 
illustrated by the crystal structure of TOB1 in complex with Caf1a (CNOT7) 
(Horiuchi et al., 2009). The crystals structure of BTG2 demonstrated the 
conserved structure of the BTG domain between BTG2 and TOB1 (Yang et al., 
2008). During the course of this work a number of amino acid residues in 
BTG2 have been recognised as essential for the BTG2-Caf1a (CNOT7) 
interaction. These amino acids, Gly-64, Tyr-65, Trp-103 and Asp-105 are 
situated within the conserved Box A and Box B regions of the BTG domain 
(Yang et al., 2008). However, no specific amino acid residues in TOB1 have 
been identified as required for its interaction with Caf1a (CNOT7). Due to the 
level of sequence conservation between BTG2 and TOB1 it can be 
hypothesised that the equivalent residues in TOB1 may play a similar role in 
conferring the Caf1a (CNOT7) interaction. Conversely, amino acids located in 
Caf1a (CNOT7) have been identified that are required for its interaction with 
BTG2 and TOB1. Replacement of Lys-203 for alanine in Caf1a (CNOT7) 
disrupts the Caf1a (CNOT7)-TOB1 interaction (Horiuchi et al., 2009). This 
substitution possibly prevents an interaction between two amino acids in close 
proximity, Lys-203 of Caf1a (CNOT7) and Trp-93 of TOB1. Furthermore, two 
additional amino acids in Caf1a (CNOT7) have been identified as required for 
its interaction with BTG2, namely Glu-247 and Tyr-260 (Aslam et al., 2009). All 
of which can be used as tools to discover specific amino acid in BTG2 and 
TOB1 that are required for the Caf1a (CNOT7) interaction.  
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3.2 Identification of candidate residues of BTG2 and TOB1 
required for the interaction with Caf1a (CNOT7) and Caf1b 
(CNOT8) 
To identify potential amino acids required for the interaction between BTG2 
and Caf1a (CNOT7), the protein sequences of the six BTG/TOB members were 
aligned using Clustalw2 (Figure 3.1). The alignment was used to identify 
conserved residues across the protein family likely to be required for the 
interaction with Caf1a (CNOT7) and Caf1b (CNOT8). The BTG domain contains 
two highly conserved regions known as Box A consisting Ⱦ-ȋȾ ?ȌǡȽȋȽ ?ȌȽ ? and Box B which is formed from 
two anti-parallȾ-ȋȾ ?Ⱦ ?ȌǤ  
To further analyse the potential role of the Box A and Box B amino acids in 
mediating the Caf1a (CNOT7)/Caf1b (CNOT8) interaction, the orientation of 
several selected amino acids of BTG2 and TOB1 was analysed using the 
published crystal structure of the BTG domain of TOB1 in complex with Caf1a 
(CNOT7) (PDB accession number 2D5R). Amino acid side chains that protrude 
towards Caf1a (CNOT7) were inspected for interactions with the deadenylase 
and evaluated as potential candidates for experimental validation (Figure 
3.2A). The structure of TOB1 N138 (the N-terminal 138 residues of TOB1 
comprising the BTG domain) interacting with Caf1a (CNOT7) confirms that 
TOB1 interacts via its BTG domain utilising its Box A and Box B domains. In 
addition, by aligning the crystal structure of BTG2 (PBD accession number 
3DJU) with that of TOB1 N138-Caf1a (CNOT7), a model was produced of the 
BTG2-Caf1a (CNOT7) interaction. The structural alignments and analysis was 
performed using PyMOL molecular modelling software. Initially, charged 
amino acids with complex side chains, which may be involved in ionic or 
hydrogen bonding, were focused upon. In addition to this PDBePISA (Protein 
Interface Surface Assemblies) analysis was conducted on the TOB1-Caf1a 
(CNOT7) crystal structure (PDB accession number 2D5R) to characterise the 
interactions between amino acids in TOB1 and Caf1a (CNOT7).  The analysis 
Chapter 3: BTG2/TOB1 interactions with Caf1a (CNOT7)/Caf1b (CNOT8) 
 
111 
 
highlighted accessible and interfacing amino acids and residues likely to cause 
hydrogen bonding or disulphide bridges.  During the course of this work 
additional amino acids were identified as required for the interaction between 
BTG2 and Caf1a (CNOT7), namely, Tyr-65, Trp-103, Asp-105 and Gly-64 (Yang 
et al., 2008). From the combined analysis several amino acids were identified 
for experimental validation (Table 3.1).  
 
 
 
Amino acid in 
BTG2 
Conserved position 
in TOB1 
Location in BTG domain 
His-53 
Tyr-65 
Asp-75 
 Tyr-103 
Asp-105 
Glu-108 
Glu-115 
His-43 
Phe-55 
Asp-65 
 Tyr-93 
Asp-95 
Glu-98 
Glu-105 
Box A 
Box A 
Between Box A and Box B 
Box B 
Box B 
Box B 
Box B 
Table 3.1 List of selected amino acids with a potential role in mediating the 
interaction with Caf1a (CNOT7)/Caf1b (CNOT8) 
 Figure 3.1 Sequence alignment of the human BTG/TOB proteins.  The alignment of the conserved BTG domain was made using Clustalw2. 
Highlighted are the highly conserved regions Box A and Box B and their secondary structure (Yang et al 2008).  In red are conserved amino acid 
residues, blue are highly similar and green are moderately similar residues.  Conserved amino acids outside the Box A and Box B regions are not 
highlighted. The arrows indicate the amino acids substituted for alanine to create interaction mutants. 
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Figure 3.2 Structural analysis of the BTG2-Caf1a (CNOT7) interaction surface. 
Amino acids predicted to be required for the BTG2-Caf1a (CNOT7) interaction and subject 
to experimental validation are shown in green.  BTG2 is represented as a light grey ribbon, 
Caf1a (CNOT7) as a dark grey surface.  This model was based on a Caf1a (CNOT7)-Tob1 
structure (PDB 2D5R) in which BTG2 (PDB 3DJU) was aligned with the TOB1 N138 
structure.  All representations were generated using PyMOL.  
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3.3 Generation of vectors for yeast two-hybrid interaction analysis 
To verify the role of the identified residues in the interaction between BTG2, TOB1 
and Caf1a (CNOT7)/Caf1b (CNOT8) yeast two-hybrid analysis was performed. The 
amino acids being investigated were substituted for alanine to evaluate their 
importance for the interaction with Caf1a (CNOT7) and Cafl1 (CNOT8). Alanine was 
used because it has a small, uncharged side chain and is relatively chemically inert 
compared to the amino acids suspected to play a role in the interaction.  
The BTG2 cDNA was PCR amplified to include an EcoRI restriction site and the HA 
epitope tag at t  ?ǯ          ?ǯ Ǥ  
digested BTG2 cDNA was cloned into the yeast expression vector pBD-Gal4 Cam via 
the EcoRI and SalI restriction sites.  This plasmid produces the Gal4 DNA binding 
domain fused to the N-terminus of BTG2 (Figure 3.3A). The HA epitope tag was 
introduced to facilitate western blot detection. The TOB1 cDNA was cloned via the 
same method into plasmid pBD-Gal4 Cam. The CNOT7 cDNA was PCR amplified to 
include XhoI restriction sites at the both its  ?ǯ ?ǯǤ
CNOT7 cDNA was cloned into the yeast expression vector pAD-Gal4-2.1, which fuses 
the Gal4 transcriptional activation domain to the N-terminus of CNOT7 (Figure 
3.3B). The Gal4 AD-CNOT7 fusion protein was detected using antibodies against the 
Gal4 AD domain. The CNOT8 cDNA was cloned via the same method in to pAD-Gal4-
2.1. All cDNA sequences were confirmed by DNA sequencing. 
To introduce the desired point mutations in BTG2 and TOB1, DNA oligos were 
designed containing the relevant modified codons and used for site directed 
mutagenesis. Plasmids containing the desired mutations were identified through 
DNA sequencing. 
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A
B
MCS
BTG2/TOB1
XhoIEcoRI
HA
EcoRI SalI
pBD-Gal4 Cam
MCS
Caf1a/Caf1b
XhoIXhoI
pAD-Gal4-2.1
XhoI
 
 
Figure 3.3 Generation of plasmids for yeast-two-hybrid interaction analysis. 
(A) Gal4 DNA binding domain hybrids. The BTG2 and TOB1 cDNAs were amplified by Ǥ ?ǯ Ǥ   ?ǯ          Ǥ   
fragments were ligated into yeast expression vector pBD-Gal4 Cam via the EcoRI and SalI 
restriction sites.  (B) Gal4 activation domain hybrids. The CNOT7 and CNOT8 cDNAs    ?ǯ  ?ǯǤ 
fragments were ligated into the yeast expression vector pAD-Gal4-2.1. 
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3.4 Identification of residues required for the BTG2 and TOB1 
interaction with Caf1a (CNOT7)/Caf1b (CNOT8) through yeast two-
hybrid analysis  
To ascertain if any of the amino acids identified are required for the interaction 
between BTG2 and TOB1 with Caf1a (CNOT7)/Caf1b (CNOT8) yeast two-hybrid 
analysis was preformed. The appropriate yeast two-hybrid vectors were 
transformed into yeast strain YRG2 and grown on media without leucine or 
tryptophan to select traǤ       Ⱦ-
galactosidase assay for each BTG2/TOB1 amino acid substitution.  
Transformation of the yeast with pAD-Gal4 and pBD-Gal4-HA confirmed the absence   Ⱦ-galactosidase activity (Figure 3.4B). Transformation of pAD-Gal4 
and pBD-Gal4-HA-BTG confirmed that BTG2 fused to the DNA binding domain was      Ⱦ-galactosidase expression (Figure 3.4B). Upon an 
interaction between BTG2 fused to the Gal4 DNA binding domain and Caf1a 
(CNOT7)    
 ?    Ⱦ-galactosidase 
expression was induced (Figure 3.4A and 3.4B). Of the seven BTG2 constructs 
containing amino acid substitutions three, H53A, E108A and E115A, retained the 
ability to interact with Caf1a ( ?ȌȾ-galactosidase expression. The 
remaining four amino acid substitutions Y65A, D75A, W103A and D105A did not Ⱦ-galactosidase expression and therefore were incapable of interacting with 
Caf1a (CNOT7) (Figure 3.4A and3.4B). From the yeast-    Ⱦ-
Galactosidase assay, protein was extracted for western blot analysis to confirm 
expression of Caf1a (CNOT7) and the various BTG2 mutants (Figure 3.4C).  
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Figure 3.4 Yeast two-hybrid analysis of the BTG2-Caf1a (CNOT7) interaction. 
(A) Schematic representing the yeast two-hybrid experiment. AD, Gal4 activation domain; 
BD, Gal4 DNA binding domain. When an interaction occurs between BTG2 and Caf1a 
(CNOT7), the Gal4-BD and Gal4-AD are brought in close proximity on the Ⱦ-Galactosidase 
promoter thereby inducing transcription (left panel). In the absence of an interaction, Ⱦ-
Galactosidase transcription is not initiated (right panel). (B) YRG2 yeast cells were 
transformed with the indicated vectors; pAD-Gal4 or pAD-Gal4-CNOT7 and pBD-Gal4-HA or 
pBD-Gal4-HA-BTG2. Ⱦ-Galactosidase activity was normalised against total protein. 
Experiments were carried out in triplicate. Error bars represent the standard error of the 
mean. (C) Western blots analysis showing expression of Gal4-BD-HA-BTG2 and Gal4-AD-
Caf1a (CNOT7). Anti-HA antibodies were used to detect Gal4-BD-HA-BTG2, anti-Gal4-AD 
antibodies were used to detect Gal4-AD-Caf1a (CNOT7).   
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Yeast two-hybrid analysis was also performed to investigate the interaction 
between Caf1b (CNOT8) and the BTG2 mutants. As expected the interaction 
between BTG2 fused to the Gal4 DNA binding domain and Caf1b (CNOT8) fused to  
 ?     Ⱦ-galactosidase expression 
(Figure 3.5A and 3.5B). Two of the seven BTG2 mutants, E108A and E115A retained  ?ȋ ?ȌȾ-galactosidase expression. 
The remaining five amino acid substitutions, H53A, Y65A, D75A, W103A and D105A,     Ⱦ-galactosidase expression and therefore were incapable of 
interacting with Caf1b (CNOT8) (Figure 3.5A and 3.5B). This is in contrast to the 
BTG2-Caf1a (CNOT7) interaction where BTG2 H53A retained the ability to interact  ?ȋ ?ȌǤ	Ⱦ-galactosidase assay I also 
extracted protein for western blot analysis to confirm expression of Caf1b (CNOT8) 
and the various BTG2 mutants (Figure 3.5C).  
The yeast two-hybrid analysis identified four BTG2 mutants, Y65A, D75A, W103A 
and D105A, which were unable to interact with Caf1a (CNOT7) and Caf1b (CNOT8). 
The H53A amino acid substitution of BTG2 was only capable of disrupting the 
interaction with Caf1b (CNOT8). Both amino acid changes E108A and E115A did not 
disrupt the interaction between BTG2 and Caf1a (CNOT7) or Caf1b (CNOT8).  
 
 
 
 
 
 
 
 
Chapter 3: BTG2/TOB1 interactions with Caf1a (CNOT7)/Caf1b (CNOT8) 
 
119 
 
 
Figure 3.5 Yeast two-hybrid analysis of the BTG2-Caf1b (CNOT8) interaction. 
(A) Schematic representing the yeast two-hybrid experiment. AD, Gal4 activation domain; 
BD, Gal4 DNA binding domain. When an interaction occurs between BTG2 and Caf1b 
(CNOT8), the Gal4-BD and Gal4-AD are brought in close proximity on the Ⱦ-Galactosidase 
promoter thereby inducing transcription (left panel). In the absence of an interaction, Ⱦ-
Galactosidase transcription is not initiated (right panel). (B) YRG2 yeast cells were 
transformed with the indicated vectors; pAD-Gal4 or pAD-Gal4-CNOT8 and pBD-Gal4-HA or 
pBD-Gal4-HA-BTG2. Ⱦ-Galactosidase activity was normalised against total protein. 
Experiments were carried out in triplicate. Error bars represent the standard error of the 
mean.  (C) Western blots analysis showing expression of Gal4-BD-HA-BTG2 and Gal4-AD-
Caf1b (CNOT8). Anti-HA antibodies were used to detect Gal4-BD-HA-BTG2, anti-Gal4-AD 
antibodies were used to detect Gal4-AD-Caf1b (CNOT8).   
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To ascertain if the equivalent amino acid substitutions in TOB1 are also capable of 
disrupting the interaction with Caf1a (CNOT7) and Caf1b (CNOT8), further yeast 
two-hybrid analysis was conducted (Figure 3.6A). All of the amino acids substituted 
in BTG2 are conserved in TOB1, apart from Tyr-65 which in TOB1 is Phe-55, a 
structurally similar amino acid. The TOB1 yeast two-hybrid vectors were co-
transfected into yeast strain YRG2 along with either pAD-CNOT7 or pAD-CNOT8. 
Transformation of the YRG2 yeast with pAD-Gal4 and pBD-Gal4-HA confirmed the    Ⱦ-galactosidase activity while transformation of pAD-Gal4 
with pBD-Gal4-HA-TOB1 confirmed that TOB1 fused to the DNA binding domain       Ⱦ-galactosidase expression (Figure 3.6B and 
3.6C). As expected transformation of yeast strain YRG2 with TOB1 fused to the Gal4 
DNA binding domain and Caf1a (CNOT7) or Caf1b (CNOT8) fused to the Gal4     Ⱦ-Galactosidase expression. This 
confirms that TOB1 is capable of interacting with Caf1a (CNOT7) and Caf1b 
(CNOT8). Two of the seven TOB1 mutants E98A and E105A retained the ability to    ? ȋ ?Ȍ   ? ȋ ?Ȍ   Ⱦ-galactosidase 
expression. The remaining five mutants H43A, F55A, D65A, W93A and D95A did not Ⱦ-galactosidase expression and therefore were incapable of interacting with 
Caf1a (CNOT7) or Caf1b (CNOT8) (Figure 3.6B and 3.6C). This was in contrast to the 
BTG2-Caf1a (CNOT7) interaction analysis where amino acid substitution H53A did 
not disrupt the interaction between BTG2 and Caf1a (CNOT7). However, the 
equitant substitution in TOB1 (H43A) did disrupt the interaction with Caf1a 
(CNOT7).  
In summary, the yeast two-hybrid analysis identified four amino acid substitutions 
that disrupt the interaction between BTG2/TOB1 and Caf1a (CNOT7) and Caf1b 
(CNOT8) (Table 3.2).  
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Figure 3.6 Yeast two-hybrid analysis of the TOB1-Caf1a (CNOT7)/Caf1b (CNOT8) 
interaction. (A) Schematic representing the yeast two-hybrid experiment. AD, Gal4 
activation domain; BD, Gal4 DNA binding domain.  When an interaction occurs between 
TOB1 and Caf1a (CNOT7) or Caf1b (CNOT8), the Gal4-BD and Gal4-AD are brought in close 
proximity on the Ⱦ-Galactosidase promoter thereby inducing transcription (left panel). In 
the absence of an interaction, Ⱦ-Galactosidase transcription is not initiated (right panel). (B) 
YRG2 yeast cells were transformed with the indicated vectors; pAD-Gal4 or pAD-Gal4-
CNOT7 and pBD-Gal4-HA or pBD-Gal4-HA-TOB1.  Ⱦ-Galactosidase activity was normalised 
against total protein.  (C) YRG2 yeast cells were transformed with the indicated vectors; 
pAD-Gal4 or pAD-Gal4-CNOT8 and pBD-Gal4-HA or pBD-Gal4-HA-TOB1.  Ⱦ-Galactosidase 
activity was normalised against total protein. All experiments were carried out in triplicate. 
Error bars represent the standard error of the mean.  
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Amino acid in 
BTG2 
Conserved position 
in TOB1 
Location in BTG domain 
Tyr-65 
Asp-75 
 Tyr-103 
Asp-105 
Phe-55 
Asp-65 
 Tyr-93 
Asp-95 
Box A 
Between Box A and Box B 
Box B 
Box B 
Table 3.2 List of identified amino acids required in mediating the interaction 
with Caf1a (CNOT7) and Caf1b (CNOT8) 
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3.5 Generation of mammalian BTG2 and TOB1 expression vectors 
To verify that the amino acid substitutions that disrupt the BTG2-Caf1a (CNOT7) 
interaction in the yeast two-hybrid analysis are also capable of disrupting the 
interaction in mammalian cells, co-immunoprecipitation analysis was preformed. To 
this end, expression vectors containing Flag and HA-tagged versions of the BTG2 
cDNA were generated. To introduce the BTG2 cDNA into the pcDNA3-Flag plasmid, 
 ?             ?ǯ   ?ǯ Ǥ
This PCR fragment was ligated into the SmaI restriction site of the pBluescript II 
KS(+) cloning vector. The pBluescript-BTG2 plasmid was digested with BamHI and 
EcoRV to release the BTG2 cDNA, which was ligated into pcDNA3-Flag (digested 
with BamHI-EcoRV). To introduce the Flag-BTG2 cDNA into plasmid pcDNA4-TO, 
the pcDNA3-Flag-BTG2 plasmid was digested with HindIII and EcoRV to release the 
Flag-BTG2 cDNA. This fragment was ligated into pcDNA4-TO plasmid through the 
HindIII and EcoRV restriction sites (Figure 3.7A). 
To introduce the BTG2 cDNA into the plasmid pCMV5-HA, plasmid pBluescript-
BTG2 was digested with XhoI to release the BTG2 cDNA. This cDNA fragment was 
ligated into the SalI restriction site of pCMV5-HA (Figure 3.7B). To introduce the 
desired point mutations into BTG2, DNA oligos were designed containing the 
relevant modified codons and used for site directed mutagenesis. Plasmids 
containing the desired mutations were identified through DNA sequencing. 
Expression plasmids containing epitope-tagged CNOT7 are described in Aslam et al 
(2009). 
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Figure 3.7 Generation of Flag-BTG2 and HA-BTG2 expression vectors. The 
human BTG2 cDNA was amplified by reverse transcriptase PCR using total RNA 
isolated from MCF- ?Ǥ ?ǯ
the ATG  ?ǯǤ
the cloning vector pBluescript II KS(+) via the SmaI restriction site to generate 
pBluescript-BTG2. (A) The BTG2 cDNA was excised with BamHI and EcoRV and 
subcloned into plasmid pcDNA3-Flag. (B) Subsequently, the Flag-BTG2 fragment 
was subcloned from pcDNA3-Flag-BTG2 into pcDNA4-TO using the HindIII and 
EcoRV restriction sites. (C) Or the BTG2 cDNA was excised from pBluescript-BTG2 
with XhoI and subcloned into plasmid pCMV5-HA via the Sal1 restriction site.  
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3.6 Confirmation of the amino acids required for the BTG2-
Caf1a (CNOT7) interaction through co-immunoprecipitation 
analysis 
To confirm the role of the selected amino acids in mediating BTG2-Caf1a 
(CNOT7) interactions in the context of mammalian cells, immunoprecipitation 
analysis was conducted. To distinguish BTG2 containing amino acid 
substitutions from endogenous BTG2, epitope tagged variants of BTG2 and 
Caf1a (CNOT7) were used. The appropriate mammalian expression plasmids 
were co-transfected into HEK293T cells before total cell lysates were produced. 
Western blot analysis of the total cell lysates was performed before the 
immuno-precipitation step to confirm equal expression of HA-CNOT7. Wild-type 
Flag-BTG2 and Flag-BTG2 containing amino acid substitutions were 
precipitated using the anti-Flag coated beads. As expected, no precipitation of 
HA-Caf1a (CNOT7) was demonstrated in the absence of Flag-BTG2 (Figure 3.8). 
By contrast, Flag-BTG2 was able to immuno-precipitate HA-Caf1a (CNOT7). Of 
the seven BTG2 proteins containing amino acid substitutions, E108A and 
W115A maintained the BTG2-Caf1a (CNOT7) interaction. A weak signal of HA-
Caf1a (CNOT7) was seen upon immunoprecipitation of BTG2 H53A. The 
remaining four amino acid substitutions, Y65A, D75A, W103A and D105A, did 
not co-precipitate HA-Caf1a (CNOT7) indicating that these amino acids are 
important for the BTG2-Caf1a (CNOT7) interaction (Figure 3.8). 
To confirm the co-immunoprecipitation result, a reciprocal co-
immunoprecipitation assay was performed using Flag-Caf1a (CNOT7) and HA-
BTG2. HEK293T cells were co-transfected with pcDNA3-Flag-CNOT7 and 
appropriate pCMV5-HA-BTG2 plasmids. Western blot analysis of the total cell 
lysates was performed before the immuno-precipitation step to confirm equal 
expression of Flag-Caf1a (CNOT7) and HA-BTG2. As expected, no 
immunoprecipitation of HA-BTG2 was seen in the absence of Flag-Caf1a 
(CNOT7) (Figure 3.9). By contrast, Flag-Caf1a (CNOT7) was able to 
immunoprecipitate wild type HA-BTG2.  
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Figure 3.8 Analysis of the Flag-BTG2-HA-Caf1a (CNOT7) interaction by co-
immunoprecipitation. HEK293T cells were transfected with pCMV5-HA-CNOT7 and 
pcDNA4-TO-Flag-BTG2, or empty vector.  Anti-Flag coated agarose beads were used to 
pull down Flag-BTG2.  The eluted protein samples were loaded on to SDS PAGE gels 
and western blot analysis was conducted using anti-Flag and anti-HA antibodies.  The 
input sample contained 2.5% of total protein as compared to the amount used for the 
immuno-precipitation.  
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Figure 3.9 Co-immunoprecipitation assay using HA-BTG2 and Flag-Caf1a 
(CNOT7). HEK293T cells were transfected with pcDNA3-Flag-CNOT7 and pCMV5-HA-
BTG2, or empty vector.  Anti-Flag coated agarose beads were used to pull down Flag-
Caf1a (CNOT7).  The eluted protein samples were loaded on to SDS PAGE gels and 
western blot analysis was conducted using anti-HA and anti-Flag antibodies.  The input 
sample contained 2.5% of total protein as compared to the amount used for the 
immuno-precipitation. 
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A weak signal was seen when BTG2 H53A or BTG2 D105A was expressed. The 
remaining three amino acid substitutions Y65A, D75A and W103A, did not co-
immunoprecipitate with Flag-Caf1a (CNOT7) indicating the importance of these 
amino acids (Figure 3.9).  
Together, the results presented in this chapter demonstrated that the amino 
acid substitutions Y65A, D75A and W103A can prevent the interaction between 
BTG2 and Caf1a (CNOT7)/Caf1b (CNOT8). The equivalent amino acid 
substitutions in Tob1, F55A, D65A and W93A also disrupt the TOB1-Caf1a 
(CNOT7)/Caf1b (CNOT8) interactions.  
 
3.7 Discussion 
The experiments described in this chapter identify three amino acids in BTG2 
and TOB1 that are required for the interactions with Caf1a (CNOT7) and Caf1b 
(CNOT8). These amino acids are Tyr-65, Asp-75 and Trp-103 of BTG2 and Phe-
55, Asp-65 and Trp-93 of TOB1. These finding are corroborated by data 
published during this study by (Yang et al., 2008), who also demonstrated that 
amino acid substitutions Y65A, W103A, D105A, and the combined amino acid 
change G64A/W103A disrupted the BTG2-Caf1a (CNOT7) interaction.  
Residues Tyr-65 of BTG2 and Phe-55 of TOB1 are positioned in the conserved 
Box A region and come into close proximity with Caf1a (CNOT7). However, after 
further analysis of the crystal structure of the TOB1-Caf1a (CNOT7) complex, 
these amino acids do not appear to from any specific interaction with amino 
acid side chains of Caf1a (CNOT7). I predict that Y65A/F55A may be required 
for maintaining the helical secondary structure of the Box A region though 
stacking interactions with the aromatic side chain of His-53 of BTG2 or His-43 of 
TOB1, respectively (Figure 3.10A). Therefore, the amino acid substitutions Y65A 
of BTG2 and F55A of TOB1 may disrupt the secondary structure of Box A thus 
preventing BTG2 and TOB1 to form interactions with Caf1a (CNOT7) and Caf1b 
(CNOT8).   
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Figure 3.10 Structural analysis of the amino acids required for the interaction 
between BTG2 and Caf1a (CNOT7). (A) Tyr-65 and His-53 of BTG2 are highlighted. 
The aromatic ring of Tyr-65 may interact through stacking interactions with the 
aromatic ring of His-53 to maintain the helical structure of Box A. (B) Asp-75 and Ile- 
68 of BTG2 are highlighted.  Asp-75 is not located in either Box A or Box B but may 
interact with Ile-68 or the protein backbone to maintain the helical structure of Box A. 
(C) Trp-103 of BTG2 and Lys-203 of Caf1a (CNOT7) are highlighted.  Trp-103 of BTG2 
is predicted to interact with the aliphatic part of Lys-203 of Caf1a (CNOT7).  Light blue, 
BTG2 (PDB accession number 3DJU); Wheat, Caf1a (CNOT7) (PDB accession number 
2D5R). The BTG2 backbone was aligned with TOB1. All representations were generated 
using PyMOL. 
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Asp-75 in BTG2 and Asp-65 in TOB1 are conserved across all members of the 
BTG/TOB family. However, these residues are not located within one of the 
highly conserved regions of the BTG domain but in the linker region between 
Box A and Box B. It is located adjacent to a proline residue indicating that it may 
be required to form a loop or turn in the protein structure. It may also form 
hydrogen Ƚ-helix backbone to maintain the secondary structure 
of the BTG domain (Figure 3.10B). I predict that the amino acid changes D75A of 
BTG2 and D65A of TOB1 cause misfolding of the BTG domain thus preventing 
the interaction with Caf1a (CNOT7). 
Trp-103 in BTG2 and Trp-93 in TOB1 are located in the middle of the Box B ǡ      Ⱦ-sheet with its aromatic side chain protruding 
towards Caf1a (CNOT7). This side chain may form direct interactions with the 
aliphatic portion of the Lys-203 side chain of Caf1a (CNOT7) (Figure 3.10C). 
Furthermore, PDBePISA analysis indicated that that TOB1 Trp-93 is fully buried 
in Caf1a (CNOT7) where it is capable of hydrogen bonding. The position of the 
side chain suggests that it is required for a direct interaction with Caf1a 
(CNOT7). It is likely that substituting aromatic amino acid like tryptophan for 
alanine, would disrupt any interaction between the residues Trp-103 of 
BTG2/Trp-93 of TOB1 and Lys-203 of Caf1a (CNOT7)/Caf1b (CNOT8). 
Co-immunoprecipitation was not used to confirm the disruption of the TOB1-
Caf1a (CNOT7) interaction as a result of the amino acid substitutions due to 
difficulties in detecting TOB1 via western blot. However, due to the high level of 
sequence and structural conservation between N-terminal domains of BTG2 and 
TOB1 (Figure 3.11A and 3.11B) and the reproducibility of the yeast two-hybrid 
results, we assume that the TOB1 W93A amino acid substitution will disrupt the 
TOB1-Caf1a (CNOT7)/Caf1b (CNOT8) interactions in mammalian cells.   
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Figure 3.11 Structural alignments of the BTG domains of BTG2 and TOB1. 
 (A) The structure of the BTG domain of TOB1-Caf1a (CNOT7) (PDB accession number 
2D5R). The predicted BTG2-Caf1a (CNOT7) interaction was produced by aligning BTG2 
(PDB accession number 3DJU) with the TOB1 N138 backbone. (B) Schematic 
representation of the structures of the BTG domains of BTG2 and TOB1. BTG2 and 
TOB1 were aligned to confirm the identical positioning of Trp-103 of BTG2 and Trp-93 
of TOB1.  Wheat, Caf1a (CNOT7); light blue, BTG2; light green, TOB1; Lys-203 of 
Caf1a(CNOT7), Trp-103 of BTG2 and Trp-93 of TOB1 are highlighted in green.  All 
representations were generated using PyMOL. 
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During the course of this work several further amino acid residues were 
identified as required for the TOB1/TOB2ȂCaf1a (CNOT7) interaction. 
Combined substitution of three leucine residues (Leu-32, Leu-35 and Leu-36) 
located close to the amino terminus of TOB1/TOB2 for glycine disrupts the 
TOB1/TOB2-Caf1a (CNOT7) interaction (Ezzeddine et al., 2012). Interestingly, 
PDBePISA analysis suggests that Leu-32 is an inacessible residue and that Leu-
35 and Leu-36 are not favourable candidates to form protein-protein 
interactions. Further data by Ezzeddine et al (2012), identified amino acids Glu-
62, Met-63 and Asp-65 as required for the TOB1/TOB2ȂCaf1a (CNOT7) 
interaction. Interestingly, yeast two-hybrid analysis conducted in this thesis also 
identified TOB1 Asp-65 as required for the TOB1-Caf1a (CNOT7) interaction. I 
preferred the use of the single amino acid substitutions W103A of BTG2 and 
W93A of TOB1 over the triple amino acid substitutions used by Ezzeddine et al 
(2012), because the latter may have a more dramatic effect on protein structure. 
On the basis of this interaction analysis, amino acid substitutions W103A of 
BTG2 and W93A of TOB1 were selected to evaluate the functional importance of 
the interactions between BTG2/TOB1 and Caf1a (CNOT7)/Caf1b (CNOT8). 
These interaction mutants can be used to investigate the importance of the 
interaction for the anti-proliferative activity of BTG2 and TOB1.  
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Chapter 4: The activity of BTG2/TOB1 is mediated 
through interactions with Caf1a (CNOT7) and Caf1b 
(CNOT8)  
4.1 Introduction 
The anti-proliferative activity of the BTG/TOB proteins has been 
demonstrated in a number of different cell lines. Over-expression of BTG1 
and BTG2 in WEHI-231 cells causes a significant decrease in the rate of cell 
proliferation (Hata et al., 2007). Interestingly, over-expression of TOB2 and 
BTG3 in the same cell line only has a marginal effect on cell proliferation 
indicating that the BTG/TOB proteins may function cell specifically (Hata et 
al., 2007). The expression of BTG/TOB proteins causes an increase in the 
number of cells in G1 suggesting they act upon the G1 to S-phase cell cycle 
transition (Ikematsu et al., 1999; Rouault et al., 1992). After expression of 
BTG1 and BTG2 in WEHI-231 the number of cells in G1 significantly 
increases, which is paralleled by a drop in the number of cells in S-phase 
(Hata et al., 2007). Progression into S-phase     ǲ  ǳyond which the cell is committed to DNA replication and division. 
Cell cycle progression is regulated by the activity of cyclin proteins and their 
corresponding cyclin-dependant kinases (CDK). For progression into S-phase 
the expression of S-phase specific genes such as Cyclin E1 and c-Myc must be 
induced. During G1, transcription of S-phase promoters is repressed by a 
transcription factor complex containing hypo-phosphorylated 
retinoblastoma protein (Rb), HDAC and E2F. To enter S-phase two cell cycle 
kinase-complexes, CDK4/6-Cyclin D and CDK2-Cyclin E work together to 
phosphorylate Rb, which displaces it from the transcription factor complex 
and relieves transcription repression (Figure 4.1). Hence, the levels and 
activity of these two cell cycle kinase-complexes directly lead to the 
transcriptional activation of S-phase promoting genes (Malumbres and 
Barbacid, 2009; van den Heuvel and Dyson, 2008). 
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Figure 4.1 Model of the mammalian cell cycle. Cell cycle progression is driven by 
different cyclin dependant dependent kinase (CDK)/Cyclin complexes. Core 
components involved in the regulation of the G1 to S-phase transition are indicated.  
The CDK4/6-CyclinD1 and CDK2-CyclinE complexes act to phosphorylate the 
Retinoblastoma (Rb) protein causing it to dissociate from its transcription factor 
complex E2F and relieve repression of S-phase promoting genes. Both CDK4/6-
CyclinD1 and CDK2-CyclinE complexes are inhibited by p15 (INK4A), p16 (INK4B) 
and p21 (Cip1/Waf1), p27 (Kip1) respectively.     
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Regulation of the G1 check point responds to signalling molecules such as 
growth factors and cellular stress such as DNA damage, both known inducers 
of BTG/TOB expression. The induction of BTG2 through p53 signalling causes 
an arrest in cell cycle progression, specifically at the G1-S check point 
through reduced Cyclin D1 transcription and CDK4 activation (Donato et al., 
2007; Guardavaccaro et al., 2000). Similarly, inhibition of TOB1 activity 
through growth factor stimulation leads to an increase in Cyclin D1 
transcription driving cell proliferation (Suzuki et al., 2002).  
 
One unresolved question in the field is the link between the BTG/TOB anti-
proliferative activity and their interactions with the Caf1a (CNOT7) and 
Caf1b (CNOT8) deadenylase subunits of the Ccr4-Not complex. To date, 
different conclusions have been drawn based on mutagenesis studies to 
disrupt the BTG/TOB-Caf1a (CNOT7)/Caf1b (CNOT8) interaction. Expression 
of Caf1a (CNOT7)/Caf1b (CNOT8) is required for efficient transition from G1 
to S phase in MCF-7 cells (Aslam et al., 2009). Interestingly, introduction of 
amino acid substitutions in Caf1a (CNOT7)/Caf1b (CNOT8) that prevent 
binding to BTG2 suggest that Caf1a (CNOT7)/Caf1b (CNOT8) does not 
required an interaction with BTG2 to facilitate cell division. Conversely, it 
was suggested that TOB1 requires an interaction with Caf1a (CNOT7) to be 
anti-proliferative in HEK293 and COS-1 cells (Horiuchi et al., 2009). However, 
again, in the study the BTG/TOB-Caf1a (CNOT7)/Caf1b (CNOT8) interaction 
was disrupted by substituting amino acid in Caf1a (CNOT7). Based on these 
reports, it is difficult to determine whether the loss of BTG2/TOB1 activity 
shown by Aslam et al (2009) and Horiuchi et al (2009) is due to prevention of 
binding with Caf1a (CNOT7) or simply due to a loss of proper Caf1a (CNOT7) 
function.  
 
A second outstanding question is the role phosphorylation plays in regulating 
the BTG2 and TOB1 anti-proliferative activity (Hong et al., 2005; Suzuki et al., 
2002; Suzuki et al., 2001). Phosphorylation of TOB1 contributes to the 
Chapter 4: The effect of BTG/TOB expression on cell proliferation 
 
137 
 
progression of thyroid cancer and is often present in early lung carcinomas 
where it heightens cancer progression (Ito et al., 2005; Iwanaga et al., 2003; 
Yoshida et al., 2003a). This evidence suggests that phosphorylation of TOB1 
leads to reduced anti-proliferative activity.  
 
Together, the current published data gives contradictory conclusions as to 
the requirement of the BTG/TOB- Caf1a (CNOT7)/Caf1b (CNOT8) interaction 
for BTG/TOB anti-proliferative activity and whether phosphorylation is 
capable of regulating that activity. To address these questions BTG2 and 
TOB1 containing amino acid substitutions that prevent the Caf1a 
(CNOT7)/Caf1b (CNOT8) interaction or phosphorylation were over 
expressed in MCF-7 cells. From this their effect on cell proliferation was 
investigated further. Initially the activity of the six BTG/TOB proteins in MCF-
7 cells was determined to identify the most relevant members to investigate 
further. Utilising the BTG2/TOB1-Caf1a (CNOT7)/Caf1b (CNOT8) interaction 
mutants identified in Chapter 3 the importance of this interaction for 
BTG/TOB anti-proliferative activity was assessed. Furthermore the 
importance of phosphorylation as a mechanism for regulating BTG/TOB 
activity was investigated though amino acid substitutions designed to 
prevent phosphorylation.     
 
During the course of this work Ezziddine et al (2012) disrupted the 
TOB1/TOB2 interaction with Caf1a (CNOT7)/Caf1b (CNOT8) by introducing 
amino acid substitutions in the TOB1/TOB2 N-terminal region. This work 
demonstrated that disrupting the TOB1/TOB2 interaction with Caf1a 
(CNOT7)/Caf1b (CNOT8) caused TOB1 and TOB2 to lose anti-proliferative 
activity. Furthermore, Ezziddine et al (2012) demonstrated that preventing 
TOB1 phosphorylation by replacing target serine residues for alanine did not 
alter the TOB1/TOB2 anti-proliferative activity.   
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4.2 Expression and anti-proliferative activity of BTG/TOB 
proteins in MCF-7 cells 
To identify which of the six BTG/TOB genes regulate cell-cycle progression in 
MCF-7 cells, we first analysed expression data previously obtained using the 
Affymetrix GeneChip platform (Mittal et al., 2011). The analysis identified 
significant levels of BTG1, BTG2, TOB1 and TOB2 mRNAs, and indicated no 
expression of BTG3 and BTG4 (Figure 4.2A). TOB1 was the most expressed 
gene and significantly higher than all other BTG/TOB members. BTG1 
expression was approximately four fold lower than that of TOB1. BTG2 
demonstrated the lowest expression level compared TOB1, TOB2 and BTG1. 
The relative expression of the BTG/TOB genes was confirmed through RT-
qPCR analysis using GAPDH or 36B4 as reference genes (Figure 4.2B, 4.2C). 
This suggests that TOB1 is the most highly expressed of the six BTG/TOB 
proteins, BTG2 is the least expressed and BTG3 and BTG4 are not transcribed 
at all.  
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Figure 4.2 Expression of BTG/TOB family members in MCF-7 cells. (A) 
Expression of BTG/TOB family members in MCF-7 cells. Data was obtained by 
genome-wide expression data using microarrays. (B) RT-qPCR analysis indicating 
the relative level of BTG/TOB mRNA compared to GAPDH in MCF-7 cells. (C) RT-
qPCR analysis indicating the relative level of BTG/TOB mRNA compared to 36B4 in 
MCF-7 cells.  
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To ascertain whether the expressed members of the BTG/TOB family 
regulate cell proliferation of MCF-7 cells, siRNA knockdown was performed. 
MCF-7 cells were treated with specific siRNA duplexes targeting BTG1, BTG2, 
TOB1 or TOB2, or non-targeting control siRNA. After 48 h, and the number of 
cells in S-phase was determined through the addition of a thymidine 
analogue (EdU) to the culture medium for 2 h before its detection via    	  ? ? ?   Ǯǯ Ǥ   
BTG1, BTG2, TOB1 and TOB2 was confirmed through RT-qPCR analysis with 
GAPDH as a reference gene (Figure 4.3A). For all tested BTG/TOB mRNAs, the 
relative mRNA abundance decreased by >75% after siRNA treatment. 
Interestingly, siRNA knockdown of BTG1 and TOB2 did not affect the number 
of cells in S-phase compared to cells treated with non-targeting siRNA. By 
contrast, siRNA-mediated knockdown of BTG2 and TOB1 caused a significant 
increase in the number of cells in S-phase (Figure 4.3B). This is surprising 
because the expression of BTG1 and TOB2 are significantly higher than that 
of BTG2. Another surprise was the lack of a significant difference in the 
number of cells in S-phase after BTG2 knockdown compared to TOB1 
knockdown, because the expression of TOB1 is approximately 8-fold higher 
than that of BTG2  (Figure 4.2A).  
In summary, Affymetrix GeneChip expression data and RT-qPCR analysis 
demonstrates that BTG1, BTG2, TOB1 and TOB2 are expressed in MCF-7 cells. 
However, only two BTG2 and TOB1 affect cell proliferation rates. The fact 
that BTG2 knockdown causes a comparable increase in the number of cells in 
S-phase as compared to knockdown of the highly expressed TOB1 suggests 
that the effect on cell proliferation of BTG2 and TOB1 is independent of gene 
expression level.  
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Figure 4.3 Increased cell proliferation following siRNA-mediated knockdown 
of BTG/TOB components. (A) RT-qPCR analysis to confirm knockdown of BTG1, 
BTG2, TOB1 and TOB2 in MCF-7 cells after siRNA transfection. 48 h after siRNA 
treatment, total RNA was isolated and subjected to RT-qPCR analysis using GAPDH 
as a reference. (B) Knockdown of BTG2 and TOB1 causes an increase in the number 
of cells in S phase. Cells in S-phase were detected by pulse labelling using the  ? ?Ǥǯ-test was used 
to calculate p-values.  * p< 0.05 (compared to non-targeting control siRNA). 
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4.3 BTG2 and TOB1 display limited redundancy      
To exclude that functional redundancy masked the involvement of BTG1 and 
TOB2 in the regulation of MCF-7 cell proliferation, dual knockdowns were 
performed for all binary combinations of expressed BTG/TOB family 
members.  
To investigate redundancy between BTG1 and BTG2, MCF-7 cells were 
transfected with a mixture of siRNA duplexes targeting BTG1 and non-
targeting siRNA, BTG2 and non-targeting siRNA, or a pool of siRNAs targeting 
both BTG1 and BTG2, respectively. Combined knockdown of BTG1 and BTG2 
was confirmed by RT-qPCR analysis with GAPDH as a reference gene (Figure 
4.4A, 4.4B). The knockdown efficiency was similar for the single and dual 
knockdown of BTG1 and BTG2. As expected, single knockdown of BTG1 had 
no effect on cell cycle progression into S-phase, whereas knockdown of BTG2 
caused an increase of cells in S-phase. The combined knockdown of BTG1 and 
BTG2 did not cause a further increase of the number of cells in S-phase as 
compared to knockdown of BTG2 (Figure 4.4C). This suggests that there is no 
functional redundancy between BTG1 and BTG2 in MCF-7 cells.     
A similar approach was used to investigate possible redundancy between 
BTG1 and TOB1. Combined knockdown of BTG1 and TOB1 was confirmed 
through RT-qPCR analysis with GAPDH as a reference gene (Figure 4.5A, 
4.5B). In this case, the knockdown efficiency of BTG1 and TOB1 was reduced 
upon combined knockdown compared to MCF-7 cells treated with the single 
siRNA. As expected, knockdown of BTG1 had no effect on progression into S-
phase, while knockdown of TOB1 caused an increase in the number of cells in 
S-phase. Importantly, the combined knockdown of BTG1 and TOB1 did not 
cause a further increase of the number of cells in S-phase as compared to 
knockdown of TOB1 (Figure 4.5C). This indicates that there is no redundancy 
between TOB1 and BTG1. Interestingly, the reduced knockdown efficiency of 
TOB1 when combined with BTG1 did not affect the number of cell in S-phase.  
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Figure 4.4 Combined knockdown of BTG1 and BTG2 does not further increase 
cell proliferation. (A, B) RT-qPCR analysis to confirm knockdown of BTG1 and 
BTG2 in MCF-7 cells after siRNA transfection. 48 h after siRNA treatment total RNA 
was isolated and subjected to RT-qPCR analysis using GAPDH as a reference. (C) 
Combined knockdown of BTG1 and BTG2 did not cause a further increase in the 
number of cells in S-phase. Cells in S-phase were detected by pulse-labelling using   ? ?Ǥ ǯ -test was 
used to calculate p-values.  * p< 0.05 (compared to non-targeting control siRNA). 
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Figure 4.5 Combined knockdown of BTG1 and TOB1 does not further increase 
cell proliferation. (A, B) RT-qPCR analysis to confirm knockdown of BTG1 and 
TOB1 in MCF-7 cells after siRNA transfection. 48 h after siRNA treatment total RNA 
was isolated and subjected to RT-qPCR analysis using GAPDH as a reference. (C) 
Combined knockdown of BTG1 and TOB1 did not cause a further increase in the 
number of cells in S-phase. Cells in S-phase were detected by pulse-labelling using   ? ?Ǥ ǯ -test was 
used to calculate p-values.  * p< 0.05 (compared to non-targeting control siRNA). 
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Combined knockdown of BTG1 and TOB2 was confirmed through RT-qPCR 
analysis with GAPDH as a reference gene (Figure 4.6A, 4.6B). The knockdown 
efficiency was similar for the single and dual knockdown of BTG1 and TOB2. 
Combined knockdown of BTG1 and TOB2 had no effect on the numbers of 
cells progressing into S-phase demonstrating that there is no redundancy 
between the proteins (Figure 4.6C).  
Similarly, no effect on cell proliferation was observed when knockdown of 
TOB2 was combined with knockdown of BTG2, or TOB1 (Figure 4.7C, 4.8C). 
Again, (combined) knockdown of TOB2 and BTG2 or TOB1 was confirmed by 
RT-qPCR analysis with GAPDH as a reference gene (Figure 4.7A, 4.7B, 4.8A 
4.8B).  
In summary, combined knockdown of BTG1 or TOB2 with the remaining 
expressed BTG/TOB genes, BTG1, BTG2, TOB1 and TOB2 does not cause a 
further increase in cell proliferation when compared to the single knockdown 
of BTG2 or TOB1. This suggests that BTG1 and TOB2 do not influence cell 
cycle progression in MCF-7 cells.  
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Figure 4.6 Combined knockdown of BTG1 and TOB2 does not further increase 
cell proliferation. (A, B) RT-qPCR analysis to confirm knockdown of BTG1 and 
TOB2 in MCF-7 cells after siRNA transfection. 48 h after siRNA treatment total RNA 
was isolated and subjected to RT-qPCR analysis using GAPDH as a reference. (C) 
Combined knockdown of BTG1 and TOB2 did not cause a further increase in the 
number of cells in S-phase. Cells in S-phase were detected by pulse-labelling using   ? ?Ǥ ǯ -test was 
used to calculate p-values.  * p< 0.05 (compared to non-targeting control siRNA). 
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Figure 4.7 Combined knockdown of BTG2 and TOB2 does not further increase 
cell proliferation. (A, B) RT-qPCR analysis to confirm knockdown of BTG2 and 
TOB2 in MCF-7 cells after siRNA transfection. 48 h after siRNA treatment total RNA 
was isolated and subjected to RT-qPCR analysis using GAPDH as a reference. (C) 
Combined knockdown of BTG2 and TOB2 did not cause a further increase in the 
number of cells in S-phase. Cells in S-phase were detected by pulse-labelling using   ? ?Ǥ ǯ -test was 
used to calculate p-values.  * p< 0.05 (compared to non-targeting control siRNA). 
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Figure 4.8 Combined knockdown of TOB1 and TOB2 does not further increase 
cell proliferation. (A, B) RT-qPCR analysis to confirm knockdown of TOB1 and 
TOB2 in MCF-7 cells after siRNA transfection. 48 h after siRNA treatment total RNA 
was isolated and subjected to RT-qPCR analysis using GAPDH as a reference. (C) 
Combined knockdown of TOB1 and TOB2 did not cause a further increase in the 
number of cells in S-phase. Cells in S-phase were detected by pulse-labelling using   ? ?Ǥ ǯ -test was 
used to calculate p-values.  * p< 0.05 (compared to non-targeting control siRNA). 
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By contrast, the percentage of cells in S-phase increased significantly upon 
combined knockdown of BTG2 and TOB1 in comparison to single knockdown 
of BTG2 or TOB1 (Figure 4.9C). As before, combined knockdown of BTG2 and 
TOB1 was confirmed through RT-qPCR analysis with GAPDH as a reference 
gene. The knockdown efficiency was comparable for single and dual 
knockdown of BTG2 and TOB1 (Figure 4.9A, 4.9B). Interestingly, the increase 
in S-phase cells caused by the combined knockdown of BTG2 and TOB1 is 
lower than would be expected for a simple additive effect suggesting that 
BTG2 and TOB1 may share overlapping functions.    
In summary, four of the six BTG/TOB proteins are expressed in MCF-7 cells. 
However, of these only two, BTG2 and TOB1, are involved in the regulation of 
MCF-7 cell proliferation. The effect of BTG2 and TOB1 may be partially 
overlapping, however, combined knockdown does cause a further increase in 
cell proliferation indicating BTG2 and TOB1 may poses some unique 
functions. 
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Figure 4.9 Increased cell proliferation upon combined knockdown of BTG2 
and TOB1. (A, B) RT-qPCR analysis to confirm knockdown of BTG2 and TOB1 in 
MCF-7 cells after siRNA transfection. 48 h after siRNA treatment total RNA was 
isolated and subjected to RT-qPCR analysis using GAPDH as a reference. (C) 
Combined knockdown of BTG2 and TOB1 further increased the number of cells in 
S-phase. Cells in S-phase were detected by pulse-labelling using the nucleoside 
analogue  ? ?Ǥǯ-test was used to calculate 
p-values.  * p< 0.05 (compared to non-targeting control siRNA). ** p< 0.05 
(compared to BTG2 or TOB1 knockdown). 
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4.4 Generation of mammalian and HA-BTG2 and HA-TOB1 
expression plasmids 
To further investigate the role of BTG2 and TOB1 in the regulation of cell 
proliferation in MCF-7 cells, mammalian expression plasmids containing 
cDNAs encoding HA-tagged BTG2 and HA-TOB1 were generated. To 
introduce the HA tag, the BTG2 cDNA was removed from plasmid pcDNA4-
TO-Flag-BTG2 using the BamHI and EcoRV restriction sites. The BTG2 cDNA 
was PCR amplified to include a BamHI restriction site followed by a sequence  ?ǯ
 ?ǯ of the stop codon. This PCR fragment was ligated into the SmaI restriction 
site of the pBluescript II KS(+) cloning vector. The pBluescript-HA-BTG2 
plasmid was digested with BamHI and EcoRV to release the BTG2 cDNA, 
which was ligated into pcDNA4-TO-Flag via the BamHI and EcoRV restriction 
sites (Figure 4.10A).  
To introduce the TOB1 cDNA into plasmid pCMV5-HA, TOB1 was amplified  ?ǯ
 ?ǯ
stop codon. This PCR fragment was ligated into the SmaI restriction site of 
the pBluescript II KS(+) cloning vector. The pBluescript-TOB1 plasmid was 
digested with XhoI to release the TOB1 cDNA, which was ligated into pCMV5-
HA digested with SalI (Figure 4.10B). To introduce the desired point 
mutations resulting in amino acid changes W103A of BTG2 and W93A of 
TOB1, DNA oligos were designed containing the relevant modified codons 
and used for site directed mutagenesis. Plasmids containing the desired 
mutations were verified by DNA sequencing. 
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Figure 4.10 Generation of HA-BTG2 and HA-TOB1 expression vectors. (A) 
Construction of plasmid pcDNA4-TO-Flag-HA-BTG2. The BTG2 cDNA was 
removed from pcDNA4-TO-Flag-BTG2 using the BamHI and EcoRV restriction 
digestion. The BTG2 cDNA was PCR amplified to included the BamHI restriction site          ?ǯ   
  Ǥ         ?ǯ    Ǥ  
fragment was ligated into cloning vector pBluescript II KS(+) via the SmaI restriction 
site to generate pBluescript-HA-BTG2. The HA-BTG2 cDNA was excised with BamHI 
and EcoRV and subcloned into plasmid pcDNA4-TO-Flag. (B) Construction of 
plasmid pCMV5-HA-TOB1.The human TOB1 cDNA was amplified by reverse 
transcriptase PCR using total RNA isolated from MCF-7 cells as a template. Primers      ?ǯ   
     ?ǯ    Ǥ
This PCR fragment was ligated into cloning vector pBluescript II KS(+) via the SmaI 
restriction site to generate pBluescript-TOB1.  The TOB1 cDNA was excised with 
XhoI and subcloned into plasmid pCMV5-HA using the SalI restriction site in the 
polylinker.  
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4.5 Generation of MCF-7 cell lines containing inducible BTG2 
cDNA expression cassettes 
To study the effect of the BTG2-Caf1a (CNOT7)/Caf1b (CNOT8) interaction 
on cell proliferation in MCF-7 cells, stable cells lines were generated that 
allow inducible expression of BTG2 and BTG2 W103A. Inducible stable cell 
lines are advantageous over transient transfection, because plasmid 
expression is limited to 24-72 h during transient transfection.  
To generate stable cell lines with inducible BTG2 expression, MCF-7 TR cells 
were used. MCF-7 TR cells were generated by transfection of MCF-7 cells 
with plasmid pcDNA6/TR that expresses the Tet repressor protein 
(Invitrogen). The BTG2 cDNA was introduced through plasmid pcDNA4-TO-
Flag-HA-BTG2. The Tet repressor acts to inhibit expression of plasmid 
pcDNA4-TO in the absence of doxycycline due the binding of the Tet 
repressor onto the Tet operator (TO) sequences located upstream of the 
BTG2 cDNA. Repression is relieved by the addition of doxycycline (a 
tetracycline derivative) to the culture medium, which binds to the Tet 
repressor thereby interfering with its ability to bind Tet operator sequences 
(Figure 4.11A).  
Thus, MCF-7 TR cells were transfected with pcDNA4-TO, pcDNA4-TO-Flag-
HA-BTG2, pcDNA4-TO-Flag-HA-BTG2 H53A or pcDNA4-TO-Flag-HA-BTG2 
W103A. After selection with zeocin, clones with stably integrated expression 
cassettes were expanded in 24-well plates. Once sufficient cell numbers were 
obtained, clonal cells were seeded into six well culture plates in medium 
containing doxycycline (1.0µg/ml) to induce cDNA expression. Total cell 
lysates were screened for BTG2 expression by western blot analysis (Figure 
4.11B).  
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Figure 4.11 Screening for BTG2 expression in MCF-7 TR stable cell lines. (A) 
Schematic representing the inducible expression cassette of plasmid pcDNA4-TO-
Flag-HA-BTG2.  (B) Identification of MCF-7 TR clones with inducible expression of 
HA-BTG2, HA-BTG2 H53A, HA-BTG2 W103A or HA-BTG2 D105A. Expression of 
plasmid pcDNA4-TO containing the BTG2 cDNA was induced by the addition of 
doxycycline to the cell media.  After 48 h total cell lysates were produced and 
subjected to western blot analysis. (C) MCF-7 TR cell lines expressing equal levels of 
HA-BTG2, HA-BTG2 H53A or HA-BTG2 W103A. MCF-7 TR BTG2 stable cell line 
clones were passaged twice in the absence of doxycycline before vector expression 
was induced again by the addition of doxycycline. After 48 h total cell lysates were 
produced and subject to western blot analysis.  
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As expected, the level of BTG2 varied across the clones as did the cell 
morphology and rate of proliferation. Clones displaying abnormal 
morphology or proliferation were discarded. The production of MCF-7 TR 
cells expressing BTG2 D105A was abandoned due to the limited number of 
positive clones and because of the successful expression of BTG2 H53A, the 
other partial Caf1a (CNOT7)/Caf1b (CNOT8) interaction mutant. From the 
remaining clones, two displaying relatively equal expression of BTG2, BTG2 
H53A or BTG2 W103A were passaged twice in the absence of doxycycline 
before BTG2 expression was induced again. Total cell lysates were produced 
and subjected to western blot analysis to identify which clones stably 
expressed BTG2. The western blot shows that in the absence of doxycycline 
there is no background expression of BTG2 (Figure 4.11C). In addition, the 
clones showed relatively equal expression of BTG2 after doxycycline 
treatment apart from BTG2 W103A clone 6, which had a higher level of BTG2 
expression. The clones taken for experimental validation were: BTG2 clone 5, 
BTG2 H53A clone 2 and BTG2 W103A clone 9. 
 
4.6 The BTG2 anti-proliferative activity requires interactions 
with Caf1a (CNOT7)/Caf1b (CNOT8) 
To investigate if the anti-proliferative activity of BTG2 is dependent upon 
interactions with Caf1a (CNOT7) and Caf1b (CNOT8), the rate of cell 
proliferation in the MCF-7 TR cell lines expressing BTG2 and BTG2 W103A 
were monitored. The MCF-7 TR stable cell lines pcDNA4-TO, pcDNA4-TO-
Flag-HA-BTG2 and pcDNA4-TO-Flag-HA-BTG2 W103A were seeded and 
cultured in the presence or absence of doxycycline. The control cell line 
containing the empty expression vector pcDNA4-TO demonstrated that the 
addition of doxycycline to the cell media does not alter cell proliferation rates 
(Figure 4.12A). Expression of BTG2 caused a decrease in cell proliferation 
compared to the MCF-7 TR cells not expressing BTG2. A significant reduction 
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in total cell population number is evident on day six, seven and eight (Figure 
4.12A). By day eight there is >25% fewer cells compared to the cell 
population not expressing BTG2 (Figure 4.12B). By contrast, expression of 
BTG2 W103A did not cause a reduction in the total number of cells compared 
to the cell population cultured in the absence of doxycycline (Figure 4.12A, 
4.12B). To confirm the importance of BTG2 - Caf1a (CNOT7)/Caf1b (CNOT8) 
interaction for the BTG2 anti-proliferative effect, the percentage of cells in S-
phase was also determined as a second measure of cell proliferation. MCF-7 
cells containing stably integrated expression vectors pcDNA4-TO, pcDNA4-
TO-Flag-HA-BTG2 and pcDNA4-TO-Flag-HA-BTG2 W103A were seeded 
before vector expression was induced by the addition of doxycycline. Control 
cells were cultured in parallel in the absence of doxycycline. The thymidine 
analogue EdU was added to the MCF-7 cell media for two hours to label cells 
in S-phase. The control cell line expressing plasmid pcDNA4-TO 
demonstrated that the addition of doxycycline to the cell media did not alter 
the number of cells entering S-phase (Figure 4.12C). After EdU incubation 
approximately 40% of nuclei incorporated the thymidine analogue in the 
pcDNA4-TO expressing control cell line. BTG2 expression caused a significant 
reduction in the number of cells in S-phase compared to the control cell 
population cultured in the absence of doxycycline. By contrast, expression of 
BTG2 W103A did not alter the number of cells in S-phase (Figure 4.12C). 
Western blot analysis of the MCF-7 TR stable cell lines cells harvested on day 
eight of the proliferation assay demonstrated that BTG2 expression is 
maintained (Figure 4.12D).  
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Figure 4.12 Interactions with the Caf1a (CNOT7)/Caf1b (CNOT8) deadenylase 
enzymes is required for the anti-proliferative activity of BTG2. (A) Reduced 
proliferation upon BTG2 expression. MCF-7 TR  BTG2 stable cell lines were seeded 
at 100,000 cells per well. Expression of BTG2, BTG2 W103A or empty vector was 
induced by addition of doxycycline. From day four until day eight, cells were 
trypsinised and counted in triplicate using a haemocytometer at 24 h intervals.  (B) 
Total number of cells after expression of pcDNA4-TO (control), BTG2 or BTG2 
W103A fǤǯ-test was used to calculate p-values.  * p< 0.05 
(compared to control cells not treated with doxycycline). (C) Expression of BTG2 but 
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not BTG2 W103A causes a reduction in the number of cells in S phase. MCF-7 TR cell 
lines were seeded onto glass cover slips and expression of pcDNA4-TO, pcDNA4-TO-
BTG2 or pcDNA4-TO-BTG2W103A induced by the addition of doxycycline.  48 h  ǡ      ȋ Ȍ  ǯ
t-test was used to calculate p-values. * p < 0.05 (compared to control cells not 
treated with doxycycline). (D) Similar levels of doxycycline-dependent expression of 
HA-BTG2 and HA-BTG2 W103A. Total cell lysates produced 8 days after induction of 
doxycycline-dependent expression and subject to western blot analysis using anti-
HA, actin used as loading control.   
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The effect on cell proliferation of BTG2 H53A was also tested. This amino acid 
substitution produces a partial disruption in the Caf1a (CNOT7) interaction 
(Chapter 3). BTG2 H53A was capable of reducing cell proliferation rates to 
the same extent as wild type BTG2. This suggests that even a weak 
interaction with Caf1a (CNOT7) is sufficient for BTG2 to function as an anti-
proliferative protein.  
Taken together, the data demonstrates that expression of BTG2 reduces cell 
proliferation by preventing cell cycle progression. Moreover, cell 
proliferation is dependent upon interactions between BTG2 and the 
deadenylases Caf1a (CNOT7) and Caf1b (CNOT8), because the reduction of 
cells in S-phase is not seen upon expression of BTG2 W103A.   
 
4.7 Effect of BTG2 expression on the expression of G1/S-
phase regulatory proteins  
To identify whether BTG2 expression affects the cellular concentration or 
expression of specific G1/S-phase regulatory proteins, RT-qPCR and western 
blot analysis were performed. The proteins investigated were Cyclin D1, 
Cyclin D3, CDK4, CDK6, p21, p27, p15 and p16. Protein lysates were 
extracted from the MCF-7 TR pcDNA4-TO and pcDNA4-TO-Flag-HA-BTG2 
stable cell lines after vector expression was induced for 72 h. The western 
blot analysis demonstrated the inducible expression of HA-BTG (Figure 
4.13A). Actin was used as a loading control. Protein levels of Cyclin D1, 
Cyclin D3, CDK4, CDK6, p21, p27, p15 did not change for the pcDNA4-TO 
stable cell line cultured in the presence or absence of doxycycline. In 
addition, the amount of protein for all the cell cycle proteins tested did not 
change upon BTG2 expression (Figure 4.13A). A western blot was also 
conducted for p16 but this protein was not detected.  
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Figure 4.13 BTG2 expression causes a reduction in CCND1 (Cyclin D1) mRNA 
but does not affect the level of cell cycle regulatory proteins. (A) Analysis of cell 
cycle regulatory proteins by western blotting. BTG2 expression was induced in MCF-
7 TR stable cell lines by the addition of doxycycline. 72 h after induction total cell 
lysates were produced and subject to western blot analysis. Actin was used as an 
equal loading control. (B)  CCND1 (Cyclin D1) mRNA levels are reduced after BTG2 
expression. BTG2 expression was induced in MCF-7 TR stable cell lines through the 
addition of doxycycline. After 48 h, total RNA was isolated and CCND1 (Cyclin D1) 
mRNA levels determined through RT-qPCR using GAPDH as a reference gene. 
Experiment    Ǥ  ǯ -test was used to calculate 
significance-values, * p=0.08 (compared to control cells not treated with 
doxycycline).  
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To investigate if BTG2 is causing a transcriptional down-regulation of CCND1 
(Cyclin D1), total RNA was extracted from the MCF-7 TR stable cells lines 
after BTG2 (or control vector) expression and subjected to RT-qPCR analysis 
using GAPDH as a reference gene. The analysis indicated a small reduction in 
CCND1 (Cyclin D1) mRNA (p-value 0.1) however, this is not statically 
significant and may be due to chance (Figure 4.13B).  
Together the western blot and RT-qPCR data produce an inconclusive view of 
the pathway used by BTG2 to regulate cell cycle progression. However, the 
RT-qPCR analysis indicates down regulation of Cyclin D1 may be a factor 
which is consistent with the current published literature (Donato et al., 2007; 
Guardavaccaro et al., 2000; Suzuki et al., 2002).  
 
 4.8 BTG2 and TOB1 require interactions with Caf1a 
(CNOT7)/Caf1b (CNOT8) to reduce cell proliferation. 
In addition to the use of cell lines containing stably integrated expression 
cassettes, transient transfections were also used to determine the effect of 
BTG2/TOB1 on cell proliferation. To this end, several transfection reagents 
were tested to identify which one combined optimal transfection efficiency 
with minimal effects on cell viability and proliferation. Using Genejuice 
(Merck), a transfection efficiency of 70% was routinely achieved 
(Appendix.1).  
 As expected, expression of BTG2, but not of BTG2 W103A, reduced the 
number of cells in S-phase as compared to cells transfected with empty 
vector (Figure 4.14A). Western blot analysis confirmed similar levels of HA-
BTG2 and HA-BTG2 W103A expression (Figure 4.14B).  Amino acid Trp-93 of 
TOB1 corresponds to Trp-103 of BTG2. As was observed for BTG2, 
expression of TOB1, but not of TOB1 W93A, resulted in a reduced percentage 
of cells in S-phase as compared to empty vector-transfected cells (Figure 
4.15A).  
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Figure 4.14 Transient expression of BTG2 but not BTG2 W103A causes a 
reduction in the number of cells in S-phase. (A) MCF-7 cells were seeded onto 
glass cover slips before transfection with pCMV5-HA-BTG2, pCMV5-HA-BTG2 
W103A, or empty vector. After 48 h, cells were incubated with the thymidine 
analogue EdU and detected by fluorescence microscope. All samples were tested in 
biological triplicate and the number of nuclei was counted for three images from  Ǥ  ǯ -test was used to calculate significance values. * p< 0.05 
(compared to control cells transfected with pCMV5-HA).  (B) Western blot analysis 
indicating similar expression of HA-BTG2 and HA-BTG2 W103A. Total cell lysates 
produced 48 h after transfection and subject to western blot with anti-HA, tubulin 
used as a loading control.   
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Figure 4.15 Transient expression of TOB1 but not TOB1 W93A causes a 
reduction in the number of cells in S-phase. (A) MCF-7 cells were seeded onto 
glass cover slips before transfection with pCMV5-HA-TOB1, pCMV5-HA-TOB1 
W93A, or empty vector. After 48 h, cells were incubated with the thymidine 
analogue EdU and detected by fluorescence microscope. All samples were tested in 
biological triplicate and the number of nuclei were counted for three images from  Ǥ  ǯ -test was used to calculate significance values. * p< 0.05 
compared to control cells transfected with pCMV5-HA.  (B) Western blot analysis 
indicating similar expression of HA-BTG2 and HA-BTG2 W103A. Total cell lysates 
produced 48 h after transfection and subject to western blot with anti-HA, actin 
used as a loading control. 
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This result demonstrates that TOB1 also requires an interaction with Caf1a 
(CNOT7)/Caf1b (CNOT8) in order to maintain its anti-proliferative activity in 
MCF-7 cells. Western blot analysis confirmed the expression of HA-TOB1 and 
HA-TOB1 W93A (Figure 4.15B). Interestingly, however, while TOB1 is 
represented as a double band on the western blot, TOB1 W93A migrates as a 
signle band. Because TOB1 contains three C-terminal phosphorylation sites 
located on serine residues Ser-152, Ser-154 and Ser-164 (Suzuki et al., 2002), 
this raised the possibility that the phosphorylation status of TOB1 W93A is 
different from the wild type protein.       
 
4.9 The anti-proliferative activity of BTG2 and TOB1 is not 
affected by post-translational phosphorylation 
Both BTG2 and TOB1 are phosphorylated at serine residues located outside 
the BTG domain. Substitution of these amino acids with alanine residues 
prevents their inactivation and results in increased anti-proliferative activity 
(Hong et al., 2005; Suzuki et al., 2002). Western blot analysis of TOB1 
indicated that it is subject to post-translation modifications which may affect 
its anti-proliferative activity.  Therefore, we reasoned that the substitution of 
the serine residues combined with the alterations W103A of BTG2 or W93A 
of TOB1 might reveal weak residual anti-proliferative activity of BTG2 and 
TOB1 that is independent of the interaction with the Caf1a and Caf1b 
deadenylase enzymes. 
To investigate if TOB1 is subject to phosphorylation that affects its anti-
proliferative activity, the three serine residues subject to phosphorylation 
were substituted for alanine. The desired point mutations were introduced 
into pCMV5-HA-TOB1 via site directed mutagenesis. Correct clones were 
identified through DNA sequencing. MCF-7 cells were transfected with 
pCMV5-HA, pCMV5-HA-TOB1 or pCMV5-HA-TOB1 S-A (serine to alanine 
mutations) and after 48 h cells in S-phase were labelled by EdU. As seen 
previously, the expression of TOB1 reduced the number of cells in S-phase 
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compared to the pCMV5-HA transfected control cells. The expression of 
TOB1 S-A reduced the number of cells in S-phase to the same extent as wild 
type TOB1, suggesting that the phosphorylation status of TOB1 does not 
affect its anti-proliferative activity in MCF-7 cells (Figure 4.16A). Western 
blot analysis confirmed the expression of HA-TOB1 and HA-TOB1 S-A (Figure 
4.16B). As expected, TOB1 S-A is represented as a single band on the western 
blot that corresponded to the lower band of wild type TOB1 indicating that 
TOB1 S-A is not phosphorylated.  
To determine if TOB1 phosphorylation is masking any anti-proliferative 
activity of TOB1 W93A the numbers of cells in S phase were determined after 
TOB1 S-A W93A expression. MCF-7 cells were transfected with the 
appropriate plasmid before cells in S-phase were labelled by EdU as describe 
previously. Expression of TOB1 S-A reduced the number of cells in S-phase 
compared to the pCMV5-HA transfected control cells. Interestingly, 
expression of TOB1 S-A W93A did not cause any reduction in the number of 
cells in S-phase demonstrating that phosphorylation is not affecting TOB1 
activity. This confirms that the loss of anti-proliferative activity witnessed in 
TOB1 W93A is causes by preventing the TOB1-Caf1a (CNOT7/Caf1b (CNOT8) 
interaction. Western blot analysis confirmed the expression of the HA-
TOB1S-A and HA-TOB1 W93A S-A (Figure 4.16D).  
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Figure 4.16 The phosphorylation status of TOB1 does not affect its anti-
proliferative activity in MCF-7 cells. (A) MCF-7 cells were seeded onto glass cover 
slips and transfected with pCMV5-HA, pCMV5-HA-TOB1 or pCMV5-HA-TOB1 S-A. 
48 h after transfection cells were incubated with the thymidine analogue EdU and 
detected after incubation with Alexa Floura 488 azide. Cells were counter stained 
with Hoechst 33342 to allow total cells to be counted on the LSM fluorescence 
microscope. Samples were tested in biological triplicate; the number of nuclei were 
counted for three images from each slide. Students t-test used to calculate statistical 
significance, * indicates a p value of < 0.05 compared to control cells transfected 
with pCMV5-HA.  (B) Western blot analysis to show the expression of HA-TOB1 and 
HA-TOB1 S-A. Total cell lysates produced 48 h after transfection and subject to 
western blot with anti-HA, Ɣ indicated none specific band, actin used as a loading 
control. (C) MCF-7 cells were seeded onto cover slips before being transfected with 
pCMV5-HA, pCMV5-HA-TOB1 S-A or pCMV5-HA-TOB1 W93A S-A. Cell were treated 
with EdU as previously described in (A), * indicates a p value of < 0.05 compared to 
control cells transfected with pCMV5-HA. (D) Western blot analysis to show the 
expression of HA-TOB1 S-A and HA-TOB1 W93A S-A. Western blot conducted as in 
(B). 
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BTG2 contains two phosphorylation sites at Ser-147 and Ser-149 within its C-
terminal region. To determine if the phosphorylation status of BTG2 or BTG2 
W103A is affecting their anti-proliferative activity Ser-147 and Ser-149 were 
replaced with alanine using site-directed mutagenesis. MCF-7 cells were 
transfected with pCMV5-HA, pCMV5-HA-BTG2, pCMV5-HA-BTG2S-A, pCMV5-
HA-BTG2 W103A and pCMV5-HA-BTG2 W103A S-A and after 48 h EdU was 
added for two hours to label all cells in S-phase. Expression of BTG2 S-A 
reduced the number of cells entering S-phase however, this reduction was 
not significantly higher than seen for wild type BTG2 (Figure 4.17A). By 
contrast, no effect on S-phase was observed upon expression of BTG2 S-A 
W103A as compared to empty vector transfected cells. As seen with TOB1 
W93A, the phosphorylation status of BTG2 W103A does not cause its loss of 
anti-proliferative activity. Western blot analysis confirmed the expression of 
the HA-BTG2, HA-BTG2S-A, HA-BTG2 W103A and HA-BTG2 W103A S-A 
(Figure 4.17B). Together it can be concluded that the amino acid 
substitutions W103A and W93A of BTG2 and TOB1, respectively, do not 
result in increased inactivation by phosphorylation. Therefore, the anti-
proliferative activity of BTG2 and TOB1 is mediated via interactions with the 
Caf1a and Caf1b deadenylase enzymes. 
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Figure 4.17 The phosphorylation status of BTG2 does not affect its anti-
proliferative activity in MCF-7 cells. (A) MCF-7 cells were seeded onto glass cover 
slips before being transfected with pCMV5-HA, pCMV5-HA-BTG2, pCMV5-HA-BTG2 
S-A, pCMV5-HA-BTG2 W103A or pCMV5-HA-BTG2 W103A S-A. 48 h after 
transfection cells were incubated with the thymidine analogue EdU and detected 
after incubation with Alexa Floura 488 azide. Cells were counter stained with 
Hoechst 33342 to allow total cells to be counted on the LSM fluorescence 
microscope. All samples were tested in biological triplicate and the number of nuclei 
were counted for three images from each slide. Students t-test used to calculate 
statistical significance, * indicates a p value of < 0.05 compared to control cells 
transfected with pCMV5-HA.  (B) Western blot analysis to show the expression of 
HA-BTG2, HA-BTG2 S-A, HA-BTG2 W103A and HA-BTG2 W103A S-A.  Total cell 
lysates produced 48 h after transfection and subject to western blot with anti-HA, 
tubulin used as a loading control.   
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4.10 Discussion 
Of the six BTG/TOB proteins, only four are expressed in MCF-7 cells: TOB1, 
TOB2, BTG1 and BTG2. Surprisingly, the anti-proliferative activity does not 
correlate with their relative mRNA level. While the expression of BTG2 was 
significantly lower than that of TOB1, knockdown of BTG2 or TOB1 resulted 
in a similar increase of cell proliferation. Furthermore, despite displaying 
significantly higher mRNA levels compared to BTG2, neither knockdown of 
BTG1 nor TOB2 affected cell proliferation.  This is surprising because BTG1 
and BTG2 share a sequence similarity of 70%, the same observation can be 
made for TOB1 and TOB2 who share a sequence similarity of 73%. This high 
level of sequence conservation suggests a level of functional redundancy 
between the pairs of BTG/TOB proteins. It would be interesting to establish 
the relative protein levels of the expressed BTG/TOB proteins in MCF-7 cells, 
because the presence of mRNA does not directly indicate the presence of a 
function protein. To this end several antibodies were tested to determine if 
endogenous BTG2 or TOB1 could be detected in MCF-7 cells via western blot 
analysis. None of the antibodies screened were able to detected endogenous 
or over expressed BTG2 or TOB1, (Appendix.2). Further analysis to    ?ǯ    
Ȁ     
into the translational regulation of these genes which may account for the 
differences between the gene expression microarray data and effect on cell 
proliferation. Furthermore, to date we do not know whether BTG1 and TOB2 
possess critical somatic mutations in the MCF-7 cells abrogating their 
activity. 
Dual knockdown of the BTG/TOB proteins demonstrated that there is no 
functional redundancy masking the possible roles of BTG1 and TOB2. By 
contrast, combined knockdown of BTG2 and TOB1 resulted in a further 
increase in cell proliferation. An interesting progression for this work would 
be to establish whether BTG2 and TOB1 regulate the mRNA abundance of the 
same genes by using microarray expression profiling. This would establish 
whether BTG2 and TOB1 influence cell proliferation via regulating the 
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abundance and translational efficiency of the same set of genes or whether 
they target different mechanisms.     
The interaction between BTG/TOB proteins and the deadenylases Caf1a 
(CNOT7) and Caf1b (CNOT8) is well established (Ikematsu et al., 1999; 
Prevot et al., 2001; Rouault et al., 1998; Winkler, 2010; Yoshida et al., 2001). 
However, the importance of the interactions in the anti-proliferative activity 
of BTG/TOB proteins was unclear. Disrupting the TOB1-Caf1a (CNOT7) 
interaction through an amino acid substitution in Caf1a (CNOT7) prevented 
the anti-proliferative effect witnessed after TOB1 over-expression (Horiuchi 
et al., 2009). Conversely disrupting the BTG2-Caf1a (CNOT7) interaction 
again through amino acid substitution in Caf1a (CNOT7) did not significantly 
alter cell proliferation rates (Aslam et al., 2009). These divergent conclusions 
were obtained by preventing the BTG/TOB interaction with Caf1a 
(CNOT7)/Caf1b (CNOT8) through amino acid substitutions in Caf1a 
(CNOT7)/Caf1b (CNOT8). Here I used the amino acid substitution W103A in 
BTG2 and W93A in TOB1, which disrupts the BTG2/TOB1-Caf1a 
(CNOT7)/Caf1b (CNOT8) interaction to investigate the anti-proliferative 
effect. Expression of BTG2 or TOB1 in MCF-7 cells inhibited cell proliferation, 
which was not observed upon expression of BTG2 W103A and TOB1 W93A. 
Based on these results, it can be concluded that the anti-proliferative activity 
of BTG2 and TOB1 requires interactions with the Caf1a (CNOT7) and Caf1b 
(CNOT8) deadenylases. This conclusion is consistent with that of Ezzeddine 
et al (2012), who independently arrived at the same conclusion during the 
course of this work. Furthermore, to verify this conclusion cell proliferation 
was monitored after BTG2/TOB1 expression in U2OS cells, the cell line used 
in the Ezzeddine et al (2012) study. Here, BTG2 and TOB1 also required an 
interaction with Caf1a (CNOT7) and Caf1b (CNOT8) to reduce the rate of cell 
proliferation, analogous to the published result by Ezzeddine et al (2012) 
(Appendix.3). 
During the course of this study, western blot analysis of TOB1 indicated that 
it may be subject to post-translation modifications due to its double band 
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pattern on western blot. The activity of BTG2 and TOB1 is inhibited by the 
phosphorylation of serine residues located in their C-terminal domain (Hong 
et al., 2005; Suzuki et al., 2001). The phosphorylation of TOB1 has been 
shown to affect TOB1 activity in lung and thyroid cancer patient samples 
where hyper-phosphorylated TOB1 heightens cancer progression. (Ito et al., 
2005; Iwanaga et al., 2003; Yoshida et al., 2003a). To date there has been no 
published data demonstrating that phosphorylation of TOB1 or BTG2 alters 
anti-proliferative activity or cancer progression in breast carcinomas. 
Western blot analysis during this study suggested that a significant fraction 
of TOB1 is phosphorylated in MCF-7 cells. Furthermore, introduction of the 
W93A amino acid substitution appears to increase TOB1 phosphorylation as 
seen through the western blot analysis. However, replacing residues Ser-152, 
Ser-154 and Ser-164 of TOB1 for alanine, which prevents phosphorylation, 
did not result in increased anti-proliferative activity. Additionally, expression 
of TOB1 S-A W93A did not reveal any weak residual anti-proliferative activity 
indicating the phosphorylation status of TOB1 is not affecting its anti-
proliferative activity. Expression of BTG2 S147A, S149A resulted in an 
decrease in cell proliferation comparable to wild type BTG2. In agreement 
with TOB1, BTG2 S-A W103A did not display an anti-proliferative activity. It 
can therefore be concluded that inactivation by phosphorylation is not the 
main mechanism of inactivation of BTG/TOB activity in MCF-7 cells. The 
reduction in anti-proliferative activity demonstrated by TOB1 W93A and 
BTG2 W103A is as a result of disrupting the Caf1a (CNOT7)/Caf1b (CNOT78) 
interaction. This conclusion is shared with Eddeddine et al (2012) who 
demonstrated that phosphorylation of TOB1 and TOB2 does not affect anti-
proliferative activity in U2OS cells.      
Additional experiments were conducted to determine if the sub-cellular 
localisation of BTG2 changed due to the W103A amino acid substitution. Both 
BTG2 and TOB1 have been shown to have increased anti-proliferative effects 
when localised to the cytoplasm (Ito et al., 2005; Iwanaga et al., 2003; 
Kawakubo et al., 2006; Kawamura-Tsuzuku et al., 2004; Maekawa et al., 
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2002; Yoshida et al., 2003a). To this end immunofluorescence was conducted. 
However, due to poor staining intensity the localisation of BTG2 and BTG2 
W103A was inconclusive (Appendix.4) 
To date evidence has indicated that expression of BTG2 leads to a down-
regulation of CCND1 (Cyclin D1) transcription a key component of G1 to S-
phase cell cycle progression (Donato et al., 2007; Guardavaccaro et al., 2000). 
Likewise, prevention of TOB1 expression leads to an increase in CCND1 
(Cyclin D1) transcription to drive cell proliferation (Suzuki et al., 2002). To 
further investigate which cell cycle regulatory proteins are affected by BTG2 
or TOB1 expression a series of western blots and RT-qPCR analysis was 
preformed to monitor cellular protein and mRNA levels. Western blot 
analysis did not identify any significant changes in the protein level of the cell 
cycle regulatory factors tested. However, this may be caused by low turnover 
rates of the proteins or due to antibody insensitivity. By contrast, RT-qPCR 
analysis suggested a small decrease in CCND1 (Cyclin D1) mRNA levels in 
MCF-7 cells after BTG2 expression. RT-qPCR analysis was conducted on MCF-
7 cells transiently transfected with HA-BTG2 and HA-TOB1 however, a 
significant reduction in CCND1 (Cyclin D1) mRNA was only seen after HA-
TOB1 expression (Appendix.5). Together this data suggests that BTG2 and 
TOB1 do not have a dramatic effect on the abundance of cell cycle regulatory 
proteins tested. Conversely, it maybe that BTG2 and TOB1 are regulating cell 
cycle progression via other signalling pathways not tested here. It would be 
interesting to identify which mRNAs are targeted by BTG2 and TOB1 to gain 
a deeper understanding as to how their expression brings about a reduction 
in cell proliferation.    
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Chapter 5 Ȃ Regulation of mRNA abundance and 
translation by BTG/TOB proteins 
5.1 Introduction 
The six BTG/TOB proteins are characterised by a conserved N-terminal BTG 
domain which binds to the Caf1a (CNOT7)/Caf1b (CNOT8) deadenylases and 
confers anti-proliferative activity. By examining the crystal structures of 
TOB1ȂCaf1a (CNOT7) and the related DEDD-type deadenylase PARN bound 
to RNA, it can be predicted that TOB1 binds away from the Caf1a (CNOT7) 
active site (Winkler, 2010). This suggests that the binding of TOB1 may not 
interfere with the deadenylase activity of Caf1a (CNOT7) and Caf1b (CNOT8). 
Furthermore, co-immunoprecipitation assays conducted have demonstrated 
that BTG2 not only co-precipitates with Caf1a (CNOT7) but also CNOT1 and 
CNOT3 (Aslam et al., 2009). CNOT1 functions as the scaffold protein for the 
Ccr4-Not complex to which Caf1a (CNOT7)/Caf1b (CNOT8) bind directly 
(Basquin et al., 2012; Lau et al., 2009; Sandler et al., 2011). The remaining 
EEP type deadenylases Ccr4a (CNOT6) and Ccr4b (CNOT6L) interact with the 
Ccr4-Not complex via Caf1a (CNOT7) and Caf1b (CNOT8) (Collart and 
Panasenko, 2012). 
The divergent C-terminal domains of the BTG/TOB family have the ability to 
mediate further protein-protein interactions possibly conferring specific 
protein function. TOB1 interacts with PABP through a C-terminal PAM2 motif 
suggesting the TOB1 can bind to the poly(A) tail of mRNA (Ezzeddine et al., 
2007; Funakoshi et al., 2007; Okochi et al., 2005). TOB1 can simultaneously 
bind to PABP and Caf1a (CNOT7) indicating a role for TOB1 as an adaptor 
protein mediating the recruitment of the Ccr4-Not complex to mRNAs 
(Ezzeddine et al., 2007).  
TOB1 may not only be recruited to poly(A) tails through PABP but can also 
interact with CPEB3 a sequence-specific RNA-binding protein in conjunction 
with Caf1a (CNOT7)/Caf1b (CNOT8). Cytoplasmic Polyadenylation Element-
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Binding protein 3 (CPEB3) recognises a U-rich RNA sequence via two RRM 
domains that also bind the C-terminal region of TOB1 (Hosoda et al., 2011). 
CPEB3 associated deadenylation and mRNA decay is dependent upon the 
recruitment of TOB1 and Caf1a (CNOT7)/Caf1b (CNOT8). This provides 
evidence that TOB1 is functioning as an adaptor protein, recruiting the Ccr4-
Not deadenylases to mRNA through both sequence specific (CEBP3) and 
general (PABP) routes. TOB1 is also implicated in general deadenylation 
coupled to termination of translation. Deadenylation mediated by eRF3 is 
catalysed by the Ccr4-Not deadenylases Caf1a (CNOT7)/Caf1b (CNOT8), 
Ccr4a (CNOT6)/Ccr4b (CNOT6L) and Pan2-Pan3 deadenylases. Interestingly, 
competitive interactions between the PAM2 motifs of eRF3, Pan3, and TOB1 
are implicated in the subsequent activation of Pan2-Pan3 and Ccr4-Not-
mediated deadenylation (Funakoshi et al., 2007).  
One unresolved question is the link between the BTG/TOB anti-proliferative 
activity and their role in mRNA translation and degradation. During the 
course of this work Ezzeddine et al (2012) highlighted this link for TOB1 and 
TOB2 which require an interaction with Caf1a (CNOT7)/Caf1b (CNOT8) to 
induce a proliferation defect. Furthermore, when TOB1 and TOB2 are   ?ǯ  ?
(CNOT7)/Caf1b (CNOT8) to reduce reporter activity and stimulate mRNA 
degradation. To date this link between anti-proliferative activity and 
regulation of mRNA translation/abundance for other members of the 
BTG/TOB family has not been established. Here I will investigate the effect 
BTG2 and TOB1 have on translation and mRNA degradation when recruited 
to mRNA using the RNA tethering assay. BTG2 and TOB1     ɉ
peptide that binds to a specific RNA hairpin loop box B motif present in the  ?ǯ Ǥ This luciferase construct can be used to 
monitor mRNA stability or translation efficiency when BTG2 and TOB1 are 
bound to it.   
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5.2 Generation of vectors for the RNA tethering assay  ɉ          N-terminal ɉ
epitope and V5 tag. The HA epitope was introduced to aid western blotting 
detection. The ɉ      ired protein to a 
corresponding RNA hair pin loop present in a luciferase reporter mRNA 
(plasmid pRL-5boxB).  
Tɉǡhe BTG2 cDNA 
was PCR amplified to include an XhoI restriction site and the HA epitope  ?ǯ
the AUG start codon and an XhoI restriction site  ?ǯ of the termination codon. 
This PCR fragment was ligated into cloning vector pBluescript II KS(+) via the 
SmaI restriction site to generate pBluescript-HA-BTG2. Plasmid pBluescript-
HA-BTG2 was digested with XhoI to release the HA-BTG2 cDNA and 
subcloned into plasmid ɉȋ	 ?Ǥ ?ȌǤ
TOB1 cDNA was PCR amplified to include an XhoI restriction site and the HA   ?ǯ   
      ?    ?ǯ  
termination codon. This PCR fragement was ligated into the cloning plasmid 
pBluescript as described previously to generate pBluescript-HA-TOB1. 
Plasmid pBluescript-HA-TOB1 was digested with XhoI and XbaI to release the 
HA- ?      ɉ     
restriction sites (Figure 5.1B). All plasmids were confirmed by DNA 
sequencing. 
To introduce the desired point mutations, DNA oligos were designed 
containing the relevant modified codons and used for site directed 
mutagenesis. The desired clones were identified through DNA sequencing.  
The amino acid substitutions introduced to BTG2 were W103A that disrupts 
the BTG2-Caf1a (CNOT7)/Caf1b (CNOT8) interaction and S147A and S149A 
that prevent post-translational phosphorylation. The equivalent amino acid 
substitutions W93A and S152A, S154A, S164A were introduced in TOB1.  
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	 ?Ǥ ?
ɉ-HA-
 ?ɉ-HA-TOB1 expression vectors. (A) 
The HA-BTG2 cDNA was generated by PCR amplification to include the XhoI  ?ǯ
 ?ǯon.  This PCR fragment 
was ligated into cloning vector pBluescript II KS(+) via the SmaI restriction site to 
generate pBluescript-HA-BTG2. The HA-BTG2 cDNA was excised with XhoI and 
subcloned into plasmid pCIɉN. (B) The HA-TOB1 cDNA was generated by PCR 
am    ?ǯ 
 ?ǯǤ
vector pBluescript II KS(+) via the SmaI restriction site to generate pBluescript-HA-
TOB1 . The TOB1 cDNA was excised with XhoI and XbaI and subcloned into plasmid 
pCIɉN.  
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5.3 Tethering BTG2 or TOB1 to the  ?ǯ reporter mRNA 
causes reduced activity dependent on interactions with Caf1a 
(CNOT7)/Caf1b (CNOT8)  
RNA tethering assays were carried out to determine if the presence of BTG2    ?ǯ    RNA alters its activity and to ascertain if any 
changes are dependent on the Caf1a (CNOT7)/Caf1b (CNOT8) interactions. 
Thus, MCF-7 cells were co-transfected with the reporter pRL-5boxB and      ɉ   -BTG2, HA-
BTG2W103A, HA-BTG2S-A or HA-BTG2W103AS-A. After transfection, total 
protein was extracted and luciferase activity determined (Figure 5.2A).    ɉ-HA-BTG2 to the luciferase mRNA caused a reduction in 
luciferase activity, which was not observed in celɉǤǡɉȂHA-BTG2 W103A to the luciferase mRNA 
did not cause a reduction in luciferase activity (Figure 5.2B). This indicates 
that the reduction in luciferase protein is dependent upon the interaction 
between BTG2 and the deadenylases Caf1a (CNOT7)/Caf1b (CNOT8). 
Tethering of BTG2 S-A to the luciferase mRNA also caused a reduction in 
luciferase activity comparable to wild type BTG2, which was not observed 
with BTG2W 103A S-A (Figure 5.2B). This indicates that the phosphorylation 
status of BTG2 does not alter its activity when tethered to a reporter mRNA.  
To confirm that reduced luciferase activity was caused by tethering of BTG2    ?ǯ UTR, we used reporter plasmid pRL-TK that does not contain the 
Bo Ǥ   ɉ-HA-
 ?ǡ ɉ-HA-BTG2  ? ? ?ǡ ɉ-HA-
BTG2 S-  ɉ-HA-BTG2 W103A S-A caused a modest reduction in 
luciferase activity compared to cells transfected with empty vector (Figure 
5.2C). Moreover, there was no significant difference between the samples ɉ
responsible for reduced luciferase activity when a reporter containing BoxB 
sequences was used. Western blot analysis was conducted on protein lysates 
to confirm expression of BTG2 (Figure 5.2D).  
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Figure 5.2 BTG2 requires interactions with Caf1a (CNOT7)/Caf1b (CNOT8) to 
 ?ǯ UTR tethering. (A) Schematic representation of 
the RNA tethering assay. (B) Decreased reporter activity upon RNA tethering of ɉN-
HA-BTG2 or ɉN-HA-BTG2 SoA, but not of ɉN- HA-BTG2 W103A or ɉN-HA-BTG2 
W103A SoA. MCF-7 cells were transfected with empty vector or plasmid pCIɉN 
containing the indicated BTG2 cDNA, and the luciferase reporter plasmid pRL-
5BoxB. Luciferase activity was measured 24 h after transfection. (C) No specific 
effect of ɉN-HA-BTG2, ɉN-HA-BTG2 W103A, ɉN-HA-BTG2 SoA and ɉN-HA-BTG2 
W103A SoA expression on the activity of a Luciferase reporter lacking BoxB 
sequences.  MCF-7 cells were transfected with empty vector or plasmid pCIɉN 
containing the indicated BTG2 cDNA, and the luciferase reporter plasmid pRL-TK. 
Luciferase activity was measured 24 h after transfection. (D) Western blot showing 
the expression for ɉN-HA-BTG2, ɉN-HA-BTG2 W103A, ɉN-HA-BTG2 SoA and ɉN-
HA-BTG2 W103A SoA.  ɉN-fusion proteins were detected using anti-HA antibodies. 
Tubulin was used as a loading control. 
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Similarly, the influence of TOB1 on reporter activity was investigated using a 
tethering assay (Figure 5.3A). As was observed with BTG2, expressiɉ-
HA-TOB1 reduced reporter activity, which was not observed upon expression ɉ-HA-TOB1 W93A (Figure 5.3B). The phosphorylation status of TOB1 did 
not affect reporter activity (Figure 5.3B). The observed effects were specific, 
because no effect of ɉ-HA-TOB1 fusion proteins was measured on reporter 
activity in the absence of BoxB motifs (Figure 5.3C). Western blot analysis 
was conducted on the protein lysates to confirm expression of the TOB1 
plasmids (Figure 5.3D).  
This data demonstrates that bin  
 ?   ?    ?ǯ  
luciferase mRNA reduces its reporter activity. This is not dependent upon the 
phosphorylation status of BTG2 or TOB1. However, tethering BTG2 W103A   ?  ? ?      ?ǯ     
luciferase activity implying that the reduced activity is due to an interaction 
with Caf1a (CNOT7) and Caf1b (CNOT8).  
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Figure 5.3 TOB1 requires interactions with Caf1a (CNOT7)/Caf1b (CNOT8) to 
 ?ǯ UTR tethering. (A) Schematic representation of 
the RNA tethering assay. (B) Decreased reporter activity upon RNA tethering of ɉN-
HA-TOB1 or ɉN-HA-TOB1 SoA, but not of ɉN- HA-TOB1 W93A or ɉN-HA-TOB1 
W93A SoA. MCF-7 cells were transfected with empty vector or plasmid pCIɉN 
containing the indicated TOB1 cDNA, and the luciferase reporter plasmid pRL-
5BoxB. Luciferase activity was measured 24 h after transfection. (C) No specific 
effect of ɉN-HA-TOB1, ɉN-HA-TOB1 W93A, ɉN-HA-TOB12 SoA and ɉN-HA-TOB1 
W93A SoA expression on the activity of a Luciferase reporter lacking BoxB 
sequences.  MCF-7 cells were transfected with empty vector or plasmid pCIɉN 
containing the indicated TOB1 cDNA, and the luciferase reporter plasmid pRL-TK. 
Luciferase activity was measured 24 h after transfection. (D) Western blot showing 
the expression for ɉN-HA-TOB1, ɉN-HA-TOB1 W93A, ɉN-HA-TOB1 SoA and ɉN-HA-
TOB1 W93A SoA.  ɉN-fusion proteins were detected using anti-HA antibodies. 
Tubulin was used as a loading control. 
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5.4 Recruitment of BTG2 and TOB1 to an mRNA leads to 
mRNA degradation via Caf1a (CNOT7) and Caf1b (CNOT8)  
To determine whether reduced reporter activity upon tethering of BTG2 or 
TOB1 was caused by mRNA degradation, or due to decreased translation, the 
RNA tethering assay was performed in combination with reverse-
transcriptase qPCR analysis (Figure 5.4A). MCF-7 cells were co-transfected 
with plasmids pRL-5BoxB and ɉǡ ɉ-HA-
 ?ǡ ɉ-HA-
 ? ? ? ?ǡ ɉ-HA- ?  ɉ-HA-TOB1 W93A before total RNA 
was extracted. Relative luciferase mRNA levels were obtained and 
normalisation to GAPDH.  
Tethering of BTG2 to the luciferase reporter mRNA caused a significant ɉ
peptide alone (Figure 5.4B). As expected, tethering of BTG2 W103A did not 
cause a significant decrease in luciferase mRNA compared to tethering of the ɉǤre obtained when TOB1 tethering was carried 
out. Tethering of TOB1 to the luciferase mRNA caused a significant decrease            ɉ
alone, which was not observed in the presence of TOB1 W93A (Figure 5.4C). 
These results indicate that tethering of BTG2 or TOB1 to the luciferase mRNA 
promotes its degradation, which is dependent upon an interaction with Caf1a 
(CNOT7)/Caf1b (CNOT8). Interestingly, tethering of BTG2 and TOB1 to the 
luciferase reporter mRNA has a greater effect on reporter activity compared 
to mRNA levels. These differences may be caused by a difference in signal to 
noise ratios between the luciferase assay and RT-qPCR analysis. However, it 
may also be the case that tethering of BTG2 and TOB1 to a mRNA has a 
greater effect on translation efficiency due to shortening of the poly(A) tail 
than on mRNA degradation.   
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Figure 5.4 BTG2 and TOB1 require an interaction with Caf1a (CNOT7)/Caf1b 
(CNOT8) to reduced mRNA abundance of a tethered mRNA. (A) Schematic 
representation of the RNA tethering assay. (B) Decreased mRNA abundance upon 
RNA tethering of ɉN-HA-BTG2 but not of ɉN- HA-BTG2 W103A. MCF-7 cells were 
transfected with empty vector or plasmid pCIɉN containing the indicated BTG2 
cDNA, and the luciferase reporter plasmid pRL-5Box5. Total RNA was isolated after 
48 h and subject to RT-qPCR analysis using GAPDH as a reference gene. (C) 
Decreased mRNA abundance upon RNA tethering of ɉN-HA-TOB1 but not of ɉN- HA-
TOB1 W93A. MCF-7 cells were transfected with empty vector or plasmid pCIɉN 
containing the indicated BTG2 cDNA, and the luciferase reporter plasmid pRL-
5BoxB. Total RNA was isolated after 48 h and subject to RT-qPCR analysis using 
GAPDH as a reference gene. 
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5.5 Identification of Ccr4-Not components required for 
reduced reporter activity caused by tethering of BTG2 or 
TOB1 
The above results show that BTG2 and TOB1 require an interaction with the 
deadenylase Caf1a (CNOT7) or Caf1b (CNOT8) to reduce reporter activity as  ?ǯǤ
of the Ccr4-Not complex are involved in the repression of reporter activity, 
the RNA tethering assay was conducted after siRNA knockdown of Ccr4-Not 
components.  
To confirm that Caf1a (CNOT7) and Caf1b (CNOT8) are required for reduced 
luciferase activity, knockdown of Caf1a (CNOT7) and Caf1b (CNOT8) was 
carried out before the RNA tethering assay was conducted. MCF-7 cells were 
transfected with siRNA against Caf1a (CNOT7) and Caf1b (CNOT8) or non-
targeting siRNA. After 48 h the cells were transfected with the reporter 
plasmid pRL-5BoxB and pɉǡ ɉ-HA-BTG2, or ɉ-HA-TOB1 before 
total protein was extracted and used for a luciferase assay (Figure 5.5A).   ǡ   
 ?   ?    ?ǯ UTR of the luciferase 
reporter mRNA in the presence of non-targeting siRNA caused a reduction in 
luciferase activity indicating that the siRNA transfection does not affect the 
 ? ?Ǥǡɉ-HA-
 ?ɉ-HA-
TOB1 after combined knockdown of Caf1a (CNOT7) and Caf1b (CNOT8), the 
repression of luciferase activity was partially reversed (Figure 5.5B).        ɉ-HA-BTG2 and ɉ-HA-TOB in Caf1a (CNOT7) and Caf1b (CNOT8) knockdown cells 
(Figure 5.5C). Western blot and RT-qPCR analysis confirmed the knockdown 
of Caf1a (CNOT7) and Caf1b (CNOT8) (Figure 5.5C and 5.5D). These results 
are consistent with the finding that tethering of BTG2 or TOB1 requires 
interactions with the Caf1a (CNOT7)/Caf1b (CNOT8) enzymes to reduce 
reporter activity as presented in Figure 5.2 and 5.3. 
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Figure 5.5 Combined knockdown of the deadenylases Caf1a (CNOT7)/Caf1b 
(CNOT8) partially rescue repression of reporter activity upon tethering of 
BTG2 or TOB1. (A) Schematic representation of the RNA tethering assay.  (B) 
Combined knockdown of the Caf1a (CNOT7)/Caf1b (CNOT8) partially rescue 
repression of reporter activity upon tethering of BTG2 or TOB1. MCF-7 cells were 
transfected with siRNA targeting CNOT7 and CNOT8 or control non-targeting siRNA. 
After 48 h cells were transfected with plasmids pCIɉN-HA, pCIɉN-HA-BTG2, pCIɉN-
HA-TOB1 and the luciferase reporter pRL-5boxB. Luciferase activity was measured 
24 h after transfection. (C)  Western blots to confirm siRNA knockdown of Caf1a 
(CNOT7)/Caf1b (CNOT8) and expression of ɉN-HA-BTG2 and ɉN-HA-TOB1 (D) 
Reverse transcriptase-qPCR analysis to confirm knockdown efficiency of CNOT7 and 
CNOT8. Total RNA was isolated 72 h after siRNA treatment and subjected to RT-
qPCR analysis using GAPDH as a reference gene. 
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To determine if the deadenylases Ccr4a (CNOT6) and Ccr4b (CNOT6L) are 
also required for the reduced reporter activity upon tethering BTG2 and 
TOB1 to a luciferase mRNA, the RNA tethering assay was conducted after 
combined Ccr4a (CNOT6)/Ccr4b (CNOT6L) knockdown. MCF-7 cells were 
first transfected with siRNA targeting Ccr4a (CNOT6) and Ccr4b (CNOT6L) or 
non-targeting siRNA. After 48 h the cells were transfected with the pRL- ?ɉǡɉ-HA-
 ?ǡ ɉ-
HA-TOB1 before total protein was extracted and used for a luciferase assay.  
Upon combined knockdown of Ccr4a (CNOT6) and Ccr4b (CNOT6L), no ɉ-
 ?ɉ-
TOB1 as compared to non-targeting siRNA treated cells (Figure 5.6B). 
Western blot analysis confirmed the   ɉ-HA-BTG2 and ɉ-HA-TOB1 in MCF-7 cells (Figure 5.6C). In addition, RT-qPCR analysis 
confirmed the knockdown of Ccr4a (CNOT6) and Ccr4b (CNOT6L) mRNA 
(Figure 5.6D). This result suggests that Ccr4a (CNOT6) and Ccr4b (CNOT6L) 
do not aff
 ? ? ?ǯǤ  
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Figure 5.6 Combined knockdown of the deadenylases Ccr4a (CNOT6)/Ccr4b 
(CNOT6L) does not affect the repression of reporter activity upon tethering of 
BTG2 or TOB1. (A) Schematic representation of the RNA tethering assay.  (B) 
Combined knockdown of the Ccr4a (CNOT6)/Ccr4b (CNOT6L) does not affect the 
repression of reporter activity upon tethering of BTG2 or TOB1. MCF-7 cells were 
transfected with siRNA targeting CNOT6 and CNOT6L or control non-targeting 
siRNA. After 48 h cells were transfected with plasmids pCIɉN-HA, pCIɉN-HA-BTG2, 
pCIɉN-HA-TOB1 and the luciferase reporter pRL-5boxB. Luciferase activity was 
measured 24 h after transfection. (C)  Western blots to confirm expression of ɉN-
HA-BTG2 and ɉN-HA-TOB1. (D) Reverse transcriptase-qPCR analysis to confirm 
knockdown efficiency of CNOT6 and CNOT6L. Total RNA was isolated 72 h after 
siRNA treatment and subjected to RT-qPCR analysis using GAPDH as a reference 
gene. 
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To determine if the Ccr4-Not components CNOT1 and CNOT3 are also 
required for the reduced reporter activity upon tethering BTG2 and TOB1 to 
a luciferase mRNA, CNOT1 or CNOT3 knockdown was combined with the 
RNA tethering assay. MCF-7 cells were transfected with siRNA targeting 
CNOT1, CNOT3 or non-targeting siRNA followed by transfection of pRL- ?ɉǡɉ-HA-
 ?ǡɉ-HA-TOB1 (Figure 5.7A, 5.8A).    ɉ-
 ?  ɉ-TOB1 to the luciferase reporter caused a 
reduction in luciferase activity in the presence of non-targeting siRNA, which 
was also observed upon knockdown of CNOT1 (Figure 5.7B). Western blot ɉ-HA-
 ?ɉ-HA-TOB1 in 
MCF-7 cells after knockdown (Figure 5.7C). In addition, knockdown of 
CNOT1 was confirmed by western blotting and RT-qPCR analysis (Figure 
5.7D).  
Up    ?ǡ        ɉ-
 ?ɉ-TOB1 was reduced to a similar extent as observed in cells treated 
with non-targeting siRNA (Figure 5.8B). Western blot analysis confirms the   ɉ-HA-BTG2 and pCɉ-HA-TOB1 in MCF-7 cells after 
knockdown (Figure 5.8C). Knockdown of CNOT3 was confirmed by western 
blotting and RT-qPCR analysis (Figure 5.8D).  
Together these experiments confirm that the deadenylases Caf1a (CNOT7) 
and Caf1b (CNOT8) are required for the reduced luciferase activity witnessed    ɉ-
 ?  ɉ-TOB1 to the luciferase mRNA. However, 
other members of the Ccr4-Not complex do not appear to be required.  
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Figure 5.7 Combined knockdown of the deadenylase CNOT1 does not affect the 
repression of reporter activity upon tethering of BTG2 or TOB1. (A) Schematic 
representation of the RNA tethering assay.  (B) Knockdown of the CNOT1 does not 
affect the repression of reporter activity upon tethering of BTG2 or TOB1. MCF-7 
cells were transfected with siRNA targeting CNOT1 or control non-targeting siRNA. 
After 48 h cells were transfected with plasmids pCIɉN-HA, pCIɉN-HA-BTG2, pCIɉN-
HA-TOB1 and the luciferase reporter pRL-5boxB. Luciferase activity was measured 
24 h after transfection. (C)  Western blots to confirm siRNA knockdown of CNOT1 
and expression of ɉN-HA-BTG2 and ɉN-HA-TOB1 (D) Reverse transcriptase-qPCR 
analysis to confirm knockdown efficiency of CNOT1. Total RNA was isolated 72 h 
after siRNA treatment and subjected to RT-qPCR analysis using GAPDH as a 
reference gene. 
Chapter 5: Regulation of mRNA abundance and translation by BTG/TOB proteins 
 
190 
 
 
Figure 5.8 Combined knockdown of the deadenylase CNOT3 does not affect the 
repression of reporter activity upon tethering of BTG2 or TOB1. (A) Schematic 
representation of the RNA tethering assay.  (B) Knockdown of the CNOT3 does not 
affect the repression of reporter activity upon tethering of BTG2 or TOB1. MCF-7 
cells were transfected with siRNA targeting CNOT3 or control non-targeting siRNA. 
After 48 h cells were transfected with plasmids pCIɉN-HA, pCIɉN-HA-BTG2, pCIɉN-
HA-TOB1 and the luciferase reporter pRL-5boxB. Luciferase activity was measured 
24 h after transfection. (C)  Western blots to confirm siRNA knockdown of CNOT3 
and expression of ɉN-HA-BTG2 and ɉN-HA-TOB1 (D) Reverse transcriptase-qPCR 
analysis to confirm knockdown efficiency of CNOT3. Total RNA was isolated 72 h 
after siRNA treatment and subjected to RT-qPCR analysis using GAPDH as a 
reference gene. 
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5.6 Discussion 
The anti-proliferative activity of BTG2 and TOB1 is dependent upon their 
interaction with the deadenylases Caf1a (CNOT7) and Caf1b (CNOT8) 
(Chapter 4) (Ezzeddine et al., 2012). One possible mechanism through which 
BTG2 and TOB1 may slow cell proliferation is to alter gene expression by 
stimulating mRNA deadenylation and degradation. Tob1 can be recruited to  ?ǯpoly(A)-binding proteins during 
termination of translation, or via sequence-specific RNA-binding proteins. In 
both cases TOB1 recruitment reduced mRNA stability and leads to mRNA 
degradation (Funakoshi et al., 2007; Hosoda et al., 2011). During the course 
of this work the artificial recruitment of TOB1 and TOB2 was shown to 
promote deadenylation via interactions with the Ccr4-Not deadenylases 
Caf1a (CNOT7) and Caf1b (CNOT8) (Ezzeddine et al., 2012). Observations 
here are consistent with the published data demonstrating that tethering 
TOB1 to an    ?ǯ       
mRNA degradation. Further to this, BTG2 was also observed to reduced the 
reporter activity when tethered to a reporter mRNA and simulate mRNA 
degradation. This result is consistent with the current hypothesis that 
BTG/TOB proteins function as recruitment factors of the Ccr4-Not 
deadenylase (Ezzeddine et al., 2007; Ezzeddine et al., 2012; Hosoda et al., 
2011). What remains unclear is how BTG2 may be recruited    ?ǯ UTR 
region of mRNAs. Whereas TOB1 and TOB2 have large C-terminal regions 
that mediate interactions with poly(A)-binding proteins and CPEB3, BTG2 
and the closely related BTG1 protein only have a short C-terminal region 
(Ezzeddine et al., 2007; Funakoshi et al., 2007; Hosoda et al., 2011). It is likely 
there are further proteins that interact with the BTG/TOB proteins to 
mediate their interaction with mRNA that have yet to be discovered.   
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A further area of ambiguity is which catalytic subunit contributes to 
deadenylation of mRNA upon recruitment by BTG/TOB proteins. The Ccr4a 
(CNOT6)/Ccr4b (CNOT6L) EEP type deadenylases interact with the Ccr4-Not 
complex through Caf1a (CNOT7)/Caf1b (CNOT8), the DEDD deadenylases. 
Both the DEDD/Caf1 and EEP/Ccr4-type subunits are active deadenylase 
enzymes in vitro. However, despite the fact that these proteins directly 
interact with each other, they regulate the abundance of different sets of 
mRNAs (Aslam et al., 2009; Mittal et al., 2011). Here we have demonstrated 
that when BTG2 and TOB1 are bound to a reporter mRNA they require an 
interaction with Caf1a (CNOT7)/Caf1b (CNOT8) to reduced reporter activity. 
During the course of this work Ezzeddine et al 2012 also demonstrated that 
tethering TOB1/TOB2 to mRNA caused increased deadenylation which was 
abolished when the TOB1/TOB2 interaction with Caf1a (CNOT7)/Caf1b 
(CNOT8) was prevented. Interestingly, here, siRNA knockdown demonstrates 
that the catalytic subunit required for reduced reporter activity is Caf1a 
(CNOT7)/Caf1b (CNOT8). This suggests that despite the interaction between 
Caf1a (CNOT7)/Caf1b (CNOT8) and Ccr4a (CNOT6)/Ccr4b (CNOT6L) the 
latter EEP type deadenylases are not necessarily contributing towards the 
reduced reporter activity and mRNA level. Previous work showed that BTG2 
co-precipitates with the Ccr4-Not components CNOT1 and CNOT3 in addition 
to Caf1a (CNOT7) (Aslam et al., 2009). Through siRNA knockdown of CNOT1 
and CNOT3, it was here demonstrated that these non-catalytic subunits play 
no role in the reduced reporter activity and mRNA degradation following 
BTG2/TOB1 tethering to a reporter mRNA. However, this does not specify 
whether Caf1a (CNOT7)/Caf1b (CNOT8) are recruited alone or in complex 
with other Ccr4-Not components via BTG2 and TOB1. Immunoprecipitation 
experiments could prove interesting and provide further information as to       ?ǯ      
Ȁ
tethering.     
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 ǡ     
 ?   ?    ?ǯ  
luciferase mRNA leads to reduced reporter activity and mRNA levels. The 
effects on reporter mRNA degradation are dependent upon the interactions 
with the Caf1a (CNOT7)/Caf1b (CNOT8) deadenylase enzymes, but do not 
appear to require the EPP-type deadenylase subunits Ccr4a (CNOT6)/Ccr4b 
(CNOT6L), or the non-catalytic Ccr4-Not components CNOT1 and CNOT3.   
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  6. Concluding Remarks 
The aim of this work was to determine whether the anti-proliferative activity 
of the BTG/TOB proteins is dependent upon their interaction with the Ccr4-
Not deadenylases Caf1a (CNOT7) and Caf1b (CNOT8). Furthermore, to 
determine if the BTG/TOB proteins could act as recruitment factors to direct 
Caf1a (CNOT7) and Caf1b (CNOT8) to mRNAs thereby reducing translational 
efficiency or inducing mRNA degradation. To achieve this, the BTG2-Caf1a 
(CNOT7) interaction was characterised to identify amino acid restudies in 
BTG2 that are required for binding to Caf1a (CNOT7)/Caf1b (CNOT8). 
Through substituting these amino acids for alanine the interaction between 
BTG2 and TOB1 with Caf1a (CNOT7)/Caf1b (CNOT8) was disrupted. Using 
these BTG2 and TOB1 constructs the importance of the BTG/TOB-Caf1a 
(CNOT7)/Caf1b (CNOT8) interaction on cell proliferation was investigated 
via several methods. Additionally, utilising BTG2/TOB1-Caf1a 
(CNOT7)/Caf1b (CNOT8) interaction mutants the ability of the BTG/TOB 
proteins to recruit the Ccr4-Not deadenylases to target mRNA was assessed. 
 
6.1 BTG/TOB interactions with the Caf1a (CNOT7) and Caf1b 
(CNOT8) deadenylases enzymes.   
The BTG/TOB proteins contain a conserved N-terminal domain that mediates 
protein-protein interaction with the Ccr4-Not deadenylases Caf1a (CNOT7)/ 
Caf1b (CNOT8). The interaction has been mapped to the structurally 
conserved BTG domain as illustrated by the crystal structure of TOB1 in 
complex with Caf1a (CNOT7) (Horiuchi et al., 2009). Previous work had 
identified a number of amino acid residues in Caf1a (CNOT7) and Caf1b 
(CNOT8) that are required for their interaction with BTG2 (Aslam et al., 
2009). Using available structural information and multiple sequence 
alignment of BTG/TOB proteins, potential amino acids required for the 
interaction with Caf1a (CNOT7) and Caf1b (CNOT8) were identified. 
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Experiments in Chapter 3 identified three amino acids in BTG2 and TOB1 
that are required for the interactions with Caf1a (CNOT7) and Caf1b 
(CNOT8). These amino acids were Tyr-65, Asp-75 and Trp-103 of BTG2 and 
the corresponding residues Phe-55, Asp-65 and Trp-93 of TOB1. On the basis 
of the interaction analysis amino acid Try-103 of BTG2 and Try-93 of TOB1 
were selected to disrupt the BTG2/TOB1-Caf1a (CNOT7)/Caf1b (CNOT8) 
interaction. From analysis of the crystal structure of BTG2/TOB1 in complex 
with Caf1a (CNOT7) the amino acid may form direct interactions with the 
aliphatic portion of the Lys-203 side chain of Caf1a (CNOT7).  
    
6.2 The BTG/TOB anti-proliferative activity is mediated 
through interactions with Caf1a (CNOT7) and Caf1b (CNOT8)  
Four BTG/TOB proteins are expressed in MCF-7 cells, however, their relative 
mRNA levels do not correlate with their anti-proliferative activities. The 
expression of TOB1 was significantly higher than BTG2 expression.  However, 
upon knockdown cell proliferation increased by the same margin. 
Furthermore, despite significantly higher expression of BTG1 and TOB2 
compared to BTG2, neither had an effect on cell proliferation. Interestingly, 
the combined knockdown of BTG2 and TOB1 increased cell proliferation 
further compared to single knockdown of BTG2 or TOB1.  
It remained unresolved as to whether the BTG/TOB anti-proliferative activity 
was dependent upon interactions with the Ccr4-Not deadenylases Caf1a 
(CNOT7) and Caf1b (CNOT8). Divergent conclusions have been drawn based 
on mutagenesis studies where amino acids were substituted in the BTG/TOB 
and Caf1a/Caf1b proteins (Aslam et al., 2009; Horiuchi et al., 2009). This 
study showed that expression of BTG2 and TOB1 caused a reduction in cell 
proliferation of MCF-7 cells. By contrast expression of BTG2 W103A and 
TOB1 W93A does not affect cell proliferation. From this data, it was 
concluded that the BTG2/TOB1 anti-proliferative activity is dependent upon 
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an interaction with Caf1a (CNOT7)/Caf1b (CNOT8). This conclusion is 
consistent with recent work by Ezzeddine et al (2012) who independently 
determined that TOB1/TOB2 requires interactions with Caf1a 
(CNOT7)/Caf1b (CNOT8) for their anti-proliferative activities.  
The over-expression of BTG/TOB proteins has been linked to the reduction in 
CCND1 (Cyclin D1) expression. Stimulating changes in CCND1 (Cyclin D1) 
maybe the cell cycle pathway targeted by the BTG/TOB proteins to reduced 
cell proliferation by stalling cells in G1. To assess this, a series of western 
blots and RT-qPCR analysis was conducted to identify any changes in protein 
of mRNA levels of the key components of the G1 to S cell cycle progression 
pathway. A significant reduction was seen in the relative level of CCND1 
(Cyclin D1) mRNA after BTG2 expression indicating that BTG2 expression is 
affecting CCND1 (Cyclin D1) expression. However, whether this is a direct 
effect of BTG2 expression is unknown as the observed reduction in CCND1 
(Cyclin D1) expression maybe an indirect consequence of reduced cell 
proliferation.      
 
6.3 Regulation of the BTG/TOB anti-proliferative activity via 
phosphorylation 
The anti-proliferative activity of BTG2 and TOB1 is regulated by the 
phosphorylation of serine residues located in the proteins C-terminal region 
(Hong et al., 2005; Suzuki et al., 2002). During the course of this work, 
western blot analysis identified that TOB1 may be subject to 
phosphorylation, which is affected by the W93A amino acid substitution. 
Interestingly, the expression of BTG2 SїA and TOB1 SїA did not increase 
cell proliferation to a greater extent than wild type BTG2 or TOB1. Therefore, 
it was concluded that phosphorylation of BTG2 and TOB1 does not affect the 
activity of BTG2/TOB1 in MCF-7 cells. This conclusion is shared with recent 
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work by Ezzeddine et al 2012 who also demonstrated that phosphorylation 
of TOB1 and TOB2 did not alter their anti-proliferative activity.   
 
6.4   
Ȁ    ?ǯ reduces 
translation and mRNA abundance 
The BTG/TOB divergent C-terminal domain mediates further protein-protein 
interactions. For instance, TOB1 can interact with PABPC1 and CPEB3, two 
RNA binding proteins (Ezzeddine et al., 2007; Funakoshi et al., 2007; Hosoda 
et al., 2011; Okochi et al., 2005; Suzuki et al., 2002). These interactions allow  ? ?ǯ
to reduced mRNA stability. Work conducted here demonstrated that   
 ?  ?     ?ǯ  eads to reduced reporter 
activity and mRNA degradation and is consistent with currently published 
data (Ezzeddine et al., 2012). An interesting progression of this work would 
be to identify the mechanism through which BTG2 interacts with mRNA 
because unlike TOB1 is cannot bind to PABP or CPEB3.  
Tethering of BTG2 W103A and TOB1 W93A to mRNA did not affect reporter 
activity or mRNA abundance indicating the interaction with Caf1a 
(CNOT7)/Caf1b (CNOT8) was required for this activity. However, it remained 
unclear as to whether other subunits of the Ccr4-Not complex were required 
for the effects observed upon tethering BTG2 to TOB1 to a reporter mRNA. 
This study indicates that Caf1a (CNOT7)/Caf1b (CNOT8) are the 
deadenylases required to reduce reporter activity and that Ccr4a 
(CNOT6)/Ccr4b (CNOT6L) are not necessary. Furthermore, the Ccr4-Not 
components CNOT1 and CNOT3, which have been shown to co-precipitate 
with BTG2 (Aslam et al., 2009) were all not required for reduced reporter 
 ? ? ?ǯǤ 
In summary, this work demonstrated that the BTG2 and TOB1 require an 
interaction with Caf1a (CNOT7) and Caf1b (CNOT8) to be anti-proliferative. 
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	ǡ
 ? ? ?ǯ
degradation which is dependent upon Caf1a (CNOT7) and Caf1b (CNOT8). 
This builds on the currently published work to suggest that the BTG/TOB 
proteins function as mRNA recruitment factor for these deadenylases. It can 
therefore be hypothesised that the BTG/TOB proteins may regulate cell 
proliferation by targeting mRNAs for degradation to modulate gene 
expression. To date the endogenous target genes of the BTG/TOB protein 
have yet to be identified. Further investigation into this would be an exciting 
next step in the field of BTG/TOB research     
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Appendix 
1. Optimisation of transfection reagents and S-phase labelling 
Using MCF-7 TR BTG2 expressing stable cell lines it was demonstrated that 
BTG2 requires an interaction with Caf1a (CNOT7)/Caf1b (CNOT8) to reduce 
cell proliferation (Chapter 4). In addition, transient transfections were used 
to induce expression of BTG2, BTG2 W103A, TOB1 or TOB1 W93A to confirm 
the requirement of the BTG2/TOB1-Caf1a (CNOT7)/Caf1b (CNOT8) 
interaction for BTG/TOB anti-proliferative activity. Unlike with stable cell 
lines, not all cells in a transient transfected population will necessarily 
incorporate the BTG2/TOB1 expression plasmid. To this end, several 
transfection reagents were tested to identify which one combined optimal 
transfection efficiency with minimal effects on cell viability and proliferation. 
A number of transfection reagents were found to alter the rate of cell 
proliferation, without the presence of a BTG2/TOB1 containing plasmid. 
GeneJuice (Novagen) was identified as the transfection reagent with the 
slightest effect on cell proliferation. Other transfection reagents evaluated 
were JetPEI (Polyplus), Fugene HD (Roche), Nucleofector V (Lonza), Calcium 
phosphate. 
To monitoring transfection efficiency, a control population of cells were 
transfected with a GFP containing plasmid in parallel to plasmid 
transfections containing the BTG2 or TOB1 cDNA (as shown in Chapter 4). 
The GFP transfected cells were used as a guide for transfection efficiency 
where numbers of cells expressing GPF were compared to total number of 
nuclei identified using Hoescht (Figure 1A). If the number of cells expressing 
GFP was below 50% the transfection efficiency was considered too low and 
the S-phase data not collected. Using Genejuice (Merck), a transfection 
efficiency of 70% was routinely achieved. To calculate total number of cells in 
S-phase the number of cells with EdU labelled nuclei were compared to total 
nuclei identified through Hoescht staining (Figure 1B).  
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Figure 1. Immunofluorescence images of EdU-labelled MCF-7 cells. (A) To 
monitor transfection efficiency MCF-7 cells were seeded onto glass cover slips and 
transfected with a GFP plasmid. 48 h after transfection cells were fixed and cell 
nuclei stained with Hoescht. Cells transfected with the GFP plasmid were not 
incubated with the thymidine analogue EdU. (B) To monitor the number of cells in 
S-phase MCF-7 cells were seeded onto glass cover slips and transfected with 
appropriate plasmid pCMV5-HA-BTG2 or pCMV5-HA-TOB1. After 48 h cells were 
incubated with EdU. Cells with incorporated EdU were detected using conjugation of 
Alexa Fluor 488 azide, and nuclei were stained using Hoescht. All samples were 
tested in biological triplicate and the number of nuclei was counted for three images 
from each slide. 
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2. Antibody characterisation to detect endogenous BTG2 and 
TOB1 via western blot  
To determine the relative protein levels of BTG2 and TOB1 in MCF-7 cells, 
western blot analysis was conducted using several commercially available 
antibodies. The MCF-7 TR stable cell lines pcDNA4-TO-Flag-HA-BTG2 and 
pcDNA4-TO-Flag-HA-BTG2 W103A were seeded in 6-well culture plates in 
the presence or absence of doxycycline. After 48 h total cell lysates were 
produced and subject to western blot analysis with anti-HA (Roche) or anti-
BTG2 (Sigma AV33561). The western blot probed with anti-HA demonstrated 
that HA-BTG2 and HA-BTG2 W103A were expressed in the presence of 
doxycycline (Figure 2). However, HA-BTG2 or HA-BTG2 W103A expression 
was not detected on an equivalent western blot probed with anti-BTG2 
(Sigma AV33561) (Figure 2). This indicates that anti-BTG2 (Sigma AV33561) 
was not able to detect BTG2 protein in MCF-7 cell lysates via western blot 
analysis.  
To confirm that the HA epitope was not interfering with the western blot 
detection of BTG2 further experiments were conducted where un-tagged 
BTG2 was over expressed in MCF-7 cells. MCF-7 cells were seeded in 6-well 
culture plates and transfected with pCMV5-HA, pCMV5-HA-BTG2 and pBabe-
puro-BTG2. After 48 h total cell lysates were produced and subject to 
western blot analysis with anti-HA (Roche), anti-BTG2 (Santa Cruz sc-
33775), anti-BTG2 (Sigma AV33561) or anti-BTG2 (Gene-Tex 1082795). 
Western blot analysis using anti-HA confirmed the transfection and 
expression HA-BTG2. All BTG2 specific antibodies were unable to detect 
BTG2 or HA-BTG2 via western blot (Figure 3). Together, this data 
demonstrated that the three anti-BTG2 antibodies tested were all unable to 
detect BTG2 over-expression in MCF-7 cells.   
To determine the endogenous expression of TOB1, one commercial antibody 
was tested. HEK293T cells were seeded in 6-well culture plates and 
transfected with pCMV5-HA, pCMV5-HA-BTG2 and pCMV5-HA-TOB1. After 
Appendix 
 
230 
 
48 h total cell lysates were produced and subject to western blot analysis 
with anti-HA (Roche) or anti-TOB1 (Santa Cruz sc-33192). Western blot 
analysis using anti-HA confirmed the transfection and expression HA-BTG2 
and HA-TOB1 (Figure 4A). The anti-TOB1 (Santa Cruz sc-33192) antibody 
did not detect HA-TOB1 via western blot (Figure 4B). Surprisingly, this 
antibody did produce a band around 20kDa, the size of BTG2, in the pCMV5-
HA-BTG2 transfected sample.  
In summary, of the four antibodies tested none were able to detect 
endogenous or over-expressed BTG2 or TOB1. Further optimisation work is 
necessary to determine the optimal conditions for each antibody for the 
detection of BTG2 and TOB1. However it may be that the antibodies are not 
specific or sensitive enough to detect BTG2 and TOB1 via western blot.   
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Figure 2. Sigma AV33561 anti-BTG2 antibody is unable to detect endogenous 
or over expressed BTG2. MCF-7 TR BTG2 and MCF-7 TR BTG2  W103A stable cell 
line cells were seeded in 6-well culture plates before doxycycline added to the media 
to induce HA-BTG2/HA-BTG2 W103A expression.  After 48 h total cell lysates were 
produced and subjected to western blot analysis with anti-HA or anti-BTG2 (Sigma 
AV33561).   
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Figure 3. Commercial anti-BTG2 antibodies are unable to detect endogenous, 
overexpressed HA-BTG2 or overexpressed un-tagged BTG2. MCF-7 cells were 
seeded in 6-well culture plates and transfected with plasmids pCMV5-HA, pCMV5-
HA-BTG2 or pBabe-puro-BTG2.  After 24 h total cell lysates were produced and 
subjected to western blot analysis using anti-HA, Santa Cruz sc-33775, Sigma 
AV33561 and Gene-Tex 1082795.  
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Figure 4. Santa Cruz anti-TOB1 antibody is unable to detect endogenous or 
over expressed HA-TOB1. HEK293T cells were seeded in 6-well culture plates and 
transfected with pCMV5-HA, pCMV5-HA-BTG2 or pCMV5-HA-TOB1.  After 24 h total 
cell lysates were produced subject to western blot analysis (A) with anti-TOB1 
(Santa Cruz sc-33192). (B) with anti-HA (Santa Cruz sc-33192). To detect HA-BTG2 
membrane was exposed with chemiluminescence regent for 2 min, for HA-TOB 
membrane was exposed with chemiluminescence regent for 10min. HA-BTG2 
expression was used to confirm successful plasmid transfection.  
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3. The anti-proliferative activities of BTG2 and TOB1 require 
interactions with Caf1a (CNOT7)/Caf1b (CNOT8) in U2OS 
cells. 
We used U2OS cells to investigate if expression BTG2 and TOB1 can reduce 
the rate of cell proliferation in bone cancer cells, and to test if their anti-
proliferative activity is dependent upon the Caf1a (CNOT7)/Caf1b (CNOT8) 
interactions in this cell type.  
Expression of BTG2 significantly decreased the number of cells in S-phase 
compare to cells transfected with the empty vector pCMV5-HA. Expression of 
BTG2 W103A did not cause a reduction in the numbers of cells in S-phase 
(Figure 5A). This demonstrates that BTG2 expression reduces cell 
proliferation rates in U2OS cells and that the Caf1a (CNOT7)/Caf1b (CNOT8) 
interaction is required for the anti-proliferative activity. Expression of HA-
BTG2 and HA-BTG2 W103A was confirmed via western blot analysis (Figure 
5C). As expected the expression of TOB1 but not TOB1 W93A reduced the 
number of cells in S-phase as compared to cells transfected with empty 
vector (Figure 5B). Western blot analysis was unable to detect HA-TOB1 or 
HA-TOB1 W93A expression. However, there is a striking reduction of cells in 
S-phase after TOB1 expression comparable to results seen after BTG2 
expression in U2OS cells. Furthermore, the results parallel those seen after 
TOB1 expression in MCF-7 cells (Chapter 4).  
These results demonstrate that BTG2 and TOB1 not only reduced the rate of 
cell proliferation in MCF-7 cells but also in U2OS cells and that BTG2/TOB1 
activity is dependent upon interactions with Caf1a (CNOT7)/Caf1b (CNOT8).  
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Figure 5. BTG2 and TOB1 require interactions with Caf1a (CNOT7)/Caf1b 
(CNOT8) for their anti-proliferative activities in U2OS cells.  U2OS cells were 
seeded onto glass cover slips before being transfected with pCMV5-HA, pCMV5-HA-
BTG2 or pCMV5-HA-BTG2 W103A. 48 h after transfection cells were incubated with 
the thymidine analogue EdU and detected after incubation with Alexa Floura 488 
azide. Cells were counter stained with Hoechst 33342 to allow total cells to be 
counted on the LSM fluorescence microscope. (A) Cells were transfected with 
pCMV5-HA, pCMV5-HA-BTG2 or pCMV5-HA-BTG2 W103A. Cells in S-phase were 
labelled with EdU and detected by fluorescence microscopy after conjugation with 
Alexa Fluor 488 azide. All samples were tested in biological triplicate and the 
number of nuclei were counted for three images from each slide. Students T test 
used to calculate statistical significance, * indicates a p value of < 0.05 compared to 
control cells transfected with pCMV5-HA. (B) Cells were transfected with pCMV5-
HA, pCMV5-HA-TOB1 or pCMV5-HA-TOB1 W93A and analysed as described in (A). 
(C) Western blot analysis of U2OS cells transfected with pCMV5-HA, pCMV5-HA-
BTG2 or pCMV5-HA-BTG2 W103A. Proteins were detected with anti-HA and anti-
Tubulin. 
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4. Cellular localisation of BTG2 and BTG2 W103A 
To determine if the localisation of BTG2 W103A is different to wild type 
BTG2, immunofluorescence was performed. The MCF-7 TR stable cell lines 
containing expression cassettes pcDNA4-TO, pcDNA4-TO-Flag-HA-BTG2 and 
pcDNA4-TO-Flag-HA-BTG2 W103A were seeded onto cover slips before 
expression was induced by the addition of doxycycline. Antibodies 
recognising the Flag epitope were used in combination with Alexa Fluor 594 
conjugated secondary antibody to detect Flag-HA-BTG2 and Flag-HA-BTG2 
W103A. 
Immunofluorescence microscopy indicated that BTG2 is dispersed in a 
granular or pin point like pattern throughout the cytoplasm. The expression 
of BTG2 W103A appears to conform to the same pattern as wild type BTG2 
(Figure 6). However, background staining from the pcDNA4-TO expressing 
stable cell line displays a similar pattern but with reduced staining intensity. 
Therefore, the cellular localisation of BTG2 and BTG2 W103A is inconclusive.  
 
 
 
 
 
 
 
 
 
 
Appendix 
 
237 
 
 
 
 
Figure 6. Cellular localisation of BTG2 and BTG2 W103A in MCF-7 cells. BTG2, 
BTG2 W103A or empty vector MCF-7 TR stable cell lines were seeded onto glass 
coverslips before vector expression was induced by the addition of doxycycline to 
the cell media.  After 48 h cells were fixed and Flag-BTG2 or Flag-BTG2 W013A  
protein was detected using anti-Flag primary antibody and an anti-mouse alexa 
Fluor 594 secondary antibody. Cells were counter stained with Hoescht to identify 
the nuclei.  Images shown are representative Z stack images. 
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5. Changes in CCND1 (Cyclin D1), p21 (Waf1/CIP1) and p27 
(Kip1) expression in response to BTG2 and TOB1 
overexpression            
To identify if expression of CCND1 (Cyclin D1), p21 (Waf1/CIP1) and p27 
(Kip1) is reduced after BTG2 or TOB1 expression, RT-qPCR analysis was 
conducted. MCF-7 cells were transfected with pCMV5-HA, pCMV5-HA-BTG2 
or pCMV5-HA-TOB1 and total RNA was extracted after 48 h. CCND1 (Cyclin 
D1), p21 (Waf1/CIP1) and p27 (Kip1) mRNA levels were determined by RT-
qPCR analysis using GAPDH as a control gene. Upon BTG2 expression, there 
was no significant change in the relative amount of CCND1 (Cyclin D1), p21 
(Waf1/CIP1) or p27 (Kip1) mRNA (Figure 7A). The assay was repeated with 
RNA extracted after 72 h but this also showed no significant difference in the 
relative level of CCND1 (Cyclin D1), p21 (Waf1/CIP1) or p27 (Kip1) mRNA. 
After TOB1 expression there was a decrease in the relative amount of CCND1 
(Cyclin D1) (p<0.1). There was no significant change in the relative amount 
p21 (Waf1/CIP1) or p27 (Kip1) mRNA (Figure 7B). This demonstrates that 
over-expression of BTG2 and TOB1 causes no dramatic change in the mRNA 
levels of CCND1 (Cyclin D1), p21 (Waf1/CIP1) or p27 (Kip1) in MCF-7 cells.  
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Figure 7. Transient expression of BTG2 and TOB1 do not strongly affect the 
level of CCND1 (Cyclin D1), p27 (Kip1) or 21 (Waf1/CIP1) mRNA in MCF-7 
cells. (A) RT-qPCR to identify changes in the level of CCND1 (Cyclin D1), p27 (Kip1) 
and p21 (Waf1/CIP1) mRNA after BTG2 expression. MCF-7 cells were transfected 
with pCMV5-HA or pCMV5-HA-BTG2. After 48 h total RNA was isolated and mRNA 
levels determined through RT-qPCR using GAPDH as a reference gene. Experiments 
were carried out in duplicate and a Student T test was used to calculate statistical 
significance. (B) RT-qPCR to identify changes in the level of CCND1 (Cyclin D1), p27 
(Kip1) and p21 (Waf1/CIP1) mRNA after TOB1 expression. MCF-7 cells were 
transfected with pCMV5-HA or pCMV5-HA-BTG2. After 48 h total RNA was isolated 
and mRNA levels determined through RT-qPCR using GAPDH as a reference gene. 
Experiments were carried out in duplicate and a Student T test was used to calculate 
statistical significance. * p value of 0.09 compared to cells transfected with empty 
vector.  
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 ?Ǥ ?ȋ ?Ȍ ?ǯ
causes reduced activity which is dependent on deadenylase 
activity but not a BTG2 interaction  
RNA tethering assays were conducted to determine if the Caf1a (CNOT7) 
deadenylase activity and interaction with BTG2 alter reporter activity when     ?ǯ     Ǥ ǡ 	-7 cells were co-
transfected with the reporter pRL-5boxB and plasmids expressing fusions of  ɉ    ?ǡ  ?  ? ? ȋ Ȍǡ   ?
E247A Y260A (BTG2 interaction mutant). After transfection, total protein 
was extracted and luciferase activity determined (Figure 8A).  ɉ-Caf1a (CNOT7) to the luciferase mRNA caused a reduction in ǡɉ
only. By contrast, tethering  ɉȂCaf1a (CNOT7) D40A to the luciferase 
mRNA did not cause a reduction in luciferase activity (Figure 8B). This 
indicates that the reduction in luciferase protein is dependent upon the 
catalytic activity of the Caf1a (CNOT7) deadenylase. Tethering of Caf1a 
(CNOT7) E247A Y260A to the luciferase mRNA also caused a reduction in 
luciferase activity comparable to wild type Caf1a (CNOT7) (Figure 8B). This 
indicates that the interaction with BTG2 does not alter the Caf1a (CNOT7) 
activity when tethered to a reporter mRNA. To confirm that reduced 
luciferase activity was caused by tethering of Caf1a (CNOT7Ȍ    ?ǯ UTR, 
we used reporter plasmid pRL-TK that does not contain the BoxB motifs.   ɉ-Caf1a (CNOT7) caused a modest reduction in luciferase 
activity compared to cells transfected with empty vector (Figure 8C). There 
was no significant di     ɉ-Caf1a ȋ ?Ȍ  ? ?  ɉ-Caf1a (CNOT7) E247A Y260A fusion proteins. 
Together this indicates that tethering of Caf1a fusion proteins is indeed 
responsible for reduced luciferase activity when a reporter containing BoxB 
sequences was used. Western blot analysis was conducted on protein lysates 
to confirm expression of Caf1a (CNOT7) (Figure 8D).  
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Figure 8. Caf1a (CNOT7) requires deadenylase activity but not an interaction 
with BTG2 to reduce reporter activity upon  ?ǯ UTR tethering. (A) Schematic 
representation of the RNA tethering assay. (B) Decreased reporter activity upon 
RNA tethering of ɉN-Caf1a (CNOT7) or ɉN-HA-Caf1a (CNOT7) E247A Y260A, but not 
of ɉN-HA-Caf1a (CNOT7) D40A. MCF-7 cells were transfected with empty vector or 
plasmid pCIɉN containing the indicated CNOT7 cDNA, and the luciferase reporter 
plasmid pRL-5BoxB. Luciferase activity was measured 24 h after transfection. (C) No 
specific effect of ɉN-Caf1a (CNOT7), ɉN-HA-Caf1a (CNOT7) D40A or ɉN-HA-Caf1a 
(CNOT7) E247A Y260A expression on the activity of a Luciferase reporter lacking 
BoxB sequences.  MCF-7 cells were transfected with empty vector or plasmid pCIɉN 
containing the indicated Caf1a (CNOT7) cDNA, and the luciferase reporter plasmid 
pRL-TK. Luciferase activity was measured 24 h after transfection. (D) Western blot 
showing the expression for ɉN-Caf1a (CNOT7), ɉN-HA-Caf1a (CNOT7) D40A or ɉN-
HA-Caf1a (CNOT7) E247A Y260A.  ɉN-fusion proteins were detected using anti-V5 
antibodies. Tubulin was used as a loading control. 
 
